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Abstract 
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease 
characterised by increases in pulmonary vasoconstriction and excessive 
remodelling of the pulmonary arteries.  Together, these processes lead to 
sustained elevations in pulmonary arterial pressure, right heart failure and 
eventual death if left untreated.  Despite the number and variety of treatment 
options available, the survival rate in incident and prevalent cases of PAH 
remains poor.  Therefore, a better understanding of the pathobiology of PAH is 
required to generate novel therapeutic approaches with improved efficiency in 
patients.  In PAH there is a well described gender bias.  Women are consistently 
reported to represent up to 75% of the total PAH population; however, the 
reasons for this female predominance remain unclear.  Recently, estrogen has 
been implicated as a major risk factor, for example, elevated estrogen levels 
and alterations in estrogen metabolism are closely correlated with PAH 
development in females.  The role of testosterone in PAH is currently under 
investigated. 
Effects of estrogen are mediated through two classical estrogen receptors (ER)-α 
and –β, or the novel G-protein-coupled estrogen receptor (GPER).  Expression of 
all of these receptors is identified in pulmonary vasculature, including in smooth 
muscle and endothelial cells.  The role they play in PAH pathogenesis in females 
is largely undetermined.  Given the diverse effects of estrogen described in the 
pulmonary vasculature during PAH, for example, proliferative effects in 
pulmonary artery smooth muscle cells (PASMCs), we hypothesised that estrogen 
receptors play an integral role in PAH in females.  To examine this, we used both 
translational and experimental studies to characterise ERs in PAH.  Chronic 
hypoxic male and female mice, and mice over-expressing the serotonin 
transporter (SERT+ mice), which demonstrate female susceptibility, were used to 
investigate the effects of an ERα antagonist in vivo.  GPER knockout mice were 
also investigated in chronic hypoxia.  In situ and in vitro studies in human 
PASMCs with ER agonists and antagonists added clinical relevance to our 
findings.  In addition, testosterone manipulation was investigated in male mice 
by castration in vivo. 
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Immunohistochemistry, immunoblotting and qRT-PCR analysis demonstrated that 
ERα was increased in PASMCs and pulmonary arteries from female PAH patients 
and chronic hypoxic mice, respectively.  On the other hand, ERβ was decreased 
in PAH and hypoxia.  It was also observed that females expressed higher levels of 
ERα in PAH compared to males whereas ERβ was lower in females.  PAH was 
assessed by measuring right ventricular systolic pressure (RVSP), right ventricular 
hypertrophy (RVH) and pulmonary vascular remodelling and muscularisation.  
Chronic hypoxia induced-pulmonary hypertension (PH) was attenuated in female 
mice dosed with the ERα antagonist MPP, shown by marked reductions in RVSP 
and pulmonary vascular remodelling.  Hypoxic male mice remained unaffected 
by MPP treatment.  Spontaneous PH and chronic hypoxia induced-PH observed in 
female SERT+ mice were reversed by treatment with MPP.  Immunoblotting and 
qRT-PCR analysis revealed that the possible mechanism involved in the 
beneficial effect of MPP in females in vivo involved restoring the dysfunctional 
bone morphogenetic protein receptor-2 (BMPR2) axis observed in PAH.  This 
effect was only observed in female mice.  In addition, chronic hypoxia induced-
PH in male and female mice was unaffected by GPER deletion.  Expression of 
GPER between female non-PAH controls and PAH patients was unchanged. 
In isolated human PASMCs estrogen induced proliferation was inhibited by MPP, 
but not PHTPP or G15, an ERβ and GPER antagonist, respectively.  The ERα 
agonist, PPT stimulated proliferation of human PASMCs.  Both estrogen and PPT 
induced proliferation was dependent on downstream PI3K/Akt and ERK MAPK 
activity.   
In males, testosterone deprivation by surgical castration had no effect on 
chronic-hypoxia induced PH.  RVSP, RVH and pulmonary vascular remodelling 
were unchanged in hypoxic castrated mice relative to sham controls.  
Testosterone levels, assessed by enzyme linked immunosorbent assay (ELISA) 
demonstrated no effects of hypoxia on plasma testosterone levels.  Testosterone 
levels were approximately halved by castration.  qRT-PCR analysis showed that 
in mouse lung there were also no difference in expression of the androgen 
receptor (AR) and 5α-reducatse, the testosterone metabolising enzyme.  
Testosterone had no effect on proliferation of human PASMCs, although its 
primary metabolite, dihydrotestosterone (DHT), stimulated proliferation in a 
dose-dependent manner. 
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In summary of these findings, we have identified an ERα-dependent mechanism 
of PAH in females, but not in males.  ERα is noticeably increased in female 
human PASMCs from PAH patients compared to male PAH patients.  Additionally, 
ERα activation in female human PASMCs leads to proliferation driven by PI3K/Akt 
and ERK MAPK activation.  Treatment with an ERα antagonist attenuated the 
development of chronic hypoxia induced-PH in females but not males, and 
reversed PH in SERT+ female mice.  We demonstrate that the mechanism 
attributed to the beneficial effect of MPP in vivo involved restoration of the 
dysfunctional BMPR2 signalling axis.  Our results suggest that increased ERα 
expression may drive PAH development in females.  Furthermore, we 
demonstrate that ERα does not play a key role in the development of hypoxia 
induced-PH in male mice.  In addition we conclude that testosterone does not 
contribute to chronic hypoxic-PH observed in males.  We suggest that altered 
local synthesis and metabolism in the lung and right ventricle may however, 
facilitate progression of established PAH in males and worsening survival rates.  
Overall, our results provide evidence for ERα in PAH development and implicate 
targeting ERs as a novel therapeutic target in PAH treatment. 
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Chapter 1. 
Introduction 
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1.1 The Pulmonary Circulation 
1.1.1  Structural Organisation 
The function of the pulmonary circulation is primarily gas exchange facilitating 
oxygen (O2) uptake and removal of carbon dioxide (CO2).  The structural and 
functional organisation of the pulmonary circulation reflects this purpose.  The 
pulmonary circulation continuously receives the entire cardiac output from the 
right ventricle which receives mixed venous blood draining into the right atria 
from the systemic circulation via the inferior and superior vena cava.  The 
pulmonary artery originates in the right ventricle where it bifurcates to become 
the left and right pulmonary artery, both of which extend into the hilum of their 
corresponding lungs.  The anatomy of the left lung is subdivided in to two 
segments, the superior and inferior lobes separated by the oblique fissure and 
each lobe receives a branch from the left pulmonary artery.  The right lung is 
divided into three lobes (superior, middle and inferior) separated by interlobular 
fissures and each is supplied with a branch resulting from the bifurcation of the 
right pulmonary artery.  Each of these five lobes can be further subdivided 
anatomically into bronchopulmonary segments and contain its own segmental 
bronchi and corresponding pulmonary arterial branch.  Each segment is 
functionally and anatomically distinct and as a consequence can function as a 
single entity meaning a single bronchopulmonary segment can be removed 
without affecting surrounding segments (Sealy et al. 1993).  Ultimately, the 
branching pattern differs between the left and right lung.  Distal branching in 
each lung continues in parallel series with the bronchial tree until the terminal 
alveoli are reached equivalent to fifteen orders of branching (Figure 1-1). 
1.1.2  Functional Organisation 
The primary lung function is closely related to structural and functional changes 
in the intima and media of pulmonary arteries as the branching system 
converges in the terminal alveoli.  In humans, the smallest noncapillary blood 
vessels are defined as an order 1 vessel.  This numbering continues with each 
proximal branch point until the main pulmonary artery (order 15) is reached 
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known as the Diameter-Defined Strahler’s system (Mandegar et al. 2004).  The 
proximal elastic arteries (orders 15-13; >1000µm diameter) are highly compliant 
and typically have an internal diameter greater than 1mm with increased elastic 
laminae in the tunica media to facilitate compliance.  The more distal muscular 
arteries (orders 13-4) are typically between 100 and 1000µm in diameter.  They 
progressively lose compliance with continual branching as a direct consequence 
of increased smooth muscle and decreased laminae in the tunica media.  
Phenotypically these arteries are defined by the predominance of smooth muscle 
in the media essential for blood pressure maintenance (HEATH & EDWARDS 
1958).  As the branching continues into orders 4-1 (<200µm diameter), medial 
smooth muscle becomes completely diminished and the resulting vessels are 
extremely thin-walled composed of endothelial cells and pericytes 
(undifferentiated smooth muscle cells) which function to facilitate blood-gas 
exchange in the alveoli (Figure 1-2). 
The human lung has a network of over 300 million arteries, veins and capillaries 
throughout the 15 orders of branching defined as the capillary network.  Each 
capillary has an internal diameter less than 10µm and supplies blood to several 
alveoli.  The capillary network functionally facilitates blood oxygenation 
therefore a diffuse network of capillaries is essential across the lung.  Following 
completion of circulation through the pulmonary capillaries, the re-oxygenated 
blood enters the pulmonary venous circulation via the venules and pulmonary 
veins until the main left and right pulmonary veins in corresponding lungs enter 
into the left atria. 
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Figure 1-1: Branching of pulmonary vasculature. 
Left, a typical lung cast is shown of pulmonary arterial branching.  Right, Distal branching in each 
lung reaching the alveoli equates to 15 orders of branching in the Strahler model.  
 
Figure 1-2: Musculature in the pulmonary arteries. 
In the distal pulmonary arteries there is a complete loss of smooth muscle in the media replaced by 
thin walls composed of endothelial cells and pericytes.  Adapted from (MacLean et al. 2000). 
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1.1.3  Structure of the Pulmonary Vascular Wall 
The architecture of the normal pulmonary vasculature is engineered to ensure a 
high compliance, low resistance network providing an extensive surface area to 
facilitate gas exchange.  In general the pulmonary vasculature has three 
concentric layers, adventitial, medial and intimal layers each composed of 
phenotypically distinct cells (Figure 1-3).  The outermost adventitial layer exists 
as a collagen matrix and contributes to the structural integrity of the vessel 
wall.  In this layer, pulmonary artery fibroblasts (PAFs) are the predominant cell 
type and have been identified to play an important role in response to 
environmental stimuli (Stenmark et al. 2006).  The longitudinal medial layer 
comprises several populations of pulmonary artery smooth muscle cells (PASMCs) 
including immature and differentiated smooth muscle cells with an underlying 
elastic layer (Stenmark & Frid 1998).  The medial layer is the predominant layer 
in the vascular wall capable of regulating vascular tone and blood pressure as 
PASMCs are the only cell type that produces a contractile response on 
stimulation.  The innermost intimal layer exists as a monocellular endothelial 
layer attached to an underlying connective tissue matrix, termed the basement 
membrane.  The pulmonary artery endothelial cells (PAECs) surround the lumen 
and are the only cell type in constant physical contact with blood flow therefore 
are proposed to be crucial in monitoring and regulating the luminal environment 
via release of various factors (Aaronson et al. 2002). 
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Figure 1-3: Cell types in the pulmonary vascular wall. 
Endothelial, smooth muscle cells, and fibroblasts compose the intimal, medial and adventitial layers 
of the pulmonary vascular wall, respectively.  Upon stress, for example hypoxia, immune cells such 
as macrophages, monocytes and dendritic cells, infiltrate the endothelial monolayer and stimulate 
pulmonary vascular remodelling. 
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1.1.4  Function of the Pulmonary Circulation 
In the adult human circulation, both the left and right ventricles are arranged in 
parallel.  Therefore, pulmonary blood flow is exactly equal to that of the left 
ventricle cardiac output and pulmonary arterial pressures (PAP) are directly 
related to cardiac output (Mandegar et.al. 2004).  The pulmonary circulation is 
normally a high flow, low-resistance, low-pressure system that transports blood 
into the pulmonary micro-circulation where the most important function is gas 
exchange.  Essentially, deoxygenated blood arriving from the systemic 
circulation is oxygenated by the rapid unloading of excess CO2 and subsequent 
binding of O2 molecules to haemoglobin, which resides within the red blood 
cells.  This maintains metabolic processes throughout the body. 
In addition to gas exchange, the lung also has important non-respiratory 
functions.  This includes a primary defence system whereby the pulmonary 
circulation acts as a physical barrier by filtering and preventing the passage of 
inhaled foreign bodies and pathogens from the respiratory system to the 
cardiovascular system (Comroe, Jr. 1966).  Within the cardiovascular system, it 
also acts as a physical barrier to prevent the passage of potentially lethal 
thrombi and embolic occlusion of essential arterial beds which may otherwise 
lead to infarction.  The pulmonary circulation is also proposed to function as a 
blood reservoir (Comroe, Jr. 1966).  The pulmonary vessels normally contain up 
to 500ml of blood and most of this can be rapidly mobilised to supply the left 
ventricle and maintain cardiac output. 
1.1.5  Control of the Pulmonary Circulation 
Major structural and functional differences exist between the systemic and 
pulmonary circulation.  The pulmonary circulation is a high flow, low-resistance, 
low pressure system to avoid the consequences of Starling forces which would 
otherwise flow the lung with oedema fluid.  Whilst in the systemic circulation, 
approximately 80% of vascular resistance is maintained by small muscular 
arterioles, resistance in the pulmonary circulation is relatively evenly distributed 
(MacLean et.al. 2000).  The pulmonary arteries contain less medial smooth 
muscle and elastin and therefore a thinner wall allowing for greater 
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distensibility (Kilner 2004).  As a consequence, PAP is typically 24/9mmHg and 
significantly lower than systemic arterial pressure (SAP), which is typically 
120/80mmHg (Morgan et al. 2004).  Similarly, the pressure gradient throughout 
the pulmonary circulation is 7-9mmHg, and up to ten-fold lower than those 
which exist in the systemic circulation. 
1.1.6  Pulmonary Vascular Resistance 
The pulmonary vascular resistance (PVR) is defined as the total peripheral 
resistance of flow which must be overcome to maintain continuous blood flow 
through the pulmonary arteries.  The laws of physics therefore predict that in 
blood flow through the pulmonary vasculature, PVR is inversely proportional to 
the fourth power of the radius of the lumen.  In other words, even small changes 
in the lumen size in pulmonary arteries can significantly change PVR and 
therefore PAP.  Intimal thickening and narrowing of the lumen in diseases such 
as pulmonary hypertension consequently results in sustained increases in PAP. 
1.1.7  Passive Regulation and Distribution of Blood Flow 
The relatively low pulmonary pressures combined with the mid-entry point of 
the artery into the lung and gravity contributes to an uneven distribution of 
blood flow throughout the pulmonary circulation.  For example, when upright, 
pulmonary blood flow to the apex of the lung is extremely low, whilst blood flow 
to the base of the lung is greatly increased.  Passive pressure distribution can be 
explained by subdividing the lung into three zones determined by the relative 
values of the pulmonary arterial pressure (Pa), pulmonary venous pressure (Pv), 
an alveolar pressure (PA) (Figure 1-4).  Zone 1 describes the upper portion of the 
lung, the apex, where blood flow is extremely low, and this can be explained 
because the apex alveolar pressure is greater than both the arterial and venous 
pressures (PA>Pa>Pv), resulting in collapse of the highly compliant vasculature.  
In zone 1, alveolar dead space occurs because the region is still being ventilated 
but not perfused.  In Zone 2, the mid-portion of the lung, arterial pressure is 
greatest, however alveolar pressure still exceeds venous pressure (Pa>PA>Pv) and 
therefore blood flow remains impaired.  As a result, in zone 2, the perfusion 
pressure and vessel recruitment for the pulmonary circulation increases.  Zone 3 
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at the base of the lung is below heart-level and therefore both the arterial 
pressure and venous pressures exceed alveolar pressure (Pa>Pv>PA) which allows 
the vessels to be maximally distended at all times.  During periods of increased 
blood flow there is substantial recruitment of the pulmonary vasculature in zone 
1 and 2 allowing an even distribution of blood flow throughout the lung (Harf et 
al. 1978). 
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Figure 1-4: Passive distribution of blood flow through the lung. 
Each lung is divided into three zones as determined by pulmonary arterial pressure (Pa), pulmonary 
venous pressure (Pv) and pulmonary alveolar pressure (PA). 
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1.1.8  Active Regulation and Distribution of Blood Flow 
In addition to passive distribution and regulation of blood flow in the pulmonary 
circulation, the active regulation is also an important determinant in pulmonary 
arterial pressure.  Active factors include circulating hormonal influences, 
respiratory gases and sympathetic nerves.  These factors all influence pulmonary 
vascular tone by affecting PVR. 
The pulmonary circulation is innervated by both the sympathetic (adrenergic) 
and parasympathetic (cholinergic) branches of the autonomic nervous system 
(Dawson 1984).  In addition, nonadrenergic noncholinergic (NANC) nerves 
regulate vascular tone (Kubota et al. 1988).  Stimulation of the sympathetic 
nervous system results in increased neuron firing, increased PVR, and as a 
consequence increased PAP (Kadowitz et al. 1974).  The pulmonary vasculature, 
particularly the PASMCs expresses α- and β-adrenoceptors, where stimulation by 
noradrenaline produces vasoconstriction and vasodilation, respectively (Hyman 
et al. 1986; Hyman et al. 1990). 
In contrast, the parasympathetic branch of the autonomic nervous system 
appears much less dense in the pulmonary arteries compared to the sympathetic 
innervations (Downing & Lee 1980).  Additionally, release of the post-ganglionic 
neurotransmitter acetylcholine has less of an effect on pulmonary vascular tone 
and PVR or PAP (Murray et al. 1986).  Functional NANC nerves have also been 
identified in pulmonary arteries, although the role of NANC nerves in the 
regulation of vascular tone remains to be described in vivo.  It has been 
observed however, in isolated pulmonary arteries that nitric oxide mediates 
relaxation which is completely unaffected by adrenergic and cholinergic 
blockade (Scott & McCormack 1999). 
 
1.2 Pulmonary Arterial Hypertension 
1.2.1  Classification 
Pulmonary arterial hypertension (PAH) is a debilitating disease characterised by 
excessive vasoconstriction and progressive remodelling in pulmonary arteries 
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leading to obliteration of pulmonary arteries and resulting in right heart failure 
and eventual death.  PAH is typically diagnosed with right heart catheterisation 
and if mean pulmonary arterial pressure (mPAP) exceeds 25mmHg at rest 
(normal mPAP value at rest is 12-16mmHg).  However, due to the diverse 
aetiology of PAH, initial diagnosis can be complicated and particularly in the 
context of a patient with multisystem disorder.  For this reason, classification of 
different groups/forms of PAH has been developed.  In the latest consensus 
meeting, the World Health Organisation (WHO) produced the Dana Point (2008) 
classification (Rosenkranz & Erdmann 2008) which led to well defined PAH 
groups.  Importantly, the subgroups of PAH share a common phenotypic 
pathobiology (Voelkel & Cool 2004).  The current Dana Point is listed in Table 1-
1.  Group 1 PAH is categorised into idiopathic PAH (IPAH), heritable PAH (HPAH), 
drug- and toxin-induced, and associated PAH (APAH), as well as persistent 
pulmonary hypertension of the new born (PPHN).  In the developing world, PAH 
can also be associated with sickle cell disease and schistosomiasis, although PAH 
due to these diseases is rare in the Western World (Peacock et al. 2013).  
Furthermore, non-arterial pulmonary hypertension can be classified into the 
following groups: pulmonary veno-occlusive disease (PVOD) and/or pulmonary 
capillary hemangiomatosis (PCH) (Group 1’); pulmonary hypertension owing to 
left heart disease (Group 2); pulmonary hypertension owing to lung disease 
and/or hypoxia (Group 3); chronic thromboembolic hypertension (CTEPH) (Group 
4), and pulmonary hypertension with unclear multi-factorial mechanisms (Group 
5). 
Despite well defined groups of PAH, symptoms develop gradually and patients 
typically remain undiagnosed.  This can be a result of the generic signs and 
symptoms associated with PAH development and patients present asymptomatic 
with mild to moderate PAH (Simonneau et al. 2009).  Only in late-stage/severe 
PAH are clinical signs apparent such as dyspnoea, angina-like chest pain, and 
fatigue.  The severity of PAH in patients is also categorised using the New York 
Heart Association (NYHA) functional classification system (class I-IV) (Table 1-2).  
The functional classification of a patient is considered both at rest and during 
physical activity and is determined by their physical limitations.  For example, in 
mild/early-stage PAH, patients appear asymptomatic and reside within class I 
whereas those most affected (late-stage PAH with right heart failure) are class 
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IV.  The NYHA (class I-IV) system is important in both the choice of PAH therapy 
and an accurate predictor of patient mortality. 
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Table 1-1: World Health Organisation (WHO) Clinical Classifications of Pulmonary 
Hypertension. 
Updated Dana Point, 2008.  BMPR2: bone morphogenetic receptor type 2; ALK-1: activin receptor 
like-kinase-1; HIV: human immunodeficiency virus. 
 
Group 1: Pulmonary Arterial Hypertension (PAH) 
 1.1 Idiopathic 
1.2 Heritable 
1.2.1 BMPR2 
1.2.2 ALK-1, endoglin (with or without hereditary hemorrhagic 
telangiectasia) 
1.2.3 Unknown 
1.3 Induced by drugs and toxins 
1.4 Associated with PAH 
1.4.1 Connective tissue diseases 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart disease 
1.4.5 Schistosomiasis 
1.4.6 Chronic haemolytic anaemia 
1.5 Persistent pulmonary hypertension of the newborn 
 
Group 1’: Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary 
hemangiomatosis (PCH) 
 
Group 2: Pulmonary hypertension due to left heart disease 
2.1 Systolic dysfunction 
2.2  Diastolic dysfunction 
2.3 Valvular disease 
 
Group 3: Pulmonary hypertension due to lung diseases and hypoxemia 
3.1 Chronic obstructive pulmonary disease (COPD) 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive 
patterns 
3.4 Sleep-related breathing behaviour 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitudes 
3.7 Developmental abnormalities 
 
Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH) 
 
Group 5: Pulmonary hypertension with unclear or multi-factorial mechanisms 
5.1 Hematologic disorders: myeloproliferative disorders, splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhands cell 
histiocytosis, lymphangioleiomyomatosis, neurofibromatosis, 
vasculitis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, 
thyroid disorders 
5.4 Other: tumoral obstruction, fibrosing mediastinitis, chronic kidney 
failure on dialysis 
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Table 1-2: Current WHO/NYHA Functional Classification of patients with Pulmonary 
Hypertension 
 
Current World Health Organisation (WHO) / New York Heart Association 
(NYHA) Classification of functional status of patients with pulmonary 
hypertension   
 
Class I Patients with pulmonary hypertension but without 
resulting limitation of physical activity.  Ordinary 
physical activity does not cause undue dyspnoea or 
fatigue, chest pain, or near syncope 
Class II Patients with pulmonary hypertension resulting in 
slight limitation of physical activity.  They are 
comfortable at rest.  Ordinary physical activity 
causes undue dyspnoea or fatigue, chest pain or near 
syncope. 
Class III Patients with pulmonary hypertension resulting in 
marked limitation of physical activity.  They are 
comfortable at rest.  Less than ordinary activity 
causes undue dyspnoea or fatigue, chest pain or near 
syncope. 
Class IV Patients with pulmonary hypertension with inability 
to perform any physical activity without symptoms.  
These patients manifest signs of right heart failure.  
Dyspnoea and/or fatigue may be present at rest and 
increased by almost any physical activity. 
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1.2.2  Epidemiology and Prognosis 
PAH is a rare disease with an annual incidence of approximately 2-3 per million 
of the population (Frost et al. 2011; Humbert et al. 2006; Ling et al. 2012).  The 
recent REVEAL Registry demographics suggest that the modern PAH patient 
population in the US with WHO Group I PAH (including idiopathic, familial, or 
associated with collagen vascular disease, congenital systemic-to-pulmonary 
shunts, portal hypertension, drugs or toxins, HIV infection, and miscellaneous 
conditions [such as splenectomy or hemoglobinopathies]) is older (mean age at 
diagnosis, 47 years) and has a higher female preponderance (Badesch et al. 
2010; Frost et.al. 2011; Thenappan et al. 2010).  The female to male ratio 
reported is as strong as 4.3:1 amongst the total PAH group (Walker et al. 2006) 
and 4.1:1 in the IPAH and APAH subcategories (Badesch et.al. 2010).  This 
female prevalence has increased since the NIH Registry in the mid-1980s (Rich et 
al. 1987) and in most clinical trials, approximately three-quarters of patients are 
females.  The reported incidence of PAH also appears to comprise a majority of 
patients in the IPAH and APAH category where the most common underlying 
associated conditions are connective tissue disease and congenital heart disease 
(Badesch et.al. 2010). 
Observed survival rates in the PAH patient population are 83%, 67% and 58% at 1, 
2 and 3 years, respectively (Humbert et al. 2010a) although younger patients 
(aged <50 years) are reported to have better survival rates (Ling et.al. 2012).  
Mortality rates in PAH are closely associated with right ventricular 
haemodynamic function and exercise limitation, however building evidence also 
shows that male sex is associated with poorer survival (Humbert et.al. 2010a; 
Humbert et al. 2010b; Sztrymf et al. 2008).  It may therefore be important to 
consider the influence of gender on disease occurrence and outcomes.  
Moreover, the survival in incident PAH (newly diagnosed) is worse than in 
prevalent patients and survival outcomes also vary considerably among different 
aetiologies of PAH.  For example, systemic sclerosis associated PAH patients 
have poorer survival than those with IPAH (Benza et al. 2012; Humbert et.al. 
2010b).  Whilst survival rates have improved in PAH in comparison with the 
established NIH Registry, recent studies indicate that PAH nonetheless remains a 
progressive, fatal disease despite advances in diagnosis and therapies (Humbert 
et.al. 2010a; Thenappan et.al. 2010). 
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1.2.3  Current Treatment Options in PAH  
Patients in the modern treatment era respond better to PAH therapies; however 
the 5 year survival rate of 65% remains troubling (Thenappan et al. 2012).  
Treatment of PAH is initiated according to the clinical aetiology and functional 
impairment (NYHA Class I-IV) of each patient.  Current therapeutic options 
target the increased pulmonary vascular resistance (PVR) associated with 
elevated vasoconstriction in the pulmonary arteries and aim to re-establish the 
balance between vasoconstriction and vasodilation.  These include targeting 
chronically impaired prostacyclin and nitric oxide synthesis, and over-production 
of endothelin (Figure 1-5).  Whilst some of them also have anti-proliferative 
properties and offer prevention of remodelling, none of the currently available 
treatments initiate regression of remodelling and the disease remains incurable.  
In addition, calcium channel blockade can be used to attenuate pulmonary 
artery vasoconstriction.  In PAH, combinations of these treatments provide the 
most effective therapeutic approach. 
1.2.3.1 Prostanoid Therapy 
Prostacyclin, synthesised in pulmonary artery endothelial cells, is a potent 
vasodilator, inhibits platelet aggregation and has anti-proliferative properties 
(Geraci et al. 1999; Hoshikawa et al. 2001).  Endothelial dysfunction is well 
described in PAH and in line with this, prostacyclin synthase is reported to be 
reduced in PAH patients (Christman et al. 1992; Galie et al. 2003) resulting in a 
deficiency of prostacyclin (PGI2) in small- and medium-sized pulmonary arteries 
(Tuder et al. 1999).  Prostanoid therapy has been a mainstay in the treatment of 
PAH for over a decade.  Currently there are three FDA (Food and Drug 
Administration) approved prostanoids: epoprostenol, treprostinil and iloprost. 
Epoprostenol is the first FDA approved prostanoid and is the first line of 
treatment for critically ill class III and IV symptoms because it is the most rapidly 
effective therapy.  Given intravenously, epoprostenol improves NYHA functional 
class, exercise tolerance, haemodynamics and survival and quality of life in PAH 
(Barst et al. 1996; McLaughlin et al. 2002; Sitbon et al. 2002).  Epoprostenol is a 
short acting vasodilator which requires chronic intravenous infusion, a major 
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limitation in its use.  Common side effects observed include headache, jaw pain, 
flushing, nausea, diarrhoea, skin rash and musculoskeletal pain. 
Treprostinil is a modern generation prostanoid with greater stability and a longer 
half life, and can be administered subcutaneously, intravenously, or as inhaled 
therapy.  Subcutaneous administration of treprostinil is most widely used and 
improves exercise capacity and haemodynamics in all aetiologies of PAH in a 
dose-dependent manner.  The intravenous and inhaled forms of treprostinil 
however, show greater tolerability and maintain improvements in 
haemodynamics (Gomberg-Maitland et al. 2005; Laliberte et al. 2004; 
McLaughlin et al. 2010).  Side effects with intravenous treprostinil are similar to 
that of intravenous epoprostenol.  Subcutaneous treprostinil is also associated 
with pain and erythema at the site of injection. 
The most recently FDA approved prostanoid is inhaled iloprost.  As iloprost 
dilates both systemic and pulmonary vasculature, inhalational administration 
and nebuliser therapy may bypass side effects associated with intravenous 
prostanoids.  Iloprost shows considerable improvements in NYHA functional class 
and survival in patients with IPAH, CTEPH and PAH associated with connective-
tissue diseases (Ewert et al. 2011; Goldsmith & Wagstaff 2004).  Due to the short 
half-life, lasting approximately 30-60 minutes, iloprost is taken six to nine times 
daily (Hoeper et al. 2000; Olschewski et al. 2002). 
1.2.4 Endothelin Antagonists 
In the dysfunctional endothelium, increased production of endothelin 1 (ET-1) 
stimulates vasoconstriction and proliferation of smooth muscle cells in 
pulmonary arteries (McCulloch et al. 1998).  In addition, plasma levels of ET-1 
are known to be increased in PAH and correlate with severity of PAH and 
prognosis (Rubens et al. 2001).  Effects of ET-1 are mediated through two main 
endothelin receptors, (ETA and ETB), both of which are G-protein coupled 
receptors.  ETA receptors are found primarily in the smooth muscle cells and are 
associated with vasoconstriction and proliferation in pulmonary arteries (Zamora 
et al. 1993).  On the other hand, ETB is mainly found in endothelial cells and to a 
lesser extent in smooth muscle cells (Hori et al. 1992; Zamora et.al. 1993).  In 
the lung, ETB receptor is involved in ET-1 clearance and stimulates the release of 
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nitric oxide and PGI2 which leads to pulmonary artery vasodilation (Fukuroda et 
al. 1992).  Following this, ETA receptor antagonists therefore provide the best 
endothelin based therapy for treating PAH. 
Currently, both selective and non-selective ET receptor antagonists (ERA) are 
approved for PAH therapy.  Bosentan is an oral non-selective ERA proven to 
improve haemodynamics in APAH (Sitbon et al. 2005) and portopulmonary 
hypertension (Hoeper et al. 2005) with NYHA functional class II and III.  Bosentan 
is associated with increased hepatic function, syncope and flushing and should 
be monitored carefully. 
Sitaxsentan and ambrisentan are selective ETA antagonists and, in theory, offer 
more selective blockade of ET-1 vasoconstrictor effects whilst maintaining 
vasodilator properties through ETB.  Improved exercise capacity and sustained 
improvements in haemodynamics were observed with both sitaxsentan and 
ambrisentan and approved for therapy in NYHA functional class II-IV (Barst et al. 
2006; Klinger et al. 2011); however sitaxsentan treatment has subsequently been 
withdrawn owing to fatal liver failure and acute hepatitis. 
Interestingly, it has been reported recently that women with PAH exhibit a 
greater clinical benefit from ERAs than men in terms of improvements in 
exercise capacity (Gabler et al. 2012).  Gender influences in treatment-response 
requires further investigation. 
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Figure 1-5: Targets of current treatment options in PAH therapy. 
Current PAH treatments target impaired NO (phosphodiesterase type 5 inhibitors) and prostacyclin 
synthesis (prostacyclin analogues), and over-production of endothelin (Endothelin receptor 
antagonists) to re-establish a balance between vasoconstriction and vasodilation.  Adapted from 
(Humbert et al. 2004). 
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1.2.4.1 Phosphodiesterase Type-5 Inhibitors 
Nitric oxide (NO) is a potent endogenous, endothelium derived vasodilator that 
directly relaxes PASMCs through stimulation of soluble guanylate cyclise and 
increased production of intracellular cyclic guanosine monophosphate (cGMP).  
Phosphodiesterase type-5 (PDE-5) degrades cGMP and is abundantly expressed in 
the lung with increased activity in PAH (Black et al. 2001).  Inhibition of this 
process using PDE-5 inhibitors such as sildenafil or tadalafil improves 
vasodilation.  In addition, these treatments have anti-proliferative properties 
(Wharton et al. 2005).  Indeed, both sildenafil and tadalafil have demonstrated 
acute and long-term beneficial effects in patients with PAH with improvements 
in NYHA functional class and exercise capacity reported (Galie et al. 2005; Galie 
et al. 2009).  Currently, these are the only two FDA approved oral PDE-5 
inhibitors for the treatment of functional classes II-III.  Minor adverse effects of 
PDE-5 inhibitors generally include headache, flushing and dyspepsia. 
1.2.4.2 Calcium Channel Blockers 
Calcium channel blockers (CCBs) are utilised in PAH patients who respond 
positively to an acute vasoreactivity test with inhaled nitric oxide, intravenous 
adenosine, or intravenous epoprostenol.  The pulmonary vasculature is only 
responsive to local mediators in approximately 5-10% of all PAH patients, 
therefore CCBs are of limited use.  In PASMCs, CCBs reduce intracellular Ca2+ and 
cellular hyperpolarisation resulting in pulmonary vascular smooth muscle 
relaxation.  Clinical trials using CCBs in PAH demonstrate improved survival rates 
in patients (Rich et al. 1992).  The agents most commonly used are long-acting 
nifedipine, diltiazem, or amlodipine.   
1.2.4.3 Combination Therapy 
Combination therapy is generally considered most effective in treatment of PAH 
and maximises clinical benefit by targeting different mechanisms of action 
(Benza et al. 2007).  For example, adjunctive therapy with sildenafil or bosentan 
has produced marked improvement in patients receiving prostacyclin therapy 
(Hoeper et al. 2003).  Overall, combination therapy aims to increase efficacy 
and reduce toxicity to improve functional status and quality of life in patients 
who are unresponsive to monotherapy. 
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1.2.5  Future Perspectives in the Treatment of PAH 
Current treatments for PAH improve symptoms and reduce severity of the 
haemodynamic disorder, however, gradual deterioration in a patient’s condition 
is still an issue and often necessitates a lung transplant after years of therapy.  
For this reason, new therapeutic options have been investigated and emerging 
trends pharmacologically target the vascular remodelling process with anti-
mitogenic, pro-endothelial function, pro-angiogenic, and anti-oxidative actions.  
In addition, regeneration using cell therapy is a novel and interesting 
therapeutic option. 
1.2.5.1 Tyrosine Kinase Inhibitors 
Recently, platelet-derived growth factor (PDGF) has been identified as a potent 
mitogen in pulmonary arteries contributing to pulmonary vascular remodelling 
and the progression of PAH (Barst 2005).  PDGF exists in five isoforms (PDGF-AA, 
PDGF-BB, PDGF-CC, PDGF-DD, and PDGF–AB) which share structural and 
functional properties with other growth factors such as vascular endothelial 
growth factor and exert their effects through two receptors, PDGFR-α and –β 
(Andrae et al. 2008; Fredriksson et al. 2004).  The PDGFRs belong to a family of 
transmembrane receptor tyrosine kinases (RTKs) and dimerisation of these 
receptors leads to an increase in kinase activity, for example Ras/MAPK, PI3K 
and phospholipase Cγ activity resulting in activation of mitogenic, pro-
migratory, and anti-apoptotic genes which contribute to the vascular 
remodelling process.  Indeed, PDGF stimulates proliferation of PASMCs 
(Schermuly et al. 2005) and over-expression of PDGF mRNA was demonstrated in 
lungs from patients with severe PAH (Humbert et al. 1998).  In vitro, the small 
molecule RTK inhibitor ST1571 (Imatinib) was found to inhibit PDGF-related 
migration, proliferation and gene transcription in human PASMCs (Pullamsetti et 
al. 2012).  Moreover, in two experimental models of PAH, Imatinib reverses 
established PAH (Schermuly et.al. 2005).  RTKs are at an early stage of clinical 
evaluation in PAH patients.  A phase II clinical study showed Imatinib reduced 
PVR, and improved cardiac output in a PAH treatment group (Hoeper et.al. 
2000); however due to serious adverse events, for example subdural 
haematomas, Imatinib was withdrawn in 2013.  The rationale behind use of RTKs 
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in PAH is very strong; however, the need to develop a safe and effective 
molecule is proving difficult. 
1.2.5.2 Cell Based Therapies 
It has been identified that PAEC apoptosis contributes to vascular cell 
proliferation in the lung and stimulates to the formation of intimal lesions 
(Taraseviciene-Stewart et al. 2001).  Disruption of endothelial integrity in 
pulmonary arterioles contributes to endothelial dysfunction associated with 
abnormal vasomotor tone and increased smooth muscle cell growth and arterial 
remodelling.  The recent interest in the role of apoptosis in the pathogenesis of 
PAH raises the possibility that novel treatments targeted toward repairing or 
regenerating lung microvascular endothelial cells.  This may provide greater 
potential for reversing both structural and functional vascular abnormalities in 
established PAH.  Indeed, cell-based gene delivery is effective in preventing 
monocrotaline-induced PAH using a variety of different therapeutic transgenes, 
including VEGF (Campbell et al. 2001), prostacyclin synthase, and endothelial 
nitric oxide synthase (eNOS) (Campbell et al. 1999).  In addition, endothelial 
progenitor cells (EPCs) have been explored as a potential source for 
neovascularisation and intravenous infusion of EPCs in patients with IPAH has 
beneficial effects on exercise capacity and pulmonary haemodynamics (Wang et 
al. 2007).  Perhaps, the combination of progenitor cells with the over-expression 
of therapeutic transgenes can provide a synergistic effect in the vasculature and 
promote regeneration of the endothelium. 
1.3 Pathobiology of PAH 
PAH is a complex disease with a multifactorial pathobiology.  Pulmonary vascular 
proliferation, vasoconstriction, and in situ thrombosis are all involved in the 
pulmonary vascular remodelling process that underlies severe PAH.  Within the 
pulmonary arteries, vasoconstriction initiated by hypoxia, elevations in 
cytoplasmic Ca2+ or decreased voltage-gated K+ channel depolarisation, is 
recognised to play a pivotal role in increasing pulmonary vascular resistance 
(PVR) and, hence, elevated pulmonary arterial pressure (PAP) (Mandegar et.al. 
2004) (Figure 1.6).  Sustained pulmonary vasoconstriction can influence PASMC 
hypertrophy and hyperplasia (Hishikawa et al. 1994) and vascular remodelling 
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involving all components of the vascular pulmonary vascular wall (smooth muscle 
cells, endothelial cells, and fibroblasts) ensues.  Together, the 
hyperproliferative and vasoconstrictive pulmonary arteries exert an excessive 
burden on the pressure-intolerant right ventricle.  Initially, the right ventricle 
undergoes compensatory hypertrophy to accommodate increased after-load and 
to overcome the downstream pressure, however over time this leads to right 
sided heart failure which is the primary cause of mortality in PAH patients 
(Humbert et.al. 2004). 
1.3.1  Pulmonary Vasoconstriction 
Pulmonary vasoconstriction is an important contributor to the elevated PVR and 
PAP observed in PAH.  In particular, hypoxic pulmonary vasoconstriction (HPV) is 
a major determinant of PAH development.  HPV is an important intrinsic 
adaptive mechanism unique to the lung which redirects the blood flow from 
poorly ventilated areas of the lung into a better ventilated area to improve 
ventilation-perfusion matching and to maximise oxygenation (Madden et al. 
1992).  In instances of chronic obstructive pulmonary disease (COPD) and high 
altitude pulmonary oedema, sustained alveolar hypoxia drives a PAH phenotype 
(Mandegar et.al. 2004).  The mechanism by which hypoxia stimulates pulmonary 
vasoconstriction is unclear, although studies point to several possible pathways.   
1.3.1.1 Hypoxic Pulmonary Vasoconstriction and Ca2+ Homeostasis 
The extent of pulmonary vasoconstriction is dependent on the levels of cytosolic 
Ca2+ and activity of voltage-gated L-type Ca2+ channels which are regulated by 
membrane potential and Ca2+ sensitivity of the contractile apparatus (actin and 
myosin).  Smooth muscle contraction is directly triggered by a rise in cytosolic 
free Ca2+ concentration which forms a complex with calmodulin (CaM).  The 
Ca2+/CaM complex interacts with contractile proteins, actin and myosin, and 
activates myosin light chain kinase (MLCK), which in turn, phosphorylates the 
myosin light chain (MLC).  This process stimulates the activation of myosin 
ATPase to generate energy and the subsequent formation of crossbridges leading 
to smooth muscle contraction and vasoconstriction (Somlyo & Somlyo 1994) 
(Figure 1-7).  On the other hand, relaxation of smooth muscle cells is initiated 
by a decrease in intracellular Ca2+ [Ca2+]i due to Ca
2+ uptake by the sarcoplasmic 
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reticulum Ca2+-ATPase pump (SERCA) within smooth muscle cells and the Ca2+ 
extrusion by Na+-Ca2+ exchanger.  In addition, smooth muscle cell contraction is 
dependent on regulation of myosin light chain phosphatase (MLCP) activity.  The 
decreased [Ca2+]i initiates dissociation of the Ca
2+/CaM complex and the 
phosphorylated MLC is dephosphorylated by MLCP (Somlyo & Somlyo 1994) 
(Figure 1-7). 
Intracellular Ca2+ is elevated in PASMCs exposed to hypoxia (Wang et al. 2005) 
and in line with this, during acute hypoxia a biphasic contraction is reported to 
coincide with elevated levels of Ca2+ (Robertson et al. 2000) which is sustained 
during hypoxia and is reversed following exposure to normoxia (Robertson et.al. 
2000).  Depolarisation and the opening of L-type Ca2+ channels are reported to 
account for the influx of Ca2+ during hypoxia (Bakhramov et al. 1998).  Indeed, 
inhibition of these channels has been shown to attenuate hypoxia induced-
vasoconstriction in pulmonary arteries (Jin et al. 1992; Leach et al. 1994).  The 
PASMCs are proposed to be the cell type responsible for monitoring the hypoxic 
environment in the vasculature.  This is supported by the observation that HPV 
still occurs in endothelium-denuded pulmonary arteries (Marshall & Marshall 
1992) (Figure 1-8). 
1.3.1.2 Hypoxic Pulmonary Vasoconstriction and K+ homeostasis 
Voltage-gated K+ channels also play an important role in the regulation of 
vascular tone and work in concert with L-type Ca2+ channels to mediate 
contraction.  In a resting smooth muscle cell, the membrane is permeable to K+ 
and voltage-activated K+ channels allow an efflux of K+ out of the cell initiating 
membrane hyperpolarisation and the closure of voltage-gated L-type Ca2+ 
channels.  Closure of K+ channels on the other hand, leads to depolarisation and 
increased [Ca2+]i. 
At rest, the PASMC membrane is more permeable to K+, however during hypoxia 
K+ currents are inhibited resulting in depolarisation of the PASMC membrane and 
an influx of Ca2+ via L-type Ca2+ channels (Yuan et al. 1993; Yuan et al. 1998).  In 
PAH, altered activity of K+ channels is reported resulting in sustained membrane 
depolarisation.  In PASMCs, downregulation of Kv1.5 and Kv2.1 channels is 
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observed in rats with chronic hypoxia-induced PAH (Michelakis et al. 2002b) and 
Kv1.5 expression is reduced in patients with IPAH (Yuan et.al. 1998). 
1.3.1.3 Hypoxic Pulmonary Vasoconstriction and Reactive Oxygen Species 
The redox hypothesis of HPV suggests that redox-sensitive membrane Kv channels 
are decreased via adaptive mitochondrial derived reactive oxygen species (ROS). 
Generation of ROS occurs during hypoxia shifting the cellular balance toward a 
more reduced state and initiates depolarisation of the PASMC membrane and 
consequently pulmonary vascular contraction (Michelakis et al. 2002a).  NADPH-
oxidases, the enzymes that function to generate superoxide, have also been 
proposed as possible oxygen sensors of HPV.  Evidence suggests that NADPH-
oxidase is activated in response to hypoxia in PASMCs (Marshall et al. 1996) and 
that the generation of superoxide and formation of hydrogen peroxide (H2O2) 
mediate HPV in the lung (Weissmann et al. 1998).  This is confirmed by the 
ability of NADPH-oxidase inhibitors to attenuate HPV in intact lungs (Weissmann 
et al. 2000).  Whilst it is suggested the role of ROS is pivotal in HPV, their exact 
role still remains unclear as there is no consensus to whether ROS production is 
increased or decreased in hypoxia. 
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Figure 1-6: Pathophysiological processes involved in PAH development and progression. 
Vasoconstriction, vascular remodelling, and in situ thrombosis contribute to the development of and sustained elevations in pulmonary vascular resistance (PVR) 
observed in PAH leading to increases in pulmonary arterial pressure (PAP).  Cyt=cytosolic; Em= extracellular membrane; SMC=smooth muscle cell; EC=endothelial 
cell.  Adapted from (Mandegar et.al. 2004). 
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Figure 1-7: Signal transduction mechanisms underlying smooth muscle cell contraction. 
Intracellular Ca
2+
 is a major determinant of smooth muscle cell (SMC) contraction.  As free Ca
2+ 
enters the SMC it forms a complex with calmodulin (CaM).  The CaM 
complex then activates myosin light chain kinase (MLCK) which subsequently phosphorylates myosin light chain (MLC).  Myosin light chain phosphatase (MLCP) 
inactivates this complex.  This stimulates ATPase activity and initiates cross-bridging between actin and myosin and contraction.  SMC contraction is also initiated by 
inhibition of K
+
 efflux by voltage-activated K
+
 channels leading to sustained depolarisation.  Calcium channel blockers (CCBs) used in PAH treatment inhibit L-type Ca
2+
 
channels and Ca
2+
 entry thereby reducing intracellular Ca
2+
 signalling and SMC contraction. 
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Figure 1-8: Proposed mechanisms involved in hypoxic pulmonary vasoconstriction 
Hypoxia results in decreased activity and expression of Kv channel function leading to elevated intracellular K
+
 and membrane depolarization.  Increased Ca
2+
 occurs 
via influx via L-type Ca
2+
 channels.  Increased activity of receptor-operated Ca
2+
 channels (ROC) and store-operated Ca
2+
 channels further contribute to increased 
intracellular Ca
2+
.  Together, these mechanisms lead to smooth muscle cell contraction and if sustained will promote proliferation. 
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1.3.2  Pulmonary Vascular Remodelling  
Under normal conditions, the structure of the pulmonary arterial wall is 
maintained by a fine balance between proliferation and apoptosis of PASMCs, 
PAECs and fibroblasts.  In PAH this balance is disrupted, and PAH is characterised 
by intimal thickening and muscularisation of the distal, previously non-muscular 
pulmonary arteries, resulting in a narrowed lumen and subsequent impairment 
of blood flow.  This process is termed pulmonary vascular remodelling and is 
considered the hallmark in PAH (Tuder et al. 2009).  Pulmonary vascular 
remodelling involves all three cell types in the vascular wall and arises from an 
increase in proliferation combined with suppression of apoptosis (Mandegar 
et.al. 2004). 
1.3.2.1 The Role of Smooth Muscle Cells in Pulmonary Vascular 
Remodelling 
Smooth muscle cells underlie the pulmonary vascular remodelling process.  
Smooth muscle hypertrophy and hyperplasia play an integral role in intimal and 
medial thickening which is widely observed in mild/early-stage PAH (Figure 1-9).  
In addition, smooth muscle cells and fibroblasts begin to produce increased 
matrix proteins, including collagen and elastin, within the media and adventitia 
contributing to medial thickness (Jeffery & Morrell 2002).  During PAH, changes 
in the phenotype of PASMCs are also described, for example, PASMCs taken from 
PAH patients exhibit a more proliferative phenotype (Eddahibi et al. 2001).  An 
increased migratory smooth muscle cell phenotype is also described.  One 
common feature to PAH is the distal progression of smooth muscle cells into the 
normally non-muscular small peripheral pulmonary arteries resulting in 
muscularisation of the terminal portion of the pulmonary artery (MacLean et.al. 
2000).  Migration from the media to the subendothelial layer results in a layer of 
cells situated between the endothelium and the internal elastic lamina, termed 
the neointima (Yi et al. 2000).  In the neointima, the smooth muscle cell 
phenotype alters from contractile to synthetic and secretes excessive 
extracellular matrix proteins contributing significantly to increased vascular 
resistance (Olschewski et al. 2001). 
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1.3.2.2 The Role of Endothelial Cells in Pulmonary Vascular Remodelling 
In severe and end-stage PAH, another important form of vascular remodelling is 
observed involving disorganised proliferation and apoptosis of endothelial cells 
leading to formation of ‘plexiform lesions’ (Cool et al. 1997; Tuder et al. 1994).  
Plexiform lesions (Figure 1-9) are typically seen arising from smaller resistance 
arteries (200-400µm) distal to the bifurcation site and are described as complex, 
glomeruloid-like vascular structures (Cool et al. 2005; Sakao et al. 2009).  They 
appear to have a complex inflammatory microenvironment distinct from 
remodeled arteries in PAH lungs.  The continuous proliferation and sprouting of 
vascular channels is associated with up-regulation of hypoxia and shear stress-
induced angiogenic mediators, such as HIF1a, VEGF-α and TGF-β1 (Jonigk et al. 
2011).  In addition, loss of tumour suppressor gene peroxisome proliferator-
activated receptor-γ (PPAR-γ), is reported in plexiform lesions of PAH patients 
(Ameshima et al. 2003).  PPAR-γ is antiproliferative and anti-inflammatory 
(Jiang et al. 1998) and has previously been shown to mediate an important 
protective role in experimental PAH (Hansmann et al. 2008).  Decreased 
production of vasodilators (Tuder et.al. 1999) and increased production of 
vasoconstrictors (Giaid et al. 1993) is also described in these plexiform lesions.  
Regardless of the histopathologic subtype involved, pulmonary vascular 
remodelling always results in obstruction of the lumen and the impairment of 
blood flow leading to increased vascular resistance. 
Importantly experimental animal models of PAH fail to recapitulate the severe 
vascular phenotype in PAH with neointimal formation and plexiform lesions.  The 
role plexiform lesions play in the pathogenesis of human PAH is therefore 
controversial.  However, the discovery of novel animal models of PAH appears to 
show endothelial cell proliferation, luminal obliteration and severe PAH as a 
result of plexiform lesions and neointimal changes.  For example, S100A4/Mts1 
protein over-expressing mice (Dempsie et al. 2011; Greenway et al. 2004), 
schistosomiasis murine model (Crosby et al. 2010) and administration of VEGF 
receptor antagonist Sugen 5416 + hypoxia rat model (Abe et al. 2010).  Since 
these lesions appear to have morphology similar to human plexiform lesions, a 
better understanding of human pathology is achievable. 
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1.3.2.3 Downstream Signalling Involved in Vascular Remodelling 
Akt, or protein kinase B, is a serine/threonine-specific protein kinase that plays 
a critical role in cell apoptosis, proliferation and migration.  In addition, Akt 
signalling is a critical mediator of cardiac hypertrophy, survival and stress.  It is 
recognised that the survival signal mediated by various growth factors and 
cytokines involves phosphatidylinositol 3’-kinase (PI3K)/Akt signal transduction 
pathway.  Vascular endothelial growth factor (VEGF) and platelet derived growth 
factor (PDGF) can induce PI3K activity in aortic endothelial cells (Guo et al. 
1995; Xia et al. 1996) and PASMCs (Goncharova et al. 2002).  Recent evidence 
has also highlighted an important role of increased thrombin-induced Akt 
phosphorylation in PASMCs in IPAH and CTEPH resulting in increased proliferation 
and leading to medial hypertrophy and vascular remodelling (Ogawa et al. 2013).  
Interestingly, Akt phosphorylation is also regulated by estrogen.  Reduced Akt 
signal transduction by estrogen reverses remodeling secondary to PH (Nadadur et 
al. 2012) and significantly reduces Akt signalling during right heart failure in PH 
(Nadadur et al. 2012). 
The mitogen-activated protein kinase (MAPK)/ extracellular signal-related kinase 
(ERK) pathway is also crucially involved in vascular remodeling and cardiac 
hypertrophy.  MAPK cascades are highly conserved signal transduction pathways 
and are believed to regulate cell and myocyte growth in response to 
developmental signals or physiologic and pathologic stimuli (Meng et al. 2011).  
Previous studies have demonstrated that ERK and p38 MAPK expression are 
increased in cardiac hypertrophy (Altamirano et al. 2009; Streicher et al. 2010).  
In the pulmonary vasculature, MAPK/ERK also plays a central role in smooth 
muscle cells in response to mechanical, hypoxic and growth-factor induced 
stimuli, in particular promoting PASMC growth (Mandegar et al. 2004).  Estrogen 
is also involved in regulation of ERK and leads to a decline in ERK1 
phosphorylation in right heart failure PH (Nadadur et al. 2012).  Collectively, 
this shows that PI3K/Akt and MAPK/ERK pathways play a pivotal role in 
regulating PASMC proliferation and migration and cardiac hypertrophy.        
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Figure 1-9: Histopathological changes observed in pulmonary vascular remodelling in 
human PAH. 
Top Left, A: a normal pulmonary artery.  Top Right, B: smooth muscle cell hypertrophy and 
proliferation leading to medial hyperplasia typically observed in mild/moderate human PAH.  
Bottom Left, C: adventitial fibrosis observed in moderate PAH.  Bottom Right, D: a plexiform lesion 
characterised by lumen obliteration observed in severe/end-stage PAH.  Adapted from (Cool et.al. 
2005). 
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1.4  Genetic Basis of Pulmonary Arterial Hypertension 
1.4.1  Bone-Morphogenetic Protein Receptor-Type 2  
PAH is a disease with an underlying genetic susceptibility.  The term heritable 
PAH (HPAH) has recently been adopted to account for PAH in families in which a 
specific genetic mutation infers susceptibility to disease development.  The 
inheritance pattern in HPAH is described as autosomal dominant implying each 
child of an affected individual is at a 50% risk of inheriting the mutant allele 
(Thompson & McRae 1970).  Like IPAH, the development of HPAH has a marked 
female predominance and in addition exhibits a genetic anticipation.  That is, 
patients with a HPAH typically present at earlier ages (Loyd et al. 1995) and are 
more likely to be female.  A candidate gene approach lead to the discovery of 
the first gene associated with HPAH.  A marker for HPAH localised on 
chromosome 2q31-32 (Nichols et al. 1997) was identified as a receptor in the 
TGF-β superfamily, bone-morphogenetic protein receptor-type 2 (BMPR2) (Lane 
et al. 2000).  Mutations in BMPR2 are responsible for approximately 80% of HPAH 
cases (Morrell 2010).  However, an incomplete penetrance is described as only 
10-20% of mutation carriers develop PAH (Newman et al. 2004).  This strongly 
suggests the presence of modifying genetic or environmental factors that infer 
an increased or decreased risk.  Indeed, alterations in estrogen metabolism and 
estrogen metabolites are associated with disease penetrance in female patients 
with a BMPR2 mutation (Austin et al. 2009). 
Although BMPR2 mutations and subsequent dysfunctional TGF-β signalling 
represent the majority of HPAH cases, alternative pathogenic mutations in the 
TGF-β family underlie PAH susceptibility.  Particularly mutations in activin 
receptor-like kinase 1 (ALK-1) are observed in hemorrhagic telangiectasia (HHT) 
and individuals present with PAH that is clinically and histopathologically 
indistinguishable from other forms of HPAH (Machado et al. 2009).  Patients with 
ALK-1 mutations, and therefore defective Smad signalling, typically have shorter 
survival times compared to BMPR2 carriers and non-carriers (Girerd et al. 2010). 
1.4.2 Normal BMP/BMPR2 and TGF-β Signalling 
BMPs are the largest group of cytokines within the TGF-β superfamily.  They are 
primarily involved in regulating growth, differentiation and apoptosis in smooth 
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muscle cells.  When co-expressed with type I BMP receptor, BMPR2 has high 
affinity for ligands BMP-2, -4, and -7.  Receptor-ligand binding stimulates 
phosphorylation of Smad1, -5 and -8, which in canonical signalling, then 
associate with Smad-4 in the cytoplasm to translocate to the nucleus (Morrell et 
al. 2009) (Figure 1-10).  The co-Smad complex is involved in regulation of 
transcription of Smad-responsive genes, for example the inhibitor of DNA binding 
family of proteins (Ids) (Miyazono & Miyazawa 2002).  Id proteins are basic helix-
loop-helix transcription factors that lack a DNA binding domain.  Four members 
of the Id family (Id1-4) have been identified in mammalian cells.  They are 
encoded by separate genes and demonstrate different expression patterns, 
hence they have various functions in several different organs.  For example, Id2 
expression is high in immune cells and developing epithelial cells, whereas Id1 
and Id3 are expressed in developing lung mesenchyme (Rudarakanchana et al. 
2002).  Id1 and Id3 are now known to be the most abundantly expressed Id 
transcripts in PASMCs and are regulated by BMP-4 and -6 (Yang et al. 2013).  Id 
signalling and other downstream signalling complexes from Smad are switched 
off by Smad ubiquitination and regulatory factors (Smurfs) (Shi et al. 2004). 
1.4.3 Consequences of Dysfunctional BMP/BMPR2 and TGF-β 
Signalling 
A critical reduction in BMPR2 expression and function due to mutations as 
observed in HPAH, leads to deficient Smad signalling.  The growth inhibitory 
effects of BMPs have been shown to be Smad1 dependent (Yang et al. 2005).  In 
particular, a loss of signalling by the Smad1/5 pathway in response to BMP2 and 
BMP4 is described following BMPR2 mutation and therefore a reduction in smooth 
muscle cell apoptosis (Yu et al. 2005).  Knockdown of BMPR2 with siRNA has also 
been demonstrated to increase the susceptibility of pulmonary artery 
endothelial cells to apoptosis (Teichert-Kuliszewska et al. 2006).  Additionally, in 
experimental PH, heterozygous BMPR2+/- mice when chronically infused with 
serotonin, develop more severe PH compared with wildtype littermates (Long et 
al. 2006).  Thus BMPR2 dysfunction also increases the susceptibility to PH when 
exposed to other environmental stimuli.  In the presence of BMPR2 mutations, 
the disruption of the normal Smad signalling pathway can also lead to activation 
of alternate p38 mitogen-activated protein kinase/extracellular signal-related 
kinase (MAPK/ERK) pathways which lead to smooth muscle cell proliferation and 
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inhibition of apoptosis (Yu et al. 2005).  It has been identified that Id1 and Id3 
induction is dependent on BMPR2 as mutations in BMPR2 reduce the BMP-4 and -6 
stimulated inductions of Id1 and Id3 in PASMCs (Yang et al, 2013).  Recently it 
has been shown that agents enhancing BMP/Smad/Id signalling are effective at 
restoring the growth suppressive effects of BMP in BMPR2 mutant cells (Yang et 
al. 2010; Yang et al. 2013). 
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Figure 1-10: BMPR2 and downstream signalling cascade.  When co-expressed with type 1 BMP receptor (BMPR1), BMPR2 has high affinity for ligands BMP-2, -4 
and -7.  In canonical signalling, ligand-receptor activation stimulates phosphorylation of Smad-1, -5 and -8 and this complex further dimerises with Smad-4 to form a 
co-Smad.  This co-Smad complex then translocates to the nucleus and regulates transcription of genes involved in growth, differentiation and apoptosis.  Dysfunctional 
BMPR2 mutations in HPAH can lead to activation of an alternate downstream signalling pathway and activation of mitogen activated protein kinases (MAPK) and as a 
consequence smooth muscle cell proliferation and inhibition of apoptosis.   
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1.4.4  Serotonin Transporter 
Additional genes also account for HPAH cases.  In particular polymorphisms in 
the serotonin transporter (SERT) may influence development of PAH in the 
presence or absence of BMPR2 mutations.  SERT is encoded by the solute carrier 
family 6 member 4 (SLC6A4) gene located on chromosome 17 position 17q11.2.  
Long (L) and short (S) functional polymorphisms are found within the promoter 
region of SERT.  The S allele results in reduced SLC6A4 transcription and 
therefore reduced SERT protein expression whereas the L allele is associated 
with a two- to threefold higher rate of gene transcription (Lesch et al. 1996).  
Indeed, the LL allele SERT polymorphism has been identified in a small cohort of 
IPAH patients (Eddahibi et.al. 2001).  SERT plays an integral role in development 
of both experimental and human PAH where it is responsible for mitogenic and 
vasoconstrictive actions of serotonin (Eddahibi et al. 1999; MacLean et al. 1996).  
Mice over-expressing the human SERT gene construct (SERT+ mice) develop 
severe PAH (MacLean et al. 2004).  In line with this, mice with targeted over-
expression of SERT in the PASMCs develop PAH (Guignabert et al. 2006), whilst 
mice devoid of the SERT gene are protected against the development of hypoxia-
induced PAH (Eddahibi et al. 2000). 
1.5  Serotonin Biosynthesis and Metabolism 
Serotonin (5-hydroxytryptamine, 5-HT) was identified chemically in 1948 
following its isolation from serum, originating in platelets (RAPPORT et al. 1948).  
Localisation of serotonin was subsequently found as a major neurotransmitter in 
the central nervous system and in the periphery in the gastrointestinal tract.  
The intestinal enetrochromaffin cells are the main site of serotonin synthesis 
with over 80% of peripheral synthesis originating in the gastrointestinal tract.  
The remaining 20% is synthesised in other cell types including serotonergic 
neurons and PAECs (Hoyer et al. 2002).  The highest concentration of serotonin 
is found in the platelets which act as a store for up to 99% of total peripheral 
serotonin via the serotonin transporter (SERT).  Although circulating serotonin is 
very low (i.e. <1nM) it controls many important physiological actions, in the 
cardiovascular system (Berger et al. 2009), the brain (e.g. control of respiration, 
memory, nociception and behaviour) and the intestine (Hoyer et.al. 2002). 
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Endogenous serotonin arises from biosynthesis from the precursor amino acid 
tryptophan (Figure 1-11).  Decarboxylation of tryptophan is catalysed by the 
enzyme tryptophan hydroxylase (TPH) to produce 5-hydroxytryptophan which 
undergoes further decarboxylation by the aromatic L-amino acid decarboxylase 
finally producing serotonin.  TPH is the rate-limiting enzyme in this two step 
biosynthetic pathway.  Currently, two genes which encode for TPH have been 
identified: Tph1 and Tph2 (Walther & Bader 2003).  These Tph isoforms share a 
71% sequence homology.  Despite being functionally identical, TPH2 is expressed 
exclusively in the brain whereas TPH1 is responsible for serotonin synthesis in 
the periphery (Nakamura & Hasegawa 2007). 
Serotonin degradation and inactivation occurs rapidly through oxidative 
deamination catalysed by the enzyme monoamine oxidase (MAO) in the liver and 
lung.  MAO exists in two isoforms, MAO-A and MAO-B, encoded by different 
genes.  MAO-A preferentially degrades serotonin to produce 5-hydroxyindol-
acetaldehyde which is subsequently oxidised to 5-hydroxyindole acetic acid (5-
HIAA) by aldehyde dehydrogenase.  5HIAA is the primary metabolite of serotonin 
and is excreted in the urine. 
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Figure 1-11: Serotonin Biosynthesis and Metabolism. 
Serotonin (5-HT) is synthesised from amino acid precursor tryptophan.  Conversion to 5-hydroxy-L-
tryptophan is catalysed by the rate-limiting action of tryptophan hydroxylase (TPH).  Subsequent 
conversion by non-specific  decarboxylase enzymes produce serotonin.  Serotonin metabolism by 
both monoamine oxidase and aldehyde dehydrogenase produces the primary metabolite 5-
hydroxyindoleacetic acid (5-HIAA).  Adapted from (Druce et al. 2009). 
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1.6  Physiological Functions of Serotonin 
Under normal circumstances, the lung vascular bed in not exposed to excessive 
serotonin levels.  However, there is evidence during PAH that there is decreased 
serotonin storage within platelets leading to enhanced plasma concentration of 
‘free’ serotonin (Herve et al. 1995).  Accumulating evidence exists describing a 
pivotal role for serotonin in development of experimental and human PAH 
(MacLean & Dempsie 2010).  Within the pulmonary circulation, serotonin 
signalling is mediated via three distinct pathway components through which 
serotonin may facilitate PAH development.  These are TPH-1, SERT and the 5-HT 
receptors, and the downstream signalling pathways activated by SERT and 5-HT 
receptors. 
1.6.1  Tryptophan Hydroxylase-1 
Peripheral synthesis of serotonin is initiated by the rate-limiting enzyme 
tryptophan hydroxylase-1 (TPH-1).  Although TPH1 is predominantly expressed in 
the intestinal enterochromaffin cells, local serotonin synthesis within the PAECs 
mediating paracrine effects are also considered important in the periphery.  
Local serotonin production in the PAECs is believed to facilitate a mitogenic and 
vasoconstrictive microenvironment in which PASMCs promote hyperplasia.  
Indeed, it has recently been shown that expression of the Tph1 gene is increased 
in lungs and PAECs from patients with IPAH (Eddahibi et al. 2006). 
Experimentally, development of chronic hypoxia-induced PH and 
dexfenfluramine-induced PAH is ablated in Tph1-/- mice devoid of peripheral 
serotonin synthesis supporting the importance of serotonin in disease 
development (Dempsie et al. 2008a; Morecroft et al. 2007).  Previously, in 
unpublished work, we have demonstrated that there is low TPH1 expression in 
PAECS from normoxic mice, however after exposure to hypoxia TPH1 is 
abundantly expressed suggesting that hypoxia induces TPH1 expression and de 
novo synthesis of serotonin.  Hypoxia and mechanical stretch have previously 
been shown to increase TPH1 expression in rabbit lung (Pan et al. 2006).  This is 
consistent with the observation that serotonin is overproduced in lungs and 
PAECs from patients with IPAH (Eddahibi et.al. 2006).  Together, this evidence 
 67 
 
indicates that peripheral serotonin plays an essential role in the development of 
PAH. 
1.6.2  5-HT Receptors 
The actions of serotonin in the periphery are numerous and complex.  This arises 
from the vast number of 5-HT receptor subtypes.  To date, there are 14 known 
structurally distinct receptors categorized into seven major subtypes (5-HT1-7) 
(Figure 1-12).  These are defined by their structure and coupling to downstream 
signal transduction pathways (Alexander et al. 2006).  Multiple splice variants 
also exist for certain receptors producing several isoforms for one receptor 
subtype, for example 5-HT1 comprises of 5-HT1A, 5-HT1B, 5-HT1D.  With the 
exception of the 5-HT3 receptor, which is a ligand-gated ion channel, 5-HT 
receptors are members of the G-protein-coupled receptor (GPCRs) superfamily 
(Hoyer et.al. 2002). 
The 5-HT GPCRs all share a similar structural homology.  They contain an 
extracellular N-terminus domain responsible for ligand binding, seven 
transmembrane α-helices, and an intracellular C-terminal domain.  Ligand 
binding initiates activation of the associated G-protein.  G-proteins exist as 
heterotrimeric structures composed of α, β, and γ subunits.  These are typically 
classified by the Gα subunit into four classes of subunits distinguished from each 
other by their sequence homology.  These include: Gs, Gi, Gq and G12/13 (Table 1-
3).  Each respective G-protein activates its own unique signal transduction 
pathway.  The effector for both the Gs and Gi pathways is the cyclic-adenosine 
monophosphate (cAMP) generating enzyme adenylate cyclase (AC).  In the Gs 
class, AC is activated and ATP catalyses conversion of cAMP, which in turn, 
activates cAMP-dependent protein kinase (PKA).  In contrast, interaction with 
the Gi subunit inhibits AC activation.  The effectors of the Gq and G12/13 subunits 
are phospholipase Cβ (PLCβ) and small G-proteins, respectively.  Typically, when 
the receptor is inactive, the receptor remains bound to an also inactive Gα-
subunit bound to guanosine diphosphate (GDP).  Upon ligand activation, a 
conformational change promotes exchange of a molecule of GDP for guanosine 
triphosphate (GTP).  In turn, G-protein activation results in dissociation of the 
Gα subunit from the Gβγ complex, and both entities activate downstream 
signalling pathways. 
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1.6.2.1  5-HT1 Receptor Subtypes 
The 5-HT1 receptor class comprises of five receptor subtypes: 5-HT1A, 5-HT1B, 5-
HT1D, 5-HT1E and 5-HT1F.  In humans, these receptors share 40-63% sequence 
homology.  The latter two subtypes are represented in lower case as their 
physiological role remains to be determined.  The 5-HT1 receptors are all 
coupled to the Gi protein and therefore stimulation of this receptor results in 
inhibition of AC and cAMP production.  Expression of all 5-HT1 receptors has been 
identified in both the CNS and the periphery and the functional roles of 5-HT1A, 
5-HT1B and 5-HT1D are well characterised in various tissues.  Specifically in the 
cardiovascular system, 5-HT1B and 5-HT1D receptors predominate (Hoyer et.al. 
2002). 
The 5-HT1B receptor is well characterised in the pulmonary circulation in both 
experimental and human PAH.  Experimentally, the 5-HT1B receptor has been 
shown to be involved in the development of chronic hypoxia induced-PAH, as 
well as in the contractile responses mediated by serotonin in the pulmonary 
arteries (Keegan et al. 2001).  Increased expression of 5-HT1B in pulmonary 
arteries from monocrotaline-treated rats also supports a role for 5-HT1B in PAH 
development (Wang et al. 2001).  Indeed, 5-HT1B receptor knockout mice exhibit 
a reduction in right ventricular systolic pressure (RVSP) and pulmonary vascular 
remodelling following exposure to hypoxia (Keegan et.al. 2001).  In addition, in 
small resistance pulmonary arteries from fawn-hooded rats which develop 
exaggerated hypoxia-induced PAH, serotonin-induced vasoconstriction is 
inhibited by the 5-HT1B selective antagonist SB224289 (Morecroft et al. 2005). 
In humans, 5-HT1B is implicated in both serotonin-induced pulmonary arterial 
vasoconstriction in small and large pulmonary arteries (MacLean 1999; Morecroft 
et al. 1999) and also in PASMC proliferation.  Moreover, pulmonary arteries from 
PAH patients show elevated expression of the 5-HT1B receptor (Launay et al. 
2002).  Evidence for a functional role of 5-HT1 in human pulmonary arteries 
originated from studies which described a vasoconstrictive property of 
sumatriptan (a 5-HT1B/D receptor agonist) (Macintyre et al. 1992).  Furthermore, 
the serotonin-induced vasoconstriction in these arteries was indeed inhibited by 
the 5-HT1B/D antagonist, GR55562, which supports 5-HT1B/D mediated 
vasoconstriction (MacLean et.al. 1996).  In addition, in PAH lungs, hypoxia 
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reduced cGMP and eNOS levels and raised vascular tone markedly potentiate 5-
HT1B mediated responses in pulmonary arteries (MacLean 1999).  It has also 
recently been demonstrated that the 5-HT1B receptor can mediate proliferation 
in PASMCs (Lawrie et al. 2005).  In the systemic circulation, serotonin mediates 
vasoconstriction via 5-HT2A receptor (Hoyer et al. 1994), therefore the 5-HT1B 
receptor could be a pulmonary selective target for PAH therapy. 
Functional interactions exist between the 5-HT1B receptors and SERT.  In the 
pulmonary circulation, this results in heightened vasoconstriction and 
proliferation.  Indeed, dual inhibition of both the 5-HT1B receptors and SERT is 
more effective in preventing hypoxia-induced PH in mice than inhibition of SERT 
alone implicating a synergistic effect between the receptor and transporter of 5-
HT (Morecroft et al. 2010).  In addition, dual blockade of both 5-HT1B and SERT is 
more effective at inhibiting serotonin-induced proliferation in both non-PAH and 
IPAH PASMCs (Morecroft et.al. 2010).  The interaction arises from stimulation of 
the 5-HT1B receptor which results in activation of rho small G protein and its 
downstream mediator ROCK.  This in turn facilitates the nuclear translocation of 
SERT-induced phosphorylated ERK1/2 and transcriptional regulation of 
proliferative genes including GATA-4 and cyclin D1 (Liu et al. 2004). 
1.6.2.2  5-HT2 Receptor Subtypes 
The 5-HT2 class of receptor share 46-50% sequence homology and couple 
preferentially to Gq, activating PLC to increase the formation of inositol 1,4,5 
trisphosphate (IP3) and 1,2-diacylglycerol (DAG).  In turn, these second 
messengers increase cytosolic Ca2+ (Hoyer et.al. 2002).  The 5-HT2A receptor is 
widely expressed in the CNS and periphery, and has been implicated in 
vasoconstriction and proliferation in PASMCs in PAH (Dempsie et al. 2008b).  5-
HT2A receptors are also demonstrated to be involved in platelet aggregation and 
thrombosis (Nagatomo et al. 2004). 
In experimental PAH, antagonism of 5-HT2A inhibits monocrotaline-induced PAH 
in mice (Hironaka et al. 2003), and also inhibits serotonin-induced pulmonary 
vasoconstriction in vessels from both normoxic and hypoxic rats (Morecroft et.al. 
2005).  In isolated rat PASMCs, activation of 5-HT2A receptors has also been 
shown to directly inhibit Kv1.5 channels, which results in decreased K
+ cellular 
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efflux and depolarisation mediating vasoconstriction (Cogolludo et al. 2006).  
Moreover, serotonin-induced proliferation in rat pulmonary arterial fibroblasts is 
5-HT2A receptor mediated (Welsh et al. 2004). 
In humans, the 5-HT2A receptor is present in human pulmonary arteries, although 
it only contributes to vasoconstriction when serotonin levels are much higher 
than the physiological range (Morecroft et.al. 1999).  Ketanserin, a selective 5-
HT2A receptor antagonist is a proven therapy for PAH, however it’s clinical 
effectiveness is limited by the expression of 5-HT2A in systemic arteries where it 
also mediates serotonin-induced vasoconstriction (Dempsie et.al. 2008a; 
Frishman et al. 1995).  In one clinical trial, ketanserin failed to improve 
pulmonary haemodynamics in either primary or secondary PH (Frishman et.al. 
1995). 
The 5-HT2B receptor has also been identified to mediate multiple effects in the 
pulmonary vasculature.  In vivo, the development of hypoxia-induced PH is 
inhibited in mice deficient for the 5-HT2B receptor, and similarly in mice treated 
with the 5-HT2B selective antagonist RS-127445 (Launay et.al. 2002).  In addition, 
this receptor is regarded to play a key role in regulating plasma serotonin levels 
in mice (Callebert et al. 2006).  The 5-HT2B receptor is also associated with 
promoting cell cycle progression in fibroblasts (Nebigil et al. 2000) and cell 
survival in cardiomyocytes (Nebigil et al. 2003) suggesting it may contribute to 
remodelling and cardiac hypertrophy.  Albeit the 5-HT2B receptor is up-regulated 
in pulmonary arteries removed from pulmonary hypertensive patients, loss of 5-
HT2B receptor function appears to predispose to dexfenfluramine-induced PAH in 
humans (Blanpain et al. 2003). 
1.6.2.3  Additional 5-HT Receptor Subtypes 
In addition to the well defined effects of 5-HT1 and 5-HT2 receptors, the 
expression of additional 5-HT receptors has also been observed in the pulmonary 
circulation.  mRNA transcripts for the 5-HT1A, 5-HT1D, 5-HT3A, 5-HT3B, 5-HT4, 5-
HT6, and 5-HT7 receptors have been identified in rabbit pulmonary arteries 
(Molderings et al. 2006).  Multiple physiological functions for these receptor 
subtypes exist in the periphery; however they appear to play a minor role in the 
receptor-dependent effects of serotonin in the pulmonary circulation.  The 
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serotonin-receptor mediated effect in PAH are assumed to be driven via 5-HT1B, 
5-HT2A and 5-HT2B. 
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Figure 1-12: Classification of 5-HT receptor subtypes. 
Those highlighted in red have been identified to mediate serotonin-induced effects in experimental 
and human PAH.  The physiological role of 5-HT receptors -5 and -6 in pulmonary hypertension is 
undetermined. 
 
Table 1-3: 5-HT receptor subtype signalling pathways. 
All 5-HT receptors are G-protein-coupled receptors (GPCRs) with the exception of 5-HT3 which is 
a ligand gated ion channel.  Activation of GPCRs activates downstream intracellular second 
messenger cascades. 
 
5-HT1
5-HT2
5-HT3
5-HT4
5-HT5
5-HT6
5-HT7
Gi/o
Gq/11
Ligand-gated  Na+ and K+ cation channel
Gs
Gi/o
Gs
Gs
cAMP
IP3 and DAG
Depolarisation
cAMP
cAMP
cAMP
cAMP
Receptor Type Mechanism
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1.6.3  Serotonin Transporter 
1.6.3.1 Structure 
The serotonin transporter (SERT) is encoded by a single gene located on 
chromosome 17q11.2.  Transcriptional regulation and function of SERT is 
controlled by a repetitive element of varying length in the promoter region of 
the gene (Ramamoorthy et al. 1998).  The alleles are commonly composed of 
either 14 short (S) or 16 long (L) repeated elements.  The L allele is associated 
with a two-to threefold higher rate of SERT gene transcription and increased 
mRNA expression, protein expression and functional activity (Lesch et.al. 1996).  
Structurally, SERT consists of an intracellular N terminus domain, 12 
transmembrane domains (6 extracellular; 5 cytoplasmic loops) and an 
intracellular C-terminus (Torres et al. 2003) (Figure 1-13). 
1.6.3.2 Function 
SERT operates as a Na+-dependent transporter, utilising the Na+ concentration 
gradient to facilitate serotonin transport across the membrane (Torres et.al. 
2003).  Binding of Na+, Cl- and serotonin induces a conformational change in the 
transporter allowing exposure of the serotonin binding site to the opposite side 
of the membrane and thus transport of substrate and ions.  Specifically the 
aspartic acid residue (D98) situated at transmembrane domain 1 (TMD1) is 
essential for serotonin recognition (Nelson 1998).  Inactivation of SERT is 
mediated by binding to an intracellular K+ via an active cysteine residue located 
on TMD3, which is consequently transported outside the cell.  Typically, 
serotonin is transported into the cell via SERT and this direction of transport is 
energetically unfavourable (net loss of K+).  To compensate, the Na+/K+-ATPase-
mediated continuous influx of K+ coupled with the continuous efflux of Na+ acts 
as an equilibrator to maintain the transmembrane concentration gradient. 
SERT activity can also be regulated via pre- and post-translational modifications.  
Allelic variation is responsible for pre-translational modification leading to 
altered expression and activity of SERT as discussed earlier.  On the other hand, 
post-translational modifications can be mediated by protein kinase C (PKC), 
protein phosphatase 2A (PP2A) and p38 (Ramamoorthy et.al. 1998). Multiple 
serine and threonine phosphorylation sites have been located on the cytoplasmic 
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domains responsible for SERT expression and trafficking from the cell 
membrane.  Activation of PKC has been shown to phosphorylate SERT in a Ca2+-
dependent manner, resulting in internalisation and decreased activity.  
Conversely, PPA2 maintains higher levels of SERT as its inhibition results in 
increased SERT membrane sequestration.  On the other hand, the mitogen 
activated protein kinase (MAPK) p38 regulates the activity in a manner distinct 
from PKC by regulating the delivery of SERT to the membrane and reducing SERT 
expression (Samuvel et al. 2005).  Moreover, it is observed that serotonin can 
also directly decrease SERT phosphorylation (Ramamoorthy et.al. 1998).  This 
negative feedback mechanism may act to prevent the internalisation of SERT in 
circumstances where extracellular serotonin levels are enhanced.  Together, 
these studies highlight the importance of SERT regulation on expression and 
function. 
 
 75 
 
 
NH2
COOH
Plasma 
Membrane
Extracellular
Intracellular
Ser559
Ser13
Thr276
Glycosylation Site
I II III IV V VI VII VIII IX X XI XII
 
Figure 1-13: Structure of the Serotonin Transporter. 
The serotonin transporter exists as an intracellular N-terminus, 12 transmembrane domains and an 
intracellular C-terminus.  The serotonin transporter structure also contains several sites that 
undergo post-translational modification, shown here in red. 
 
 76 
 
1.7  Serotonin Hypothesis of PAH 
The ‘serotonin hypothesis’ of PAH arose in the 1960s when an ‘epidemic’ of PAH 
was reported in women taking the appetite suppressant drug, aminorex.  In fact, 
aminorex was associated with a >30 fold increased incidence of PAH (Abenhaim 
et al. 1996; Kramer & Lane 1998).  In the 1980s, the new generation of 
anorexigens, the fenfluramines, were also found to be associated with PAH.  The 
anorexigens and fenfluramines were later identified to be indirect serotonergic 
agonists evoking release of serotonin by acting as SERT substrates (Rothman et 
al. 1999).  Following the observation from a multicentre study that the incidence 
of PAH had a strong correlation with these appetite suppressant pills, there was 
a complete withdrawal of all aminorex/fenfluramine-based anorexigens for 
clinical use in obesity. 
Both aminorex and fenfluramine are amphetamine-like drugs.  They influence 
serotonin signalling by interacting with SERT.  Inside the cell, these substrates 
compete with monoamines for vesicular sequestration via the vesicular 
monoamine transporter (VMAT).  Once inside the cell they subsequently disrupt 
vesicular monoamine storage and promote serotonin release (Rothman et.al. 
1999).  Often the fenfluramines were co-administered with phentermine (‘fen-
phen’) which is also a SERT substrate and MAO inhibitor.  Combined, these 
treatments potentiated accumulation of plasma serotonin via increased 
serotonin release and decreased metabolism.  These observations formed the 
basis of the ‘serotonin hypothesis’. 
The ‘serotonin hypothesis’ was consistent with reports based on elevated 
circulating levels of serotonin in PAH patients and individuals with platelet 
storage disorders who also appear susceptible to PAH (Herve et al. 1990; Herve 
et.al. 1995).  However, controversy in the ‘serotonin hypothesis’ was highlighted 
following the observation that serotonin levels were not necessarily elevated 
with fenfluramine treatment.  The ‘fen-phen’ combination was associated with 
decreases in plasma serotonin levels in humans (Rothman & Baumann 2002) and 
patients receiving fenfluramines had plasma serotonin levels within the normal 
physiological range (Kawut et al. 2006).  This converging evidence suggests that 
elevated plasma serotonin levels are not essential in the development of 
anorexigen-induced PAH.  Perhaps serotonin concentrations in local 
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microenvironments surrounding PASMCs and PAECs may be more indicative of 
susceptibility to anorexigen-induced PAH. 
Experimentally the ‘serotonin hypothesis’ has been supported.  It has been 
shown previously that dexfenfluramine-induced PAH is evident in wildtype mice 
although this effect is ablated in Tph1-/- mice.  This definitively shows that 
dexfenfluramine mediates PAH via a peripheral serotonergic mechanism 
(Dempsie & MacLean 2008).  Dexfenfluramine also promotes development of PAH 
in rats by potentiating acute hypoxic pulmonary vasoconstriction (Eddahibi et al. 
1998).  However, the exact role of the fenfluramines in PAH remains obscure as 
dexfenfluramine has also been shown to protect against the development of 
both hypoxia- and monocrotaline-induced PAH (Rochefort et al. 2006). 
Non-serotonergic mechanisms have also been reported for fenfluramines in PAH.  
For example, the fenfluramine, dexfenfluramine, has been reported to directly 
inhibit K+ channels (Weir et al. 1996) and increase intracellular Ca2+ (Reeve et al. 
1999) which act to promote vasoconstriction and proliferation.  In addition, 
metabolism of dexfenfluramine produces the metabolite nordexfenfluramine 
which exhibits agonistic activity at 5-HT2A, 5-HT2B, and 5-HT2C receptors 
(Rothman & Baumann 2002).  The roles of the 5-HT2A and 5-HT2B receptors in 
PAH were described previously. 
1.8  Serotonin Transporter in PAH 
The SERT is particularly highly expressed in both platelets and lungs.  Serotonin 
mediates its effects by binding to cell surface serotonin receptors, which initiate 
intracellular signalling, or it can be transported into the cell via SERT (Figure 1-
14).  In both experimental and human PAH, SERT is proposed to play a key role 
in disease pathogenesis.  There is evidence suggesting a link between SERT 
polymorphisms with the development of PAH.  In one report, the L allele variant 
was found to be more prevalent in the homozygous form in 65% of IPAH patients 
associated with increased expression and activity of SERT, compared to 27% in 
controls (Eddahibi et.al. 2001).  Additionally, the LL genotype is observed in 56% 
of patients with chronic obstructive pulmonary disease associated with more 
severe PAH (Eddahibi et al. 2003).  Patients with this polymorphism appear to 
have an earlier age of diagnosis and/or shorter survival rate in IPAH and HPAH 
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compared to those with an S-allelic polymorphism.  Interestingly in HPAH, an 
interaction between SERT polymorphisms and BMPR2 mutations is also proposed 
determining susceptibility to PAH (Willers et al. 2006).  Ubiquitous SERT over-
expression and/or activity are observed in the pulmonary arteries and lungs from 
patients with both IPAH and HPAH, and secondary PAH (Eddahibi et.al. 2001).  
Furthermore, PASMCs derived from IPAH patients exhibit an exaggerated 
proliferative phenotype in response to serotonin or serum dependent on SERT 
activity (Eddahibi et.al. 2006).  Serotonin-induced proliferation in PASMCs 
involves SERT-dependent generation of reactive oxygen species (ROS), activation 
of the extra-cellular regulated kinase (ERK) and the RhoA/ROCK pathway (Liu 
et.al. 2004; MacLean & Dempsie 2010).  Once inside the nucleus, pERK1/2 can 
further phosphorylate mitogenic transcription factors such as GATA-4 and cyclin 
D1.  The serotonin-induced proliferation in PAFs is also mediated via SERT, as 
citalopram can successfully block these effects (Welsh et.al. 2004).  Hence, 
evidence suggests that internalisation of serotonin through SERT is essential for 
the mitogenic properties of serotonin in PASMCs and PAFs.  On the other hand, 
SERT expression is low in PAECs and is believed not to be involved in the 
formation of plexiform lesions observed in severe/end-stage PAH (Eddahibi et.al. 
2001). 
In experimental PAH an increase in SERT mRNA levels has also been observed in 
lungs from rats exposed to chronic hypoxia localised to newly remodelled distal 
pulmonary arteries.  Basal SERT expression was absent suggesting that in vivo, 
large pulmonary arteries do not phenotypically express SERT under normoxic 
conditions and that induction occurs in response to hypoxia (Eddahibi et.al. 
1999).  Indeed, mice over-expressing SERT (SERT+ mice) exhibit increased RVSP 
and pulmonary vascular remodelling, and also develop exaggerated hypoxia-
induced PAH (MacLean et.al. 2004).  Interestingly, it was later identified that 
only SERT+ female mice develop an exaggerated PAH phenotype implicating a 
gender susceptibility dependent on circulating serotonin.  Indeed, 17β-estradiol, 
the main circulating female hormone, increased expression of SERT in PASMCs 
(White et al. 2011).  Similarly, mice with targeted SERT over expression in 
PASMCs develop PAH (Guignabert et.al. 2006).  Pulmonary arterial remodelling in 
SERT+ mice is associated with elevated RhoA/ROCK signalling and ROCK 
inhibition ablates PAH in SERT+ mice (Mair et al. 2008).  Conversely, mice devoid 
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of the SERT gene are less susceptible to the development of hypoxia-induced 
PAH (Eddahibi et.al. 2000).  In addition, the SERT inhibitor citalopram protect 
against hypoxia-induced PAH in mice (Morecroft et.al. 2010) and fluoxetine 
attenuates monocrotaline-induced PAH in rats (Guignabert et al. 2005).  
Monocrotaline-induced PAH in rats is associated with an up-regulation of SERT, 
and the protective effects of statins described in monocrotaline-induced PAH is 
dependent on down-regulation of SERT (Laudi et al. 2007). 
Continually building evidence supports the ‘serotonin hypothesis’ of PAH.  
Substantial evidence exists implicating serotonin signalling, particularly SERT 
and 5-HT receptors, in the vascular remodelling process and pulmonary arterial 
vasoconstriction.  Targeting heightened serotonin signalling offers new 
pulmonary-specific therapeutic targets for PAH.  Certainly, a combined approach 
targeting dual inhibition of the 5-HT1B receptor and SERT would provide a novel 
and effective treatment for PAH. 
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1-14: Serotonin signalling in the pulmonary vasculature. 
Serotonin is synthesised in the endothelium by tryptophan hydroxylase (TPH-1).  Serotonin is then 
released and mediates effects on underlying smooth muscle via 5-HT receptors and the serotonin 
transporter (SERT).  Specifically stimulation of 5-HT1B and 5-HT2A initiates smooth muscle 
contraction.  5-HT1B can also stimulate proliferation. 
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1.9 Estrogen 
1.9.1 Synthesis and Metabolism 
The female sex hormones are steroid hormones which comprise both estrogens 
and progesterones.  The primary source and synthesis of these hormones occurs 
in the ovarian follicles and the corpus luteum in the female reproductive tract 
and play a key role in development of secondary sex characteristics.  To a lesser 
extent, estrogen synthesis can also take place in liver and adipose tissue and 
expression of estrogen-synthesising enzymes in vascular smooth muscle and 
endothelial cells (Tofovic 2010) implicates the importance of ‘local’ estrogen 
synthesis and autocrine/paracrine effects of estrogen in the periphery and 
cardiovascular tissues (Simpson & Davis 2001).  The synthesis of estrogens is 
controlled by the hypothalamic-pituitary-gonadal axis (HPG axis) which involves 
various endocrine hormones secreted from the hypothalamus and pituitary gland 
of the brain.  In particular, luteinising hormone (LH) released from the pituitary 
stimulates synthesis of estrogen, and follicle stimulating hormone (FSH) 
increases transcription of aromatase, the enzyme specific to estrogen synthesis.  
The continuous modulation of this group of hormones in females by positive-and 
negative-feedback forms the basis of the reproductive cycle.  Estrogens exist as 
three major naturally occurring isoforms: estrone (E1), estradiol (E2) and estriol 
(E3).  Estradiol is the predominant circulating hormone in pre-menopausal 
women, whilst estrone is important during the menopause and estriol during 
pregnancy. 
 
The biosynthesis of estrogen is initiated by the synthesis of androstenedione 
from the precursor cholesterol (Figure 1-15).  Androstenedione provides an 
intermediate stage in metabolism from which estradiol can be synthesised by 
two distinct pathways, either immediately or through testosterone.  The 
cytochrome P450 enzyme CYP19A1, or aromatase, converts androstenedione to 
estrone, which in turn is converted to estradiol by 17β hydroxysteroid 
dehydrogenase –type 1 (17βHSD-1).  Alternatively, reduction of androstenedione 
to testosterone, which requires a second 17βHSD isoform (17βHSD-2) occurs 
followed by aromatisation of testosterone to estradiol.  The molecular biology 
and steroidogenesis of estrogen is well described (Payne & Hales 2004).   
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Estradiol is then rapidly metabolised by oxidation (Figure 1-14).  Oxidative 
metabolism occurs primarily in the liver producing hormonally non-estrogenic 
metabolites ready for elimination from the body.  Estradiol and estrone are in 
equilibrium with 17βHSD-1, and oxidation/reduction occurs at the carbon-17 
(C17) position and favours formation of estrone.  Further metabolism of estradiol 
occurs, for example, at the C16, C4 and C2 positions producing biologically 
active metabolites.  Several members of the cytochrome P450 (CYP450) family 
are essential in mediating this nicotinamide adenine dinucleotide phosphate 
(NADPH)-dependent oxidative metabolism of estradiol.  Specifically CYP1A1, 
CYP1A2 CYP1B1, and CYP3A4 appear critical in the formation of 2- and 4-
hydroxy-derivatives.  The 2-hydroxylation pathway is the major metabolic 
pathway in the liver whereas 4-hydroxylation constitutes a relatively minor 
pathway in estrogen metabolism.  The 2-and 4-hydroxy-derivatives are then 
further converted to 2- and 4-methoxy metabolites by the catechol-O-
methyltransferase (COMT) enzyme.  Elimination of these metabolites can occur 
at either the hydroxyl- or methoxy-metabolite stage if they undergo sulphation 
by sulphotransferases (SULTs) to hormonally inactive water-soluble metabolites 
and subsequent excretion by the kidneys via urine.  There are multiple pathways 
via which estradiol can be metabolised (Zhu & Conney 1998). 
 
  
 
 
 
 
 
Binding to Estrogen Receptors
Genomic and Non-genomic mediated effects
 
Figure 1-15: Estrogen biosynthesis and metabolism. 
Androstenedione is derived from the precursor cholesterol.  Estradiol is synthesised immediately by aromatase (CYP19A1) to estrone (E1) or through testosterone by 
17β hydroxysteroid dehydrogenase (17βHSD-1).  Further metabolism of estradiol by cytochrome P450 enzymes (CYP450) CYP1A1, CYP1A2, CYP3A4 and CYP1B1 
produces 2-and 4-hydroxy-metabolites.  Subsequently these are metabolised to 2- and 4-methoxy-metabolites by cathecol-O-methyltransferase (COMT).  Adapted 
from (Tsuchiya et al. 2005). 
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1.9.2  Estrogen Effects in the Systemic Circulation 
Estrogen exerts diverse cardiovascular effects in both males and females.  There 
is a wealth of evidence implicating cardio-protective and vaso-protective effects 
of estrogen in cardiovascular disease.  Indeed, the incidence of cardiovascular 
disease is higher in men than that of age-matched pre-menopausal women, 
although these gender differences narrow after the menopause when the 
protection against cardiovascular disease is lost (Meyer et al. 2006).  A strong 
link between estrogen levels and hormone replacement therapy and 
cardioprotection is proposed (Rosano et al. 2003). 
Estrogen intimately regulates fundamental cardiovascular functions, including 
blood pressure, blood flow, vasodilation and vasoconstriction, vascular 
inflammation and remodelling atherosclerosis through diverse effects on various 
components of the vascular wall, such as endothelial and smooth muscle cells.  
Both acute and long term vasodilator effects of estrogen are mediated in part 
via generation of endothelium-derived NO and are attenuated by NO synthase 
(NOS) inhibitors (Caulin-Glaser et al. 1997).  Additionally, estrogen treatment 
can attenuate the vasoconstrictive properties of many mediators including 
phenylephrine and 5-HT in aorta and coronary arteries and decreases 
sympathetic nervous system –induced vasoconstriction (Dubey et al. 2004). 
Experimental studies also indicate that estrogen can protect blood vessels from 
atherosclerosis lesion formation in apolipoprotein E (ApoE) deficient mice (ApoE-
/-) (Bourassa et al. 1996), lower plasma levels of low density lipoprotein 
cholesterol (LDL) and raise levels of high density lipoprotein cholesterol (HDL) 
(Soma et al. 1993; White 2002).  Estrogen also appears to have a blood pressure 
lowering effect evidenced by changes in blood pressure throughout the 
menstrual cycle (Dunne et al. 1991) and during pregnancy (Siamopoulos et al. 
1996). 
Endothelial progenitor cells (EPCs) derived from bone marrow cells, are actively 
involved in cardiovascular homeostasis.  EPCs repair endothelial damage and 
function and promote angiogenesis (Mayr et al. 2011).  In fertile women, EPC 
populations are higher than in men; however, their numbers are subject to 
fluctuations with the hormonal cycle and fall after the menopause (Fadini et al. 
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2008).  The number and function of EPCs may therefore reflect the degree of 
cardiovascular protection in females and explain the lower prevalence of 
cardiovascular disease in premenopausal women. 
1.9.3  Estrogen Metabolite Effects in the Systemic Circulation 
Catcholestradiols and methoxyestradiols also exert cardio-protective effects in 
the cardiovascular system.  The effects of these metabolites are unlikely to 
involve estrogen receptors however, as catecholestradiols have approximately 
one-fourth the binding affinity of estradiol, and methoxyestradiols do not 
significantly bind to ERs (Dubey et al. 2000).  Estrogen metabolites exert effects 
on endothelial and vascular smooth muscle cells.  2-methoxyestradiol, 2-
hydroxyestradiol and 4-methoxyestradiol all inhibit migration, proliferation and 
collagen synthesis in human and rodent vascular smooth muscle cells.  The 
mechanism of this inhibition involves blocking free-radical production as both 2-
hydroxyestradiol and 2-methoxyestradiol are potent anti-oxidants (Seeger et al. 
1997).  In endothelial cells, 2-hydroxyestradiol and 2-methoxyestradiol stimulate 
the generation of the potent vasodilator prostacyclin and NO (Seeger et al. 
1999).  In vivo, 2-methoxyestradiol has been shown to attenuate both renal and 
cardiovascular injury by reducing blood pressure and cardiac hypertrophy 
associated with chronic NOS inhibition (Tofovic et al. 2005a). 
1.9.4  Estrogen Effects in the Pulmonary Circulation 
There is a striking female predominance reported in idiopathic and familial 
forms of PAH with females up to four times as likely to present with disease as 
males (Badesch et.al. 2010; Humbert et.al. 2006).  Endogenous and exogenous 
sex hormones represent a biologically relevant potential risk factor, and in 
particular estrogens are implicated in PAH pathogenesis.  For example, 
polymorphisms in aromatase, the estrogen synthesising enzyme, and ESR1/ERα, 
are associated with elevated estrogen levels in the lungs of female patients and 
predispose to portopulmonary hypertension (Roberts et al. 2009a; White et al. 
2012a).  Additionally, altered estrogen metabolism by CYP1B1 is implicated in 
idiopathic and heritable PAH (White et.al. 2012a) and CYP1B1 represents a 
modifier gene that drives susceptibility in females heritable PAH patients 
harbouring a BMPR2 mutation (Austin et.al. 2009; West et al. 2008). 
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Despite the well observed female susceptibility in clinical PAH, this is not 
translated to the currently utilised animal models of PH.  In fact, males exhibit 
more severe monocrotaline- and hypoxia-induced PH compared to females 
(Rabinovitch et al. 1981) and estrogen exerts protective effects on pulmonary 
vasculature and improves right ventricular contractility (Giuberti et al. 2007; 
Lahm et al. 2012a; Resta et al. 2001).  This is defined as the ‘estrogen paradox’ 
whereby the higher incidence and prevalence of PAH in females in the clinic is 
not represented by the animal models most commonly used to study the disease.  
For this reason, the observed gender bias in human PAH remains unclear. 
Estrogen mediated protection in PH appears to involve several mechanisms.  
Estrogen is reported to inhibit induction of endothelin-1, a potent mitogen and 
vasoconstrictor in pulmonary arteries, following chronic hypoxia (Earley & Resta 
2002), an effect which is absent in ovariectomised rats.  Estrogen may also 
increase vascular NO production (Gonzales et al. 2001) and prostacyclin 
(Sherman et al. 2002).  Together these effects of estrogen promote pulmonary 
vasodilation.  This effect was confirmed in pulmonary arteries from proestrous 
females, characterised by physiologically high estrogen levels, whereby the 
vasoconstrictor response to vasoactive agents such as KCl and phenylephrine, 
and hypoxia was attenuated (Lahm et al. 2007).  Additionally, estrogen is 
suggested to have inhibitory effects of Ca2+-dependent mechanisms of smooth 
muscle cells contraction (Murphy & Khalil 2000), protein kinase C (Kanashiro & 
Khalil 2001) and Rho-kinase (Shimokawa & Takeshita 2005).  The latter may also 
have important implications for inhibiting smooth muscle cell proliferation and 
migration. 
Increasing evidence from experimental animal studies implicates a protective 
role of estrogen in PH.  In vivo, estrogen ameliorates monocrotaline induced-PH 
in mechanisms dependent on NO and prostacyclin stimulation and a decrease in 
signalling through the endothelin-1 pathway (Yuan et al. 2013).  Estrogen also 
appears important in attenuation of hypoxia induced-PH in male rats by reducing 
pulmonary vascular remodelling (Lahm et.al. 2012a).  In the heart, estrogen also 
mediates RV cardioprotective effects.  Estrogen induces RV angiogenesis and 
reverses right ventricular hypertrophy (Nadadur et al. 2012; Umar et al. 2011a), 
and importantly restores RV contractility and function by enhancing right 
ventricular ejection fraction and cardiac output (Lahm et.al. 2007; Matori et al. 
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2012; Umar et.al. 2011a).  Since RV function is the most important prognostic 
factor in determining survival in PAH and women often have improved survival 
rates, it may not be surprising that estrogen exerts beneficial effects in the RV.  
Certainly, there is a correlation between estrogen levels and RV function 
described in humans (Ventetuolo et al. 2011). 
The absence of a suitable model in which to study the female predisposition to 
PAH however, has limited research into the role of estrogen in PAH 
pathogenesis.  In recent models of pulmonary hypertension dependent on 
serotonin, estrogen has been identified as a risk factor in pulmonary arteries.  In 
SERT over-expressing mice (SERT+), S100A4/Mts1 over-expressing mice and in 
dexfenfluramine-induced PH a female susceptibility is described dependent on 
circulating endogenous estrogen (Dempsie et.al. 2011; Dempsie et al. 2013; 
White et.al. 2011).  In particular, estrogen was shown to increase expression of 
tryptophan hydroxylase -1 (TPH1), the enzyme responsible for 5-HT synthesis, 
and 5-HT1B in pulmonary artery smooth muscle cells (White et.al. 2011) 
suggesting estrogen may stimulate a mitogenic environment in smooth muscle 
cells in females.  The complexity of the ‘estrogen paradox’ suggests that 
multiple pathways must be involved in generating the female predisposition.  For 
example, although in IPAH and HPAH women are over represented, estrogen 
appears protective in development of PAH in high-altitude natives distinct from 
IPAH and HPAH (Scherrer et al. 2006) and postmenopausal women with systemic 
sclerosis are at increased risk for development of PH (Scorza et al. 2002).  The 
interest in addressing the gender bias in PAH is continually expanding. 
1.9.5  Estrogen Metabolite Effects in the Pulmonary Circulation 
Evidence also suggests that metabolites of estrogen also play an important role 
in pulmonary vasculature and PAH.  In general it is regarded that metabolites of 
the 16-hydroxylation and 4-hydroxylation pathways have proinflammatory, 
mitogenic and angiogenic properties, whilst the 2-hyroxylation pathway 
produces estrogen metabolites with anti-inflammatory, antiproliferative and 
antiangiogenic properties (Dubey et.al. 2004) (Figure 1-16).  Like estrogen, the 
majority of studies implicate a protective role of non-estrogenic 
hydroxyestradiols and methoxyestradiols metabolites in the pulmonary 
circulation. 
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In monocrotaline and hypoxia-induced PH, 2-hydroxyestradiol and 2-
methoxyestradiol have been shown to attenuate pulmonary vascular and cardiac 
remodelling, as well as reducing mortality (Tofovic et al. 2005b; Tofovic et al. 
2005c; Zhang et al. 2007).  Pharmacological concentrations of 2-
methoxyestradiol also inhibits serum induced proliferation in pulmonary artery 
endothelial cells, smooth muscles cells and fibroblasts (Tofovic et al. 2008).  A 
recent study suggests reduced activity of the 2-hydroxylation pathway and 
reduced 2-hydroxyestradiol to 16α-hydroxyestrone ratios in urine in women with 
familial PAH (Austin et.al. 2009).  In line with this, administration of exogenous 
16α-hydroxyestrone to female mice induces PH (White et al. 2012).  A shift 
toward the 16-hydroxylation pathway may therefore be pathogenic in PAH in 
females.  Moreover, increased expression of CYP1B1, the major enzyme in the 4-
hydroxylation pathway is increased in IPAH and HPAH (White et al. 2012).  This 
may also have important implications in PAH development in females by 
increasing potentially mitogenic and inflammatory metabolites although the 4-
hydroxylation pathway has not been investigated in experimental PH. 
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Figure 1-16: Effects of estrogen metabolites in pulmonary arteries. 
17β-estradiol is metabolised by cytochrome P450 (CYP) enzymes to produce 2- and 4-
hydroxyestradiol metabolites.  Further metabolism by catechol-O-methyltransferase (COMT) 
produces 2- and 4-methoxyestradiols, respectively.  Both 2-hydroxy and 2-methoxyestradiol have 
been shown to inhibit pulmonary artery smooth muscle cell (PASMC) proliferation, whilst 16α-
hydroxyestradiol stimulates proliferation.  The effect of 4-hydroxylation is on PASMC is unknown.  
(* studied in experimental PH).  Adapted from (Mair et al, 2013). 
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1.10 Estrogen Receptors 
The impact of estrogen physiology in reproductive functions and in wider roles 
including modulation of inflammation, brain and behaviour, and cardiovascular 
functions, is achieved through activation of cellular hormone-specific estrogen 
receptors (ERs).  Two distinct types of signalling are described for estrogen: non-
rapid ‘genomic’ signalling and rapid ‘non-genomic’ signalling (Mendelsohn 2002).  
In the genomic pathway, estrogens bind to intracellular ERs inducing a 
conformational change and results in direct regulation of gene transcription.  In 
contrast, non-genomic signalling occurs rapidly through the activation of second 
messengers and signal transduction.  Recent identification of ERs located on the 
plasma membrane may also be accountable for rapid non-genomic estrogen 
signalling (Aronica et al. 1994; Pietras & Szego 1977).  Therefore activation of 
both intracellular and/or membrane receptors mediate physiological estrogen 
responses. 
 
1.10.1  Classical Estrogen Receptors: Subtypes and 
Structure 
The classical ERs belong to the steroid/thyroid superfamily of nuclear receptor 
transcription factors.  Until 1995 it was assumed there was only one ER 
responsible for mediating all of the physiological and pharmacological effects of 
natural and synthetic estrogens.  This receptor is now referred to as ERα 
following the cloning of the second ER, ERβ from various species (Enmark et al. 
1997; Mosselman et al. 1996; Tchoudakova et al. 1999; Todo et al. 1996; 
Tremblay et al. 1997).  ERα and ERβ are the products of separate genes, ESR1 
and ESR2 on chromosome 6q25.1 and chromosome 14q23.2, respectively (Enmark 
et.al. 1997; Menasce et al. 1993).  For ERα, at least two splice variants are 
recognised (ERα-36 and ERα46), whereas four splice variants exist for ERβ (ERβ2, 
-4, -5, and Xexon5).  They are composed of three independent but interacting 
functional domains: the NH2-terminal or A/B domain, the C domain or DNA-
binding domain (DBD), and the D/E/F or ligand-binding domain (LBD) (Figure 1-
17).  The DBD is involved in DNA recognition and binding and is the most 
evolutionary conserved domain in ERs.  It contains two zinc fingers which play a 
crucial role in receptor dimerisation and in binding of receptors to specific 
estrogen receptor response elements (EREs) in target genes. 
 91 
 
 
On the other hand, the LBD of the NH2-terminal is not highly conserved, and 
represents the most variable domain in both sequence and length.  LBD mediates 
ligand binding, receptor dimerisation, and transactivation of target gene 
expression by binding estrogen as well as other estrogenic ligands.  
Transcriptional activation is facilitated by two distinct activation functions (AF), 
AF-1 and AF-2 in the LBD.  AF-1 is constitutively active independent of the 
presence of a ligand but provides a more robust up-regulation of gene 
transcription in synergy with AF-2 (Kushner et al. 2000).  Both ER isoforms show 
a degree of selectivity with respect to AF regions: ERα predominantly mediates 
transcriptional activation via AF-1 whilst ERβ appears to regulate transcription 
via AF-2 function.  Interestingly, comparison of the AF-1 domains in the two ERs 
has identified that ERα and ERβ often have opposing actions under the same 
conditions in the same cells lines (Nilsson et al. 2001). 
 
1.10.2  Classical Estrogen Receptors: Activation and 
Mechanism of Action 
Binding of estrogens and/or pharmacological agents to the ERs induces 
conformational changes in the receptor and this promotes changes in the rate of 
transcription of estrogen regulated genes.  AF-1 and AF-2 must interact with co-
regulator complexes (either co-activators or co-repressors) to activate or 
suppress gene expression, although there are far fewer nuclear receptor co-
repressors.  Briefly, four major signalling mechanisms of classical ERs have been 
described (Figure 1-18).  In classical genomic signalling, ERs must cooperate as 
dimers in order to translocate from the cytosol to the nucleus.  Following 
receptor dimerisation in the cytosol upon ligand binding, activation involves 
dissociation from chaperone proteins followed by the direct activation of EREs in 
the promoters of target genes in the nucleus.  As a consequence of gene 
regulation, protein translation is affected resulting in alterations in cell 
function.  Alternatively, interaction with other transcription factor complexes 
lacking ERE-sequences, for example Fos/Jun complexes (Kushner et al. 2000) 
occurs in the tethered pathway via the ER dimer complex and by utilising 
activator-protein-1 (AP-1).  Another alternative mechanism of ER action involves 
ligand-independent activation through other signalling pathways, for example 
growth factor signalling.  In this instance, growth factor signalling leads to 
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activation of kinases that may phosphorlyate and thereby initiate dimerisation of 
ERs and regulation of target genes. 
 
In addition to the classical genomic pathway of estrogen involving slow 
transcriptional effects, there are well depicted rapid effects occurring within 
seconds or minutes of estrogen addition.  Although these rapid effects have been 
extensively studied it is still unclear whether or not classical membrane-bound 
ERs are involved or if there is a distinct membrane associated receptor.  For 
example, these effects may be attributed to the third estrogen receptor, 
GPR30/GPER, which is a G-protein coupled receptor (Carmeci et al. 1997; 
Filardo et al. 2000; Moriarty et al. 2006). 
 
1.10.3  The Novel G Protein-Coupled Receptor, GPR30/GPER: 
Structure and Mechanism of Action 
Both genomic and rapid signalling events initiated by estrogen have solely been 
attributed to membrane bound classical ERs, ERα and ERβ.  However, in the last 
few years, the discovery of a 7-transmembrane G protein-coupled receptor, 
GPR30/GPER, has been attributed to both rapid and transcriptional events in 
response to estrogen (Filardo & Thomas 2005; Nilsson et.al. 2001; Prossnitz et 
al. 2008).  GPER was identified in multiple organs, and in ER-negative breast 
cancer cell lines (Carmeci et al. 1997) and as such has suggested a possible link 
to physiologic responses in estrogen-responsive tissues and cancers.  The 
functional role of GPER involves the rapid activation of mitogen activated 
protein kinases (MAPK) (Filardo et al. 2000), PI3K activation and calcium 
mobilisation (Bologa et al. 2006) and hence rapid responses in target organs.  For 
GPER-mediated transcriptional activation, GPER signalling requires epidermal 
growth factor receptor (EGFR) and occurs through rapid ERK1/2 phosphorylation 
in triggering the genomic response to estrogen leading to stimulation of c-fos 
and cyclin D1 expression (Maggiolini et al. 2004).  Rapid signalling events 
mediated by GPER leading to transcriptional activation and ligand-dependent 
activation in the genomic model of ER activity may work in concert to generate 
estrogen mediated alterations in gene expression. 
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Figure 1-17: Schematic representation of estrogen receptor subtypes ERα and ERβ. 
The domains of the receptor include the DNA-binding domain (DBD), the ligand-binding domain (LBD) and two transcriptional activator functions (AF-1 and AF-2).  
Percentage sequence homology between ERs is indicated in ERβ.  The central and most conserved domain is the DBD. 
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Figure 1-18: Schematic representing the possible mechanisms of action utilised by ERs. 
ER- estrogen receptor; TF, transcription factor; PI3K, phosphoinositide-3-kinase; MAPK, mitogen-
activated protein kinase; GF, growth factor; P, phosphorylation.  Adapted from (Heldring et al. 
2007a)..
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1.11 Estrogen Receptors in Disease 
Estrogens influence many physiological processes in mammals.  As well as a 
fundamental role in reproduction, estrogens are known to be involved in 
cardiovascular and respiratory health, bone integrity, immune responses and 
cognition and behaviour.  For example, women show a significant increase in 
blood pressure following the onset of menopause (Dubey et al. 2002).  It is 
therefore not surprising that ERs have a wide tissue distribution and also differ 
in their distribution patterns (Nilsson et.al. 2001).  Given this widespread role of 
estrogen, pathophysiological implications are evident and a divergent role 
between genders in many diseases is plausible. 
 
1.11.1  Estrogen Receptors in Cancer 
Estrogen plays a central role in the development of breast cancer and cancers in 
other estrogen sensitive tissues such as the endometrium and ovaries (Zhu et al. 
2012).  ER positive breast cancer is in fact accountable for almost 75% of all 
breast cancers.  ERα is considered pro-proliferative in certain tissues and 
cancers whereas ERβ is more widely regarded as possessing anti-proliferative 
properties (Paruthiyil et al. 2004).  In particular, ERα status is the most 
important predictor of breast cancer prognosis (Burns & Korach 2012) and 
several sequence variations or single nucleotide polymorphisms (SNPs) in ESR1 
are associated with either an increased or a decreased risk of breast cancer 
(Yaich et al. 1992; Zuppan et al. 1991).  In breast cancer, binding of estrogen to 
ERs stimulates tumour development and progression by regulating estrogen-
dependent transcription of proliferative factors and mediators of cellular growth 
(Deroo & Korach 2006).  An increase in cell division and DNA synthesis is 
regarded to increase risk for replication errors and detrimental mutations 
resulting in disruption of normal cellular processes such as apoptosis, 
proliferation and DNA repair.  Currently, both selective estrogen receptor 
modulators (SERMs) and aromatase inhibitors are used in the treatment of ER-
positive breast cancer.   
 
Non-small-cell lung cancer (NSCLC) is also influenced by hormonal status in 
which aromatase is considered a key predictive biomarker for treatment.  Both 
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ERα and ERβ are expressed in normal and cancerous lung epithelium and 
estrogen elicits gene transcription that stimulates cell proliferation and inhibits 
cell death (Kazmi et al. 2012).  Additionally, GPER expression is enhanced in 
lung cancer cells and tumours compared to normal lung (Jala et al. 2012). 
 
1.11.2  Estrogen Receptors in Cardiovascular Disease 
Given that the incidence of cardiovascular disease is low in premenopausal 
women but increases substantially to levels comparable to men following the 
menopause, infers that estrogens may protect the female cardiovascular system.  
Functional ERs have been detected in human endothelial cells, vascular smooth 
muscle cells and in cardiomyocytes and it is well established that estrogen can 
cause vasodilation by both ER-dependent and independent mechanisms (Dubey 
et.al. 2002). 
 
Polymorphisms in both ERs have been associated with cardiovascular disease.  
Identified polymorphisms in ERα have been linked to severity and risk of 
coronary artery disease (Kunnas et al. 2000; Lu et al. 2002; Pollak et al. 2004) 
and increased risk of myocardial infarction and blood pressure in men (Peter et 
al. 2005; Shearman et al. 2003).  In females, reduced levels of ERα by epigenetic 
regulation and gene methylation have also been associated with development of 
coronary artery disease (Losordo et al. 1994) whereas ERα appears highly 
expressed in normal arteries.  In carotid arteries of healthy female mice, the 
protective effects of estrogen in response to vascular injury are mediated by ERα 
(Pare et al. 2002).  ERα activation in carotid artery also stimulates eNOS and NO 
production promoting vasodilation and inhibition of inflammation (Chambliss et 
al. 2000) and prevents endothelial injury.  On the other hand, ERβ 
polymorphisms have attributed to left ventricular mass and left ventricular wall 
thickness in women with hypertension (Peter et.al. 2005) and with blood 
pressure in men (Ellis et al. 2004; Pedram et al. 2008).  In line with this, anti-
fibrotic effects in the heart appear ERβ dependent (Pedram et.al. 2008) and 
estrogen therapy can reduce cardiac hypertrophy in ERα deficient mice but is 
ineffective in ERβ deficient mice (Babiker et al. 2004) suggesting a crucial role 
for ERβ in cardiac hypertrophy.  In addition, ERβ knockout mice show abnormal 
vascular function and hypertension as well as increased mortality (Pelzer et al. 
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2005; Zhu et al. 2002).  Together these studies implicate a wide variety of roles 
for ERs in the heart and vasculature. 
 
GPER is also widely distributed in cardiovascular tissue including the human 
heart (Kvingedal & Smeland 1997; Owman et al. 1996) and aortic endothelial and 
smooth muscle cells (Takada et al. 1997).  Indeed, GPER is an important 
regulator of estrogen in the cardiovascular system (Olde & Leeb-Lundberg 2009).  
Rapid events mediated by estrogen, such as vasodilation have been attributed to 
GPER activation (Lindsey et al. 2011) and is regarded to be an endothelium 
dependent NO-derived mechanism (Broughton et al. 2010).  In addition, GPER 
mediated regulation of blood pressure and vascular tone has been described 
(Haas et al. 2009; Martensson et al. 2009).  GPER characterisation in 
cardiovascular disease remains the least well defined, however, the 
understanding of ERs in cardiovascular disease is consistently improving and ER 
targeted therapies become an increasingly viable treatment of cardiovascular 
disease. 
 
1.11.3  Estrogen Receptors in Pulmonary Hypertension 
Gender appears to exert regulatory effects on human lung development and in 
healthy and diseased lung.  Expression of ERs has been identified in human lung 
(Mollerup et al. 2002) suggesting estrogens play an important role in the lung.  In 
fact, ERα and ERβ are required for the formation and maintenance of full 
competent alveoli in female mice, but not in male mice (Massaro & Massaro 
2004; Massaro & Massaro 2006).  In addition, female ERβ knockout mice have 
abnormal lung structures creating systemic hypoxia leading to ventricular 
hypertrophy and hypertension (Morani et al. 2006).  It is likely then, that the ER 
pathway way contributes to sexual dimorphism in lung physiology and 
pathophysiology. 
 
Despite the well documented female susceptibility of PAH in females the 
‘estrogen paradox’ continues to impede experimental investigations into the 
gender disparity.  Recent evidence however, suggests the action of estrogen in 
the lung during PH is ER-dependent.  In males, estrogen-induced rescue of PH is 
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believed to be mainly mediated through ERβ by reducing pulmonary fibrosis 
(Umar et.al. 2011a).  In addition, Genistein, a natural soybean-derived 
phytoestrogen which shows much higher affinity for ERβ than ERα attenuates 
development of monocrotaline-induced PH in male rats (Matori et.al. 2012).  
Furthermore, estrogen-induced protection against right heart failure in both 
male and female rats is reported to be directly mediated through ERβ (Nadadur 
et.al. 2012).  On the other hand, important protective effects of estrogen on 
haemodynamics and RVH in hypoxic PH are demonstrated to be mediated by ERα 
(Lahm et.al. 2012a).  A role for both ERs in the lung during PH development is 
likely and further studies utilising intact females investigating endogenous and 
exogenous estrogen and ERs is required to complete the gender puzzle. 
 
In clinical PAH, altered ER expression and signalling in the lung is reported.  
ESR1/ERα transcript is increased in lungs of female patients with PAH relative to 
non-PAH controls (Rajkumar et al. 2010) and polymorphisms in ESR1 have also 
been associated with an increased risk of developing portopulmonary 
hypertension (Roberts et al. 2009).  Additionally, an evolutionary conserved 
estrogen receptor binding site has been identified in BMPR2, and estrogen 
signalling through ERα suppresses the BMPR2 signal (Austin et.al. 2009).  In 
contrast, in animal studies, ERα protein expression in the lung is unchanged in 
rats with right heart failure compared to control rats, although ERβ is 
significantly reduced in lungs from rats with right heart failure (Matori et.al. 
2012).  The loss of ERβ expression is rescued with Genistein therapy.  Alterations 
in ER signalling and/or tissue distribution during PAH may therefore contribute 
to the female predominance in PAH. 
 
Very little is known about the role of ERs in the right ventricle.  Expression of 
ERα and ERβ has been confirmed in the right ventricle suggesting estrogen may 
mediate effects on cardiomyocytes in PAH (Matori et.al. 2012; Nadadur et.al. 
2012).  Indeed expression of ERβ is significantly reduced in the RV from rats with 
right heart failure (Matori et.al. 2012).  Moreover, estrogen exerts beneficial 
effects on RV function in monocrotaline- and hypoxia-induced PH (Lahm et.al. 
2012a; Umar et.al. 2011a) where the mechanism of action is ER dependent.  The 
loss of ERβ also results in development of right ventricular hypertrophy (Morani 
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et.al. 2006).  To date, there is no clinical data in humans investigating the role 
of ERs in the RV.  However, together with the current animal studies, it is 
conceivable that estrogen does mediate a cardioprotective function through ERs 
given that RV function strongly correlates with estrogen levels (Ventetuolo et.al. 
2011). 
1.12 Estrogen Receptors as a Therapeutic Target in 
Pulmonary Hypertension 
There is no doubt that estrogen has a fundamental role in the physiology and 
pathophysiology of various organs, including the lungs and cardiovascular 
system.  Development of new therapies targeting estrogen receptors in 
pulmonary hypertension may provide novel treatment options considering the 
female preponderance. 
Selective estrogen receptor modulators (SERMs) are an interesting class of 
compounds that act on estrogen receptors.  They are characterised by their 
varying actions between tissues, thereby granting the possibility to selectively 
inhibit or stimulate estrogen-like action in target tissues.  Such selectivity is 
made possible by the fact that the estrogen receptors of different target tissues 
vary in chemical structure.  These differences allow estrogen-like drugs, such as 
SERMs, to act in different ways with the estrogen receptor of different tissues.  
For example, tamoxifen, the first SERM to be extensively researched for breast 
cancer, is an antagonist in the breast reducing cell proliferation, but in the 
uterus acts as an agonist inducing cell proliferation.  On the other hand, 
raloxifene, is an antagonist at breast and uterine tissue, reducing breast cancer 
risk without stimulation of uterine cell division.  However, raloxifene has 
estrogen agonistic properties toward the bone and cardiovascular system (Black 
et al. 1994; Leung et al. 2007); it may therefore be possible to develop a SERM 
therapy in PAH. 
It has been reported that raloxifene improves endothelial function by increasing 
plasma nitric oxide and inhibition of endothelin-1 in healthy post-menopausal 
women (Saitta et al. 2001).  In monocrotaline induced-PH, raloxifene attenuates 
progression of right ventricular hypertrophy and pulmonary arterial thickening 
(Nishida et al. 2009).  Since raloxifene activates ERβ more effectively than ERα, 
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this supports previous studies which show estrogen mediated protection is ERβ-
dependent (Matori et.al. 2012; Umar et.al. 2011a).  In addition, raloxifene 
enhances endothelial derived NO to promote vasodilation in isolated rat 
pulmonary arteries (Chan et al. 2007).  Importantly, the pulmonary vasodilator 
response to raloxifene is sex dependent relaxing pulmonary blood vessels in male 
rats more effectively than female rats (Chan et al. 2005) although it is unknown 
whether similar sex-related effects occur in vivo in the pulmonary circulation.  
The effect of tamoxifen in the pulmonary circulation and experimental PH is 
unknown. 
1.13 Testosterone 
1.13.1  Synthesis and Metabolism 
Testosterone is the main steroid hormone in the androgen group, although the 
androgen group comprises testosterone precursors and metabolites.  
Testosterone is primarily biosynthesized in the testes of males and in the ovaries 
of females, although small amounts are also secreted from the adrenal cortex, 
skin and adipose tissue (Channer 2011).  In men, testosterone plays a central 
role in the development of male reproductive tissues as well as promoting 
secondary sex characteristics.  Other roles for testosterone have also been 
described, such as in the prevention of osteoporosis (Tuck & Francis 2009) and as 
a risk factor in cardiovascular disease (Nettleship et al. 2009) and prostate 
cancer (Hyde et al. 2012). 
Androstenedione is a 19-carbon steroid hormone produced as an intermediate in 
the biochemical pathway that produces both the androgen testosterone and the 
estrogens, estrone and estradiol.  Androstenedione originates either from 
conversion of dehydroepiandrosterone (DHEA) or from 17α-hydroxyprogesterone 
by the enzymes CYP17A1 and 3β-hydroxysteroid dehydrogenease-1 (3β-HSD1), 
respectively (Figure 1-19).  These two metabolites share a common precursor- 
17α-hydroxypregnenolone, a product of oxidative metabolism of cholesterol.  
DHEA can be further metabolised to androstendiol by 17β-HSD2 whilst 17α-
hydroxyprogesterone is converted to androstenedione by CYP17A1.  Formation of 
testosterone from androstendiol and androstenedione involves 3β-HSD isoforms, 
3β-HSD1 and 3β-HSD-2 and -3, respectively.  Testosterone can then be 
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bioconverted into 17β-estradiol via aromatase, or into its immediate 5-alpha 
reduced dihydro-metabolites: 5α-DHT, via the enzyme 5α-reductase and 5β-DHT 
via the enzyme 5β-reductase.  Subsequently, these dihydro-androgens undergo a 
3α- or 3β-hydroxylation via the enzymes 3α- or 3β-HSD to produce biologically 
inactive tetrahydro-androgens which are excreted.  It is important to note that 
the dihydro-and tetrahydro-androgens are non-aromatisable, thus they cannot 
be bioconverted into estrogens. 
Like other steroid hormones, the synthesis of testosterone is regulated by the 
HPG-axis.  LH secreted from the pituitary stimulates Leydig cells in the testes to 
produce testosterone and testosterone negative feedback to the pituitary blocks 
the actions of gonadotropin releasing hormone (GnRH) from the hypothalamus. 
The physiology of testosterone is complex as the amount of biologically active 
testosterone is determined by sex hormone binding globulin (SHBG) and albumin.  
Approximately only 1-2% of testosterone is “bioavailable” or “free”, whereas the 
majority circulates bound to SHBG (50-60%) and serum albumin (40—50%) (Dunn 
et al. 1981). 
1.13.2  Androgen Receptor: Activation and Mechanism of 
Action 
Testosterone exerts its effect in cells by binding to the androgen receptor (AR).  
The AR belongs to the superfamily of nuclear receptors responsible for mediating 
transcriptional events in cells and the AR gene is located on the X chromosome 
at position 12.  Testosterone can activate AR directly, or following its conversion 
to DHT by the enzyme 5α-reductase.  In fact, DHT is 10-times more potent in 
activation of AR than testosterone itself (Liu et al. 2003).  . 
Generally, activated AR upon ligand binding undergoes conformational changes 
to form a homodimer after dissociation from heat shock proteins and 
translocates to the nucleus to interact with androgen response elements (AREs) 
in the promoters of target genes.  In the AR protein, the LBD is involved in 
dimerisation and ligand binding, whilst the DBD region allows AR to bind to DNA 
in cells.  No membrane bound AR has been characterised, however as well as 
genomic transcriptional events, testosterone can mediate non-genomic rapid 
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signalling events involving second messenger cascades including cytosolic 
calcium, and activation of protein kinase A, protein kinase C and MAPK (Kousteni 
et al. 2001). 
The actions of testosterone are mainly mediated by binding to AR.  Given that 
testosterone exerts broad biological effects on many target organs, expression of 
AR is also found in non-reproductive tissues.  AR is known to be expressed in 
other tissues such as skeletal muscle (Snochowski et al. 1980), bone (Riggs et al. 
2002) and the brain (McGill, Jr. et al. 1980).  Importantly, AR is also found in 
cardiomyocytes (Marsh et al, 1998), endothelial cells, vascular smooth muscle 
cells and fibroblasts (Lin et al. 1982).  AR is also important in the developing 
lung and during lung cancer (Mikkonen et al. 2010).  Therefore, testosterone and 
DHT effects are implicated in the heart and vasculature. 
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Figure 1-19: Androgen biosynthesis and metabolism. 
Circulating carbon-19 precursors are converted to intermediates dehydroepiandrosterone (DHEA) 
and 17α-hydroxyprogesterone.  Further metabolism of these produces testosterone via the 
hydroxysteroid dehydrogenase enzymes.  Testosterone metabolism by aromatase produces 
estradiol, or by 5α-reductase enzymes produces the primary metabolite dihydrotestosterone (DHT).  
DHT is inactivated by conversion to 3α-and 3β-androstanediol which are excreted in urine. 
 
 
1.14 Androgen Effects in Systemic Circulation 
1.14.1  Testosterone and DHT 
As male sex is regarded as a major risk factor for the development of 
cardiovascular disease, it is thought that androgens, including testosterone, 
promote detrimental effects on the heart and vasculature.  In fact, androgen 
replacement is associated with cardiovascular-related adverse events in men of 
all ages (Basaria 2010; Fernandez-Balsells et al. 2010).  Moreover, high 
testosterone levels are associated with higher mortality rates due to 
cardiovascular disease and diabetes (Araujo et al. 2011; Grossman & Messerli 
2011; Stanworth & Jones 2009). 
Several lines of evidence implicate a negative effect of testosterone in 
vasculature.  Both testosterone and DHT stimulate proliferation of rat vascular 
smooth muscle cells (Fujimoto et al. 1994) and DHT increases macrophage and 
foam cell and plaque formation in atherosclerosis (McCrohon et al. 1999; 
McCrohon et al. 2000) suggesting a promitogenic and proinflammatory effect of 
these androgens in cardiac vasculature.  Testosterone is also reported to 
increase synthesis of angiotensin-II, a potent vasoconstrictor and mitogen known 
to induce hypertension and atherosclerosis (Reckelhoff et al. 2000) and lowers 
HDL and raises LDL in vascular smooth muscle cells (Goh et al. 1995).  In 
contrast, in cholesterol fed rabbits, testosterone appears anti-atherosclerotic 
independent of lipids (Alexandersen et al. 1999).  On the other hand, in clinical 
data, men with an aromatase deficiency exhibit accelerated atherogenesis 
(Reckelhoff 2001).  Perhaps the disparity between studies reflects local 
metabolism of testosterone to estrogen which exerts protective effects on the 
endothelium (Dubey et.al. 2002). 
In addition, in rat models of hypertension, males exhibit higher blood pressure 
than age-matched females, which is prevented by castration and reproduced 
following testosterone treatment in spontaneously hypertensive (SHR) and Dahl 
salt-sensitive rats (Dubey et.al. 2002; Reckelhoff 2001).  Epidemiological studies 
also show an inverse correlation between testosterone and blood pressure in 
men (Khaw & Barrett-Connor 1988).  There is strong evidence that both 
testosterone and DHT cause structural and morphological changes in the human 
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heart (Achar et al. 2010) and act through the AR to initiate cardiac hypertrophy 
(Hayward et al. 2000).  Altered metabolism of estrogen is predicted to play a 
pivotal role in testosterone-induced cardiac hypertrophy as males with LVH have 
increased expression of 5α-reductase and AR in the heart (Thum & Borlak 2002).  
Moreover, treatment with an AR antagonist significantly improves LVH in 
patients (Baltatu et al. 2003).  The effect of endogenous and exogenous 
androgens on cardiac remodelling and function remains controversial, however, 
and is further complicated by aromatisation to estrogen. 
1.14.2  DHEA 
Extensive evidence implies a beneficial effect of DHEA on cardiovascular 
function.  Numerous epidemiological studies have indicated that low plasma 
levels of DHEA and its sulphated form, DHEAS, are associated with elevated 
cardiovascular risk (Abbasi et al. 1998; Shono et al. 1996), cardiovascular 
morbidity (Alexandersen et al. 1996; Trivedi & Khaw 2001), coronary artery 
disease (Herrington et al. 1990; Ishihara et al. 1992; Mitchell et al. 1994) or 
atherosclerotic vascular diseases (Bernini et al. 1999; Bernini et al. 2001) 
irrespective of gender. 
In animal studies, administration of DHEA attenuates development of 
atherosclerosis and plaque progression (Aragno et al. 2000; Ayhan et al. 2003; 
Eich et al. 1993; Gordon et al. 1988) and protects against ischemic-reperfusion 
injury and kidney injury following hypertension (Aragno et.al. 2000; Ayhan et.al. 
2003).  In addition, DHEA is suggested to have a protective effect on the 
endothelium, increasing endothelial proliferation and preventing endothelial cell 
apoptosis independent of AR and ERs (Liu et al. 2007; Williams et al. 2002).  
Antioxidant properties of DHEA have also been described in the heart and 
vasculature (Savineau et al. 2013). 
1.15  Androgen Effects in Pulmonary Circulation 
1.15.1  Testosterone and DHT 
There is very limited data on the role of androgens in the pulmonary circulation 
and in PAH.  In the few studies to date, testosterone has been identified as a 
potent vasodilator in isolated human pulmonary vasculature (Rowell et al. 2009; 
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Smith et al. 2008).  It is in fact a more potent vasodilator than estrogen in this 
vascular bed (English et al. 2001).  The effect of testosterone is proposed to be a 
rapid, non-genomic effect independent of AR and the endothelium and NO 
(Jones et al. 2002; Yue et al. 1995).  Instead, the mechanism of vasodilation 
appears to involve inhibition of Ca2+ entry via voltage gated calcium channels 
(Hall et al. 2006; Scragg et al. 2004).  Moreover, the action of testosterone is 
direct and not dependent on conversion to estrogen by aromatase as both 
aromatase inhibition and ER antagonism fail to prevent the vasodilatory response 
(Deenadayalu et al. 2001; Teoh et al. 2000; Tep-areenan et al. 2002) 
In vivo, a correlation between the RV and testosterone is proposed.  The degree 
of RVH in rats exposed to high altitude is greater in castrated males treated with 
testosterone (Vander et al. 1978) and the effects of hypoxia and testosterone 
appear additive.  Recently, the first evidence for a role of testosterone in PH 
was reported.  Hemnes et al (2012) showed that testosterone induced right 
ventricular fibrosis and increased cardiac myocyte size in the pulmonary artery 
banding (PAB) model of PH.  The effects of testosterone in the RV were observed 
in the absence of any effects on haemodynamic properties, for example, right 
ventricular systolic pressure and cardiac output were unaffected by testosterone 
manipulation.  This suggests, at least in PH, that the effects of testosterone are 
primarily involved in dysfunctional RVH and during RV stress and increased 
afterload in PAH drive the differences in survival rates between males and 
females (Hemnes et al. 2012). 
1.15.2  DHEA 
The effect of DHEA on PAH has been investigated in humans and animal models.  
It has been described as having a multifunctional protective role in PAH.  In rats, 
DHEA treatment prevents and reverses chronic hypoxia induced-PH involving a 
decrease in pulmonary artery remodelling, especially PASMC proliferation and 
prevention of RVH (Hampl et al, 2003; Bonnet et al, 2003).  Indeed, in patients 
with PH associated with chronic obstructive pulmonary disease (COPD), chronic 
DHEA treatment improves pulmonary haemodynamics (Dumas de la Roque et al, 
2012). 
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In isolated PASMCs, DHEA directly inhibits Ca2+ influx and decreases KCl-induced 
contraction in isolated pulmonary artery (Bonnet et al, 2003).  Vasodilator 
properties of DHEA have also been demonstrated in chronic hypoxic male rats 
and monocrotaline models associated with both opening of voltage gated 
potassium channels (Farrukh et al, 1998; Gupte et a, 2002) and increased 
expression and function of pulmonary artery Ca2+-activated K+ channels (Bonnet 
et al, 2003; Hampl et al, 2003).  Additionally, an antioxidant property of DHEA in 
human PASMCs decreases proliferation and resistance to apoptosis by modulating 
mitochondrial functions (Dumas de la Roque et al, 2010).  In line with this, DHEA 
reverses pulmonary arterial remodelling by various pathways such as normalising 
RhoA/ROCK activity in hypoxia (Homma et al, 2007), decreasing Src/STAT3 
activation with resorted BMPR2 (Paulin et al, 2011) and decreased accumulation 
of HIF-1α in PASMCs during hypoxia (Dessouroux et al, 2008).  DHEA may 
therefore provide a promising therapeutic option in PAH therapy. 
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1.16 Aims  
The principal aim of this research was to investigate the role of classical 
estrogen receptors ERα and ERβ, and the novel G-protein coupled receptor, 
GPER in PAH in males and females.  We also wished to determine the role of 
testosterone in development of PAH in males.  These aims were investigated 
using the following approaches: 
• Determine localisation of estrogen receptors lung and pulmonary artery 
smooth muscle cells in experimental and translational PH (Chapter 3) 
• Characterise ERα in two in vivo models of PH: chronic hypoxia and SERT+ 
mice (Chapter 3) 
•  Determine a mechanism for estrogen and estrogen receptor signalling in 
experimental and translational PH (Chapter 3) 
• Characterise the role of GPER in GPER-/- male and female mice in the 
chronic-hypoxic PH model (Chapter 4) 
• Identify the influence of testosterone in PH development in vitro and in 
vivo by testosterone manipulation (castration) (Chapter 5). 
 
 
Chapter 2. 
Materials and Methods 
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2  
2.1 Materials 
All chemicals and reagents obtained were of the highest grade and quality and 
supplied by the following companies: Innovative Research of America (Florida, 
USA), Sigma Aldrich (Poole, UK); Tocris Bioscience (Bristol, UK); Invitrogen 
(Paisley, UK), Fisher Scientific (Loughborough, UK) and Applied Biosystems/Life 
Technologies (Paisley, UK).  All cell culture reagents were provided by Sigma 
Aldrich (Poole, UK) or Gibco (Paisley, UK), unless otherwise stated.  Fetal Bovie 
Serum was supplied by Sera Laboratories International (West Sussex, UK). 
2.2 Ethical Information 
All experimental animal procedures conform with the United Kingdom Animal 
Procedures Act (1986) and with the ‘Guide for the Care and Use of Laboratory 
Animals’ published by the US National Institutes of Health (NIH publication No. 
85-23, revised 1996), and ethical approval was also granted by the University 
Ethics Committee.   
Experimental procedures utilising human pulmonary artery smooth muscle cells 
(hPASMCs) conformed with the principles outlines in the Declaration of Helsinki 
and were approved by Cambridgeshire 1 Research Ethics committee (REC 
reference: 08/H0304/56). 
2.3 Methods 
2.3.1 Animal Models 
2.3.1.1  Wildtype Mice 
Wild-type inbred C57BL/6JOlaHsd male and female mice were obtained from 
Harlan Laboratories, Carshalton, UK.  Mice were shipped at 6 weeks of age and 
were housed in the Central Research Facility in the University of Glasgow for one 
week to acclimatise before exposure to any surgical procedures. 
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2.3.1.2  SERT+ Mice 
Mice over-expressing the human serotonin transporter gene transcript were 
generated and supplied by Professor Tony Harmer, University of Edinburgh, UK.  
SERT+ mice were generated using the C57BL/6 x CBA wild-type strain.  The 
transgene was introduced using a 500-kb yeast artificial chromosome (YAC35D8) 
containing the human SERT gene flanked by 150 kb of 5’ and 300kb of 3’ 
sequence, with the “short” allele of the SERTLPR in the promoter region in the 
10-repeat allele of the variable number tandem repeat in intron 2.  In situ 
hybridisation analysis has previously shown that the expression of the human 
SERT gene closely resembles the pattern of the endogenous mouse SERT gene.  
Genotyping was performed by PCR on tail biopsies to confirm the expression of 
the human SERT transgene.  C57BL/6 x CBA littermate mice were studied as 
controls for SERT+ mice.  
2.3.1.3 GPER(-/-) Mice 
GPER(-/-) mice were supplied by Frederick Leeb-Lundberg (Lund University, 
Sweden).  The mouse model was developed with a completely disrupted GPER 
gene locus.  This was achieved using a targeting vector containing a lox-flanked 
mGPER ORF and a lox-flanked TkNeo cassette assembled from a murine 129/SvJ 
BAC-clone.  To provide negative selection, the long arm was flanked with a 
PGKDt-a expression cassette.  The GPER gene was deleted by transient 
expression of cAMP response element- recombinase.  This targeting strategy 
resulted in deletion of the whole GPER open-reading frame.  The chosen three 
clones were injected into C57BL/6 blastocysts which were implanted into 
pseudopregnant females and the deletion was backcrossed six generations into 
the C57BL/6 genetic background.   C57BL/6 mice were therefore studied as wild 
type controls for GPER(-/-) mice. 
All mice were housed with littermates in the Central Biological Research Facility 
at the University of Glasgow.  In all mouse studies, mice were exposed to a 
continuous 12 hour light/dark cycle with access to food and water ad libitum. 
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2.3.2 MPP Dihydrochloride Administration 
Under general anaesthesia, 1%-3% (v/v) isoflurane supplemented with O2, pellets 
containing either MPP Dihydrochloride [chemical name- 1,3-Bis(4-
hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole 
dihydrochloride] (MPP) (0.56mg/14 day pellet, Innovative Research of America, 
Florida, USA) or vehicle pellets were inserted subcutaneously into the dorsal 
neck using a sterile 12-gauge hypodermic needle prior to hypoxic exposure for 14 
days.  The unique engineering of the Matrix Driven Delivery (MDD) pellet system 
effectively and continuously allowed the diffusion of MPP into the animal at a 
concentration of 2mgkg-1day-1.  Vehicle pellets are composed and designed to 
perform exactly as active pellets, but contain no active product.  The unique 
engineering of the Matrix Driven Delivery (MDD) pellet system effectively and 
continuously allowed the diffusion of MPP into the animal at a concentration of 
2mgkg-1day-1.  Vehicle pellets are composed and designed to perform exactly as 
active pellets, but contain no active product.  This is the first study to 
administer MPP in pellet form, although, previously this pellet delivery system 
has been shown to work effectively at releasing 17β-estradiol in mice (White et 
al, 2011) and we therefore consider this an effective, consistent and reliable 
method of drug delivery.  Limitations of these pellets however, include the 
inability to compensate for varying body weights over the experiment duration.  
48 hours after insertion of MPP/vehicle pellets, mice were exposed to 14 days 
chronic hypoxia. 
2.3.3  Chronic Hypoxia 
The development of hypoxia induced-pulmonary hypertension (PH) was achieved 
using a hypobaric hypoxic chamber.  Mice were subjected to 14 days of an 
atmospheric pressure of 550mbar.  The gradual depressurisation from ~1000mbar 
(ambient room pressure) to 550mbar reduces the oxygen availability from ~21% 
O2 to ~10% O2 and results in sustained hypoxic pulmonary vasoconstriction and 
the development of PH.  During this time, room temperature was maintained at 
21˚C-23˚C with a relative humidity of 30 – 50% and mice were re-housed with 
clean bedding and food/water every 5–7 days. 
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2.3.4  Bilateral Orchidectomy 
For pre-operative care, male mice were administered the analgesic 
buprenorphine (0.1mgkg-1) and 4mlkg-1 sterile saline via intra-peritoneal 
injection.  Bilateral orchidectomy, (removal of both testicles) was performed 
under general anaesthesia (1%-3% (v/v) isoflurane supplemented with O2) in 6 
week old male C57BL/6 wild-type mice.  This technique removes the sex organs 
responsible for the production of the male sex hormone, testosterone.  Briefly, a 
small incision was made in the scrotum, each testicle was then pushed down 
through the incision and removed via cauterisation through the vas dererens.  1–
2 surgical staples were used to close the ventral incision in the scrotum.  
Surgical staples were used for accuracy and consistency, and moreover to reduce 
the chances of infection as a complication during suturing.  For post-operative 
care, a non-steroidal anti-inflammatory drug, carprofen (2.5mgkg-1) and 4mlkg-1 
sterile saline were administered via intra-peritoneal injection.  Staples were 
removed one day following surgery and mice were given a further 4 weeks to 
recover from surgical procedure as well as allowing complete depletion of 
circulating testosterone levels.  An interval of 14 days post orchidectomy surgery 
has previously demonstrated the absence of any detectable plasma testosterone 
levels (Wichmann et al. 1996).  Sham- operated mice received a lateral incision 
in the scrotum although the testes and vas deferens remained intact.  At 10 
weeks, mice were placed in 14 days of hypobaric hypoxia and the assessment of 
PAH was performed on removal at 12 weeks. 
One week following surgery, mice were monitored on a daily basis, and 
thereafter on a weekly basis, to ensure full recovery from surgery with an 
absence of any infections at both the wound site and overall general health. 
Experimental design for each in vivo study described above is shown in Figure 2-
1.  In all studies, C57Bl/6 mice were used at 6-12 weeks of age; however SERT+ 
mice and wildtype counterparts were required to be used at 20 weeks (~5-6 
months) as it is at this age only that female mice exhibit the PH phenotype.  One 
limitation of using mice of varying ages, and of interest in this study, is the 
concentration of circulating estrogen in these mice may fluctuate at different 
ages. 
114 
 
 
Day -2 
6 weeks of age
MPP Administration
Day 0 
6 weeks of age
Normoxia/Hypoxia
Day 14 
8 weeks of age
PAH Assessment
A.
Day -2 
20 weeks of age
MPP Administration
Day 0 
20 weeks of age
Normoxia/ Hypoxia
Day 14 
22 weeks of age
PAH Assessment
Day 0 
6 weeks of age
Sham/Castration
Day 28 
10 weeks of age
Normoxia/Hypoxia
Day 42 
12 weeks of age
PAH Assessment
B.
C.
 
 
 
Figure 2-1: In vivo study design. 
(A). C57Bl/6 male and female mice were dosed with MPP/vehicle for 2 weeks in the 
presence/absence of hypoxia.  In vivo haemodynamics were assessed in these mice at 8 weeks of 
age.  (B). SERT+ female mice were dosed with MPP/vehicle from 20 weeks of age for 2 weeks in 
the presence/absence of hypoxia and haemodynamics assessed at 22 weeks.  (C). Male mice 
underwent sham/orchidectomy surgery at 6 weeks of age.  Following 4 weeks recovery, mice were 
placed in normoxic/hypoxic conditions for 2 weeks and haemodynamics were assessed at 12 
weeks. 
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2.4 Assessment of PAH 
2.4.1  Haemodynamic Measurements 
The induction of general anaesthesia was supplied via exposure to 3% (v/v) 
isoflurane supplemented with O2.  Acceptable anaesthesia at this point was 
observed by shallow abdominal respiration prior to removal and weight 
measurements.  Mice were then placed in a facemask and continuously received 
1-2% (v/v) isoflurane to maintain adequate general anaesthesia.  Before 
initiation of surgical procedure, general anaesthesia was confirmed by assessing 
the absence of hind limb and tail reflex.  These reflexes were also routinely 
assessed throughout the procedure.   
2.4.1.1 Mechanism of fluid filled catheter system 
Haemodynamic pressures were measured using a fluid filled catheter system 
implanted transdiaphragmatically into the right ventricle or directly into the 
carotid artery for measurement of right ventricular systolic pressure and 
systemic arterial pressure, respectively.  Fluctuations of vascular pressure 
caused a pulsation of the saline column within the catheter leading to changes in 
the resistance.  These changes in pressure were converted to an electrical signal 
and the output measured using a digital recorder (BIOPAC Systems, Inc, USA).  
The sampling rate was recorded as 200 samples/second.      
2.4.1.2 Calibrating the system 
The catheter was calibrated using a sphygmomanometer to a baseline of 0mmHg 
or atmospheric pressure (open to air) and a maximum of 150mmHg.  In addition, 
pressure tubing was assessed to ensure they were free of air bubbles.  A wave 
test was also applied to check for oscillations as an indicator of harmonic 
characteristics of the system (one oscillation was observed before wave returned 
to baseline).      
2.4.1.3 Accuracy of system 
Although use of the fluid filled catheter system is advantageous in that it 
provides direct and continuous measurements of arterial pressure, this system is 
not suited for continuous prolonged recording.  Common sources of error 
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associated with the fluid filled catheter system include clotting or kinking in the 
cannula and bubbles in the cathter-transducer system resulting in decreased 
resonant frequency.  Continuous flushing of the catheter system with heparin to 
prevent clotting of the catheter may result in volume overload in the mouse.  
Moreover, there is associated morbidity and mortality with use of this surgical 
system.  Use of the Millar catheter with a transducer mounted on the catheter 
tip would minimise these inaccuracies and the pressure-volume loop (PV loop) 
system would provide a more thorough analysis of the heart functionality, 
including stroke volume and end-systolic and –diastolic volumes in future studies.    
2.4.2  Right Ventricular Systolic Pressure 
Right ventricular systolic pressure (RVSP) was measured by a transdiaphragmatic 
approach.  Briefly, a small portion of skin was removed from the ventral chest to 
expose the anterior sternum.  A 25mm gauge heparinised needle was then 
advanced into the mid-portion of the abdomen using a micromanipulator.  A 
negative pressure reading was indicative of entry into the diaphragm and used as 
a marker for gauging to the right ventricle.  The right ventricle was punctured 
through the right ventricular free wall and the pressure was confirmed by a 
characteristic waveform such as in Figure 2-2.  From this recording, a 
measurement of RVSP was deduced and used as an indice of PAH.  Following a 
five-to-eight minute trace, a control was performed by advancing the needle 
further into the heart to obtain left ventricular (LV) pressure and a typical LV 
waveform.  At necropsy validation of right ventricular pressure was also assessed 
microscopically by confirming the presence of a puncture wound in the right 
ventricle free wall.  The continuous measurement of RVSP was achieved using a 
calibrated 25mm gauge heparinised saline filled needle attached to an Elcomatic 
E751A pressure transducer connected to a MP100 data acquisition system 
(BIOPAC Systems Inc, Santa Barbra, USA).  Specifically, mean RVSP, systolic and 
diastolic RVSP were measured at three independent areas of the trace which 
were steady.  In each instance, the same peak following the reduction in 
transmural pressure was recorded. 
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Figure 2-2: Representative image of right ventricular pressure. 
Three second representative recording of right ventricular pressure in a normoxic wild type mouse.  
Approximate heart rate= 360.0 beats per minute (bpm).  Low heart rates indicated could be a result 
of prolonged anaesthesia (normal adult mouse heart rate= ~500-600bpm). 
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Figure 2-3: Representative image of systemic arterial pressure. 
Three second representative recording of systemic arterial pressure in a normoxic wild type mouse.  
Approximate heart rate= 300.0 beats per minute (bpm).  Closure of the aortic valve is indicated by 
the dicrotic notch.  Low heart rates indicated could be a result of prolonged anaesthesia (normal 
adult mouse heart rate= ~500-600bpm). 
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2.4.3  Systemic Arterial Pressure 
Systemic arterial pressure (SAP) was obtained by cannulation of the left common 
carotid artery.  The carotid artery was exposed by an incision in the ventral neck 
and located by blunt dissection down the muscle lying inferior to the trachea.  
The left common carotid artery is typically positioned ~2mm lateral (left) and 
less than ~1mm posterior to the trachea.  Precision dissection was used to 
isolate the carotid artery from the vagus nerve running parallel to the artery and 
without severing the nerve.  To tie the artery distally to the heart a suture (5.0 
silk non-braided) was used and an arterial clip (Harvard Apparatus, Boston, USA) 
was placed on the artery to occlude blood flow through the lumen proximal to 
the heart.  Following an incision through the arterial wall, a heparinised saline-
filled polypropylene cannula (Harvard Apparatus, Boston USA) was advanced 4-
5mm into the artery and secured in place using a suture and the arterial clip 
removed.  Continuous measurement of SAP was obtained using the same 
technique as for RVSP with an Elcomatic E751A pressure transducer and an 
MP100 data acquisition system (BIOPAC Systems Inc, Santa Barbra, USA).  A 
typical SAP waveform is shown in Figure 2-3. 
Following measurement of RVSP and SAP, mice were killed by cervical 
dislocation.  The heart and lungs were then dissected out immediately en bloc 
and placed in ice cold physiological saline solution (PSS; pH 7.4; mmol/L, NaCl 
119, NaHCO3 25, KCl 4.7, KH2PO4 1.2, MgSO4 0.6, CaCl22.5, C6H12O6 11.1).  Liver, 
spleen, kidneys and uterus/testis were also dissected out and snap frozen in 
liquid nitrogen for storage in -80˚C conditions until further use. 
2.4.4 Right Ventricular Hypertrophy 
The right ventricle (RV) and the left ventricle plus septum (LV+S) were dissected 
free from surrounding pericardial fat and large blood vessels at necropsy.  The 
RV was dissected from the LV+S and both were dry blotted.  Right ventricular 
hypertrophy (RVH) was measured as a ratio of the right ventricular free wall (RV) 
over the LV+S and the ratio (RV/LV+S) was used in PAH assessment. 
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2.4.5  Pulmonary Vascular Remodelling 
3µm sagittal sections of lung were stained with α- smooth muscle actin (α-SMA) 
and microscopically examined in a blinded fashion.  Pulmonary arteries assessed 
were <80µm external diameter and were not associated with an airway.  The 
arteries were considered muscularised by the presence of a distinct think 
vascular wall visible for at least half the diameter of the vessel.  Four to six lung 
sections were analysed per group and approximately 100 arteries were counted 
per sagittal lung section.  The percentage of remodelling was expressed as a 
percentage from the number of muscularised vessels/total number of vessels x 
100. 
2.5 Histology 
2.5.1  Fixation 
Human lung sections were supplied by Prof. Nicholas Morrell (Papworth Hospital, 
Cambridge, UK).  Information regarding the part of lung removed from the 
patients at the hospital is unknown.  Patient information for lung sections is 
depicted in Table 2-1.  Low patient numbers are due to the rare nature of the 
PAH and are described as a limitation in experiments. 
Following death, the superior and inferior lobe from the right lung were 
dissected free and harvested in 10% (v/v) neutral buffered formalin (NBF: 90% 
distilled H2O, 10% formalin, 33mmol/L NaH2PO4, 45mmol/L Na2HPO4) for 24 
hours under gentle agitation.  Formalin fixed lungs were then paraffin-embedded 
and 3µm sagittal sections cut and mounted onto salinised glass microscopic 
slides.   
2.5.2  Immunolocalisation of Estrogen Receptors in the Human 
Lung   
3µm human lung sections were de-parrafinised in xylene and rehydrated through 
100% ethanol to 70% ethanol and deionised water (100% xylene > 100% ethanol > 
90% ethanol > 70% ethanol > deionised water; 10 minutes each step).  Following 
rehydration, heat-induced epitope retrieval was performed for 20 minutes in 
10molL-1 citric acid buffer (pH6.0) and then cooled to room temperature.  Lung 
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sections were rinsed in deionised water for 10 minutes and then 
phosphobuffered saline (TBS).  Endogenous peroxidise activity was then blocked 
via incubation in methanol containing 3% (v/v) hydrogen peroxide (H2O2) for 20 
minutes at room temperature (Sigma Aldrich, Poole, UK).  Non-specific blocking 
using Normal Horse Serum (2.5%) (Vector Laboratories, Peterborough, UK) was 
performed for 1 hour at room temperature before addition of primary antibody 
or IgG control overnight at 4oC in diluent (15% (v/v) primary antiserum, 10% 
(w/v) BSA in PBS).  See Table 2.2 for antibody concentrations.  A negative 
control was also utilised by incubating a slide with antibody diluent only and 
appropriate IgG controls were used.  Subsequently, sections were washed in TBS 
for 2 x 10 minutes at room temperature.  Secondary incubation using anti-rabbit 
horseradish peroxidise polymer (Vector Laboratories, Peterborough, UK) was 
performed for 1 hour at room temperature followed by 2 x 10 minute washes in 
PBS.  Following secondary incubation, protein visualisation was achieved under 
the microscope with the DAB substrate kit (3,3- diaminobenzidine, hydrogen 
peroxide and nickel solution; Vector Laboratories, Peterborough, UK) until a 
dark-brown staining was apparent which was typically 3-5 minutes.  To stop the 
immunoperoxidase reaction sections were placed in deionised water.  Sections 
were counterstained in haematoxylin and allowed to develop a blue/purple 
background before sections were dehydrated in an increasing ethanol gradient to 
histoclear (70% ethanol > 90% ethanol > 100% ethanol > 100% xylene; 10 minutes 
each step).  Finally, glass coverslips were mounted onto each slide using Tissue-
Mount (Sakura Finetek, Alphen aan den Rijnm, Netherlands). 
2.5.3  Alpha Smooth Muscle Actin and Von Willebrand Staining  
α-SMA staining was used to confirm pulmonary vascular remodelling and 
muscularisation in mouse models and smooth muscle staining in human lung 
sections.  Von Willebrand staining (vWF) was utilised to confirm endothelial cells 
staining in human lung sections.  3µm mouse/human lung sections were de-
parrafinised in xylene for 30 minutes and rehydrated through an alcohol gradient 
to water (100% ethanol (x2), 90% ethanol (x1) and 70% ethanol (x1)).  Heat-
induced epitope retrieval was carried out in 10mmol-1 citric acid buffer (pH6.0) 
for 20 minutes followed by a period to cool.  Non-specific blocking using Normal 
Horse Serum (2.5%) (Vector Laboratories, Peterborough, UK) was performed for 1 
hour at room temperature before addition of primary antibody or IgG control 
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overnight at 4oC in diluent (15% (v/v) primary antiserum, 10% (w/v) BSA in 
PBS).α-SMA/vWF primary antibodies were incubated over night at 4oC in diluent 
(15% (v/v) primary antiserum, 10% (w/v) BSA in PBS).  Endogenous peroxidise 
activity was then blocked via incubation in methanol containing 3% (v/v) 
hydrogen peroxide (H2O2) for 20 minutes at room temperature (Sigma Aldrich, 
Poole, UK).  Incubation with anti-rabbit horseradish peroxidise polymer 
conjugated secondary antibody (ImmPress anti-rabbit IgG peroxidise, Vector 
Laboratories, Peterborough, UK) was performed for 1 hour at room temperature 
followed by 2 x 10 minute washes in PBS.  α-SMA/vWF staining was then 
visualised using DAB substrate kit producing a dark-brown colour within 3-5 
minutes.  Sections were counterstained with Harris haemotoxylin to develop a 
blue/purple background for clearer visualisation.  Sections were then 
dehydrated in increasing ethanol concentrations to histoclear before mounting.  
Concentrations of antibodies used in immunohistochemistry are depicted in 
Table 2-2. 
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Table 2-1: Clinical characteristics for human lung sections.  All available information for 
patients from Papworth Hospital, Cambridge is depicted in table.  Duration of disease length and 
treatment course was unavailable.  HPAH=heritable PAH; IPAH=idiopathic PAH. 
 
 Available Patient Information BMPR2 Mutation 
Control   
1. Female; No information available  
PAH   
1. 
 
 
2. 
Female; HPAH; aged 38 years; transplant; 
mean PAP 56mmHg; IV epoprostinil 
treatment 
 
Female; HPAH; aged 30 years; transplant; 
mean PAP 46mmHg; IV iloprost and 
sildenafil 
No 
 
 
Yes 
   
3. Female; IPAH; aged 44; transplant; mean 
PAP 86mmHg; IV epoprostinil 
No 
   
 
 
123 
 
Table 2-2: Antibodies used for Immunohistochemistry.  α-SMA=alpha smooth muscle actin; 
BMPR-II=bone morphogenetic protein receptor-II; ERα=estrogen receptor alpha; ERβ=estrogen 
receptor beta; GPER= G-protein coupled estrogen receptor; vWF=Von Willebrand Factor. 
Antibody Type (Clone) Source 
(Catalogue number) 
 
Immunohistochemistry 
Dilution used 
α-SMA Rabbit polyclonal Abcam (ab5694)  1:500 (0.2µgml-1) 
 
ERα Rabbit polyclonal Santa Cruz (sc-7207) 1:200 (1µgml-1) 
 
ERβ Rabbit polyclonal Abcam (ab-3577) 1:200 (5µgml-1) 
 
GPER Rabbit polyclonal Abcam, (ab-39742) 1:100 (5µgml-1) 
 
vWF Rabbit polyclonal Dako (A0082) 1:1000 (0.1µgml-1) 
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2.6 Vascular Reactivity 
2.6.1 Small Vessel Wire Myography 
Intralobar pulmonary artery was used for determination of pulmonary vascular 
reactivity.  Briefly, the intralobar pulmonary artery (~250µm diameter) was 
dissected from the left lung located posterior to the hilum.  Once isolated, the 
surrounding parenchyma and airway smooth muscle was gently removed from 
the pulmonary artery and the artery was placed in ice cold PSS until use. 
Small vessel wire myography was used to assess the vascular reactivity in mice.  
A 4-channel wire myograph (DMT Multi Wire Myograph, Denmark) organ bath was 
prepared with 5ml of PSS, heated to 37oC ± 0.5oC and continuously bubbled with 
16% O2, 5% CO2 and 79% N2, designed to replicate gas composition and conditions 
observed in the lung in vivo.  Following dissection from the lung, intra-lobar 
artery was divided into 2mm segments and two sections of stainless steel wire 
(40µm diameter, 3cm length) were passed through the vessel lumen and tied to 
their respective mounting jaws on the myograph and the vessel was securely 
tightened (Figure 2-4).  Once mounted the vessels were allowed to equilibrate 
for ~30 minutes under resting/zero tension. 
2.6.2 Application of Tension 
The pulmonary circulation is a low pressure system with pulmonary arterial 
pressures between 9-18mmHg.  To replicate in vivo pressures, control vessels 
from normoxic mice were set up with a tension to achieve a normal transmural 
pressure from 12-16mmHg representative of a normoxic mouse pressure in vivo. 
On the other hand, vessels from hypoxic mice were set up at tensions equivalent 
to their elevated in vivo mean pressures observed in PAH (25-30mmHg).  These 
pressures were achieved by altering the force transducer in millinewtons (mN) 
and the pressure was deduced from the force of the tension using the equation 
in Figure 2-5.  For these, resting/zero tension when no force is applied (Xo), 
active tension when force is applied and wires are stretched (Xi) and passive 
force (F) values were required.  In addition, 2 (mm) was used as the constant for 
vessel length (L).  The internal circumference with wires just touching before 
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application of tension is equal to (2+π) x wire diameter (40µm)= 205.6 µm.  
Tension was applied incrementally until the appropriate pressure was achieved. 
 
Figure 2-4: Wire myograph set-up. 
Used to study small resistance vessels, vascular reactivity in the lung was assessed in 2mm 
sections of pulmonary intralobar artery. 
Potassium chloride (KCl) was the contractile agent used to initiate depolarisation 
and contraction in smooth muscle cells.  KCl-induced smooth muscle cell 
contraction is due to membrane depolarisation causing Ca2+ entry through 
voltage-operated Ca2+ channels and a reduction in K+ efflux (Ganitkevich et al. 
1991).  After a 30 minute equilibration, the response to 50mmolL-1 KCl was 
determined for a 30 minute period.  The maximum KCl response produced from 
two consecutive readings was used to normalise the contraction in these vessels.  
A contractile response of ≥ 1 millinewton (mN) was considered sufficient to 
perform a cumulative concentration response curve. 
2.7 Serotonin Cumulative Concentration Response Curve 
A baseline tension was established in vessels prior to commencing the 
cumulative response curve to the potent pulmonary vasoconstrictor serotonin 
(Sigma Aldrich, Poole, UK).  Curves were initiated at the lowest concentration of 
1x10-9 molL-1 and increased in 0.5 log increments to a final organ bath 
concentration of 1x10-4 molL-1.  For consistency between vessels and 
experiments, serotonin was added once the vascular response had reached a 
plateau which was typically following ~3 minutes.  Data was analysed using 
Myodaq/Myodata 2.01 M610+ software and GraphPad Prism 5.0© was used to 
derive Emax and EC50 values. 
2mm intra-
lobar 
pulmonary 
artery 
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 (2π) x F
2 x L (205.6 + 2(Xi – Xo)) / 1000
Pi=
 
 
Figure 2-5: Equation to calculate transmural pressure.  
The calculated Pi value must be divided by 0.1333 in order for successful conversion to mmHg.  
F=force (mN); L=length of vessel (2mm); Xi=active tension; Xo=resting/zero tension.  205.6µm is 
the calculated internal circumference of the wires when using 40µm diameter wires. 
2.8 Tissue Culture 
All tissue culture procedures were carried out in sterile conditions using a 
Biological Safety Class II vertical laminar flow cabinet.  Human pulmonary artery 
smooth muscle cells (PASMCs) were the cell model utilised, provided by 
Nicholas. W. Morrell, University of Cambridge, UK.  Cells were stored at 37oC 
and maintained in 5% CO2, 95% air. 
2.8.1  Human Pulmonary Artery Smooth Muscle Cells 
Briefly, PASMCs utilised were derived from pulmonary arteries (1-3mm arterial 
diameter) from non-heritable idiopathic PAH patient origin or were obtained 
from non-PAH donors undergoing lung biopsies and studied as controls.  Patient 
information for cell lines utilised is depicted in Table 2-3.  PASMCs were grown 
in a 75cm2 culture flask and media was replaced every 48 hours.  Cells were 
grown in Dulbeccos’s Modified Eagle Medium (DMEM; Gibco, Paisly, UK) 
supplement with 10% (v/v) fetal bovine serum (Sera Laboratories International, 
West Sussex, UK), 2mmolL-1 glutamine, and sterile filtered antibiotic antimycotic 
solution (contains 10,000 unitsml-1 penicillin G, 10mgml-1 streptomycin sulphate 
and 25µgml-1 amphotericin B; Sigma Aldrich, Poole, UK).  Cells were passaged 
when the monolayer approached 90% confluency to prevent cell growth arrest by 
cell contact inhibition.  For passaging, cells were rinsed with two washes of 
0.06% (v/v) trypsin-ethylenediamine tetra-acetic acid (EDTA) (trypsin-EDTA; 
Gibco, Paisly, UK) and placed at 37oC to encourage the monolayer to detach 
from the flask surface.  Once 95% cells were detached, which was typically 
following less than 5 minutes incubation, 10ml 10% (v/v) FBS DMEM was added to 
the flask to neutralise the trypsinisation reaction.  For plating of cells, cell 
density was assessed using a haemocytomoeter. 
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2.8.2 Proliferation Assays Using [3H]-Thymidine Incorporation 
The [3H] thymidine incorporation assay is a reliable assay used to measure 
proliferation by directly measuring DNA synthesis.  It utilises a strategy wherein 
radioactive labelled [3H]-thymidine is incorporated into new strands of 
chromosomal DNA during mitosis.  PASMCs (passage 3-5) were seeded in 24 well 
plates (growth area 2.0cm2) at a density of 10,000 cells per well and grown to 
60% confluency in 10% (v/v) FBS DMEM.  Cells were then quiesced in 0.2% (v/v) 
FBS phenyl-red free DMEM for a period of 24 hours prior to addition of agonist for 
72 hours.  After 48 hours, where appropriate, all antagonists were added 30 
minutes before addition of agonist.  Drugs applied were replaced every 48 hours 
and for the last 24 hours, 0.1µCi [3H]-thymidine was added to each well.  To stop 
the experiment following 72 hours incubation, cells were washed twice in PBS.  
Protein was precipitated by three washes in 5% (w/v) trichloroacetic acid 
followed by addition of 0.3molL-1 NaOH for 30 minutes to promote cell lysis.  The 
total volume of each well (500µl) was then transferred to a 1.5ml eppendorf and 
1ml Eicoscint A scintillation fluid (Eicoscint, Atlanta, USA) was added to each 
tube.  The radioactivity level of [3H]-thymidine was measured as an index of 
DNA synthesis in a Wallac Scinitillation counter (PerkinElmer, Cambridge, UK).  
Data are expressed as fold change compared to 2.5% FBS control.  Proliferation 
data are expressed as fold change compared to 2.5% FBS control. 
Estrogen receptor agonists: PPT (chemical name: 4,4',4''-(4-Propyl-[1H]-pyrazole-
1,3,5-triyl)trisphenol); DPN (chemical name: 2,3-bis(4-Hydroxyphenyl)-
propionitrile) and G1 (chemical name: (±)-1-[(3aR*,4S*,9bS*)-4-(6-Bromo-1,3-
benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]- 
ethanone) were used at a concentration range between 0.001-10 nmolL-1.  All 
estrogen receptor antagonists: MPP (MPP dihydrochloride); PHTPP (chemical 
name: 4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol) 
and G15 (chemical name: (3aS*,4R*,9bR*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-
3a,4,5,9b-3H-cyclopenta[c]quinoline) were used at a concentration of 1µmolL-1. 
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Table 2-3: Clinical characteristics and patient information for human PASMCs.  All available 
patient information received from University of Cambridge is depicted in table below.  HPAH= 
heritable PAH; IPAH= idiopathic PAH. 
 
 
 Available Patient Information BMPR2 Mutation 
Control   
 Female  
1. 58 year old No 
2. 64 year old No 
3. 59 year old No 
4. 
 
5. 
64 year old 
 
72 year old 
No 
 
No 
  
Male 
 
 
1. 62 year old with emphysema No 
2. 72 year old No 
3. 76 year old No 
   
PAH   
 Female  
1. 24 year old; IPAH  
2. 30 year old; HPAH Yes (R899X) 
 
3. 39 year old, HPAH Yes (N903S) 
   
 Male  
1. 23 year old, HPAH Yes 
2. 43 year old, IPAH No 
3. 56 year old, IPAH No 
 
 
129 
 
2.9 Western Blotting 
2.9.1  Human PASMCs 
Human PASMCs were seeded (passage 3-5) in 6 well plates (growth area 9.6cm2) 
at a density of 25,000 cells per well and grown to 80% confluency in 10% (v/v) 
FBS DMEM.  Cells were then quiesced for 24 hours in 0.2% (v/v) FBS DMEM 
followed by addition of agonist and/or antagonist for experiment dependent 
required times.  The experiment was terminated by placing the 6-well plates on 
ice and the media was immediately aspirated and cells were subsequently 
washed in ice cold PBS three times.  Ice cold radioimmunoprecipitation assay 
(RIPA)-buffer (64mM HEPES, pH7.5, 192mM NaCl, 1.28% (v/v) Triton-X-100, 0.64 
(w/v) sodium deoxycholate, 0.1% (w/v) SDS, 0.5molL-1 sodium fluoride, 5mmolL-1 
EDTA, 0.1molL-1 sodium phosphate, 1µgml-1 soyabean trypsin inhibitor, 1µgml-1 
benzamidine, 0.01mmolL-1 PMSF) was then added to each well for 15 minutes 
under gentle agitation.  Following this, cell lysates were collected by scraping 
and collected samples were stored at -80oC until further use. 
2.9.2  Mouse Pulmonary Arteries 
Main left and right mouse pulmonary arteries and pulmonary trunk were 
dissected out at necropsy as these are the smallest that can be practically 
dissected from the mouse and provide a valid representation of the pulmonary 
circulation.  Immediately following death, the pulmonary arteries were snap 
frozen in liquid nitrogen and transferred to -80oC until required.  Pulmonary 
arteries from one mouse were placed in 150µl of RIPA-buffer with three 5mm 
stainless steel balls (QIAGEN®, Manchester, UK).  Pulmonary arteries were 
homogenised using a QIAGEN® TissueLyser II for 2 minutes (4 x 30 second 
intervals).  Protein samples were then placed on ice to rest for 30 minutes prior 
to being centrifuged at full speed for 15 minutes at 4oC.  Supernatant was 
removed and placed in a fresh tube and then stored at -80oC until use for 
Western Blot protein analysis. 
2.9.3  SDS-PAGE 
Protein was separated using SDS-PAGE (sodium dodecyl sulphate polyacrylamide 
gel electrophoresis), a technique that separates the proteins according to their 
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molecular weight.  Briefly, protein samples were loaded at 10-20µgml-1 as 
assessed using a BCA (bicinchoninic acid) Protein Assay (Thermo Scientific) and 
standard curve analysis.  Protein samples were subjected to reducing conditions 
in the presence of NuPAGE® LDS (lithium dodecyl sulphate) Sample Buffer (4X) 
and NuPAGE® Reducing Agent (10X) (10mmolL-1 dithiothreitol) and heated to 
70oC for 10 minutes.  Samples were loaded into NuPAGE® Novex® 4-12% Bis-Tris 
Precast Gels and subjected to 150V constant in the presence of NUpAGE® MES or 
MOPS SDS Running Buffer.  SeeBlue Plus2 pre-strained size standard (1kb) 
(Invitrogen, Paisley, UK) was used as a basis for protein molecular weight 
comparison.  Once the samples had been fractionated they were transferred to a 
polyvinylidene difluoride (PVDF) membrane (Millipore, County Durham, UK) for a 
30V constant for 2 hours to allow high protein absorption.  The protein-loaded 
PVDF membrane was then washed for 15 minutes three times in Tris-buffered 
saline (20mmolL-1 Tris pH7.5, 150mmolL-1 NaCl) containing 0.1% (v/v) Tween-20 
(TBST; Sigma Aldrich, Poole, UK). 
2.9.4  Immunoblotting 
Immunoblotting was the analytical technique used to detect proteins.  Initially, 
membranes were blocked in 5% (w/v) non-fat dry milk suspended in TBST at 
room temperature under gentle agitation to prevent interactions between the 
membrane and primary antibody used for detection of target protein.  Following 
this, membranes were washed as before in TBST and were exposed to primary 
antibody diluted in 5% (w/v) bovine serum albumin (BSA; Sigma Aldrich, Poole, 
UK) in TBST overnight at 4oC.  See Table 2-4 for optimised antibody 
concentrations.  Subsequently, membranes were washed in TBST before addition 
of horse-radish peroxidise (HRP) conjugated secondary antibody diluted in 5% 
(w/v) non-fat dry milk-TBST for 1 hour at room temperature.  Again membranes 
were thoroughly washed in TBST to limit background activity.  Protein was 
visualised using the enhanced chemiluminescent detection system (ECL-
detection system; Amersham Bioscience UK Ltd. Buckingham, UK).  Briefly, 
membranes were exposed for 1 minute to a 1:1 dilution of ECL solution mix, dry 
blotted and placed in a light sensitive cassette.  General purpose Kodak X-ray 
photographic film was used to develop and visualise proteins. 
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2.9.5  Quantitative Analysis of Protein 
α-tubulin was used as a loading control where the molecular weight did not 
overlap with the size of previously analysed proteins.  Equal loading was 
assessed by densitometrical analysis and performed using TotalLab TL100 
software via calculation of protein:α-tubulin ratio. 
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Table 2-4: Table of antibodies used for immunoblotting. 
Primary antibodies were applied to membrane overnight at 4oC in 5% (w/v) BSA-TBST.  
Secondary antibodies were applied for 1 hour at room temperature in 5% (w/v) non-fat dry milk-
TBST  
Reactive 
Protein 
Molecular 
weight 
Primary 
antibody 
dilution 
Supplier 
(Catalogue 
Number) 
Antibody 
Origin 
Secondary 
antibody 
dilution 
BMPR2 115kDa 1:500 BD 
Transduction 
Laboratories 
 
Mouse 
monoclonal 
1:5000 
ERα 66kDa 1:250 Santa Cruz (sc-
7207) 
Mouse 
monoclonal 
1:5000 
ERβ 63kDa 1:1000 Cell Signalling 
Technology 
#5513 
(discontinued) 
 
Rabbit 
polyclonal 
1:5000 
ERβ 55kDa 1:1000 Abcam 
(ab3577)  
 
Rabbit 
monoclonal 
1:5000 
GPER 55kDa 1:250 Abcam 
(ab39742) 
 
Rabbit 
polyclonal 
1:5000 
α-tubulin 50kDa 1:5000 Abcam 
(ab7291) 
 
Mouse 
monoclonal 
1:10,000 
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2.10 mRNA Expression  
2.10.1  Mouse Lungs 
One lobe dissected from the right lung was lysed in 700µl QIAzol Lysis Reagent 
(QIAGEN®, Manchester, UK).  Briefly the lung lobe was placed in an RNase free 
2ml tube with one 5mm stainless steel ball and homogenised using a QIAGEN® 
TissueLyser II for 2 minutes (4 x 30 second intervals). 
2.10.2  Human PASMCs 
Human PASMCs (passage 3-5) were seeded in 6 well plates at a density of 25,000 
cells per well and grown to 90% confluency in 10% (v/v) FBS DMEM.  Cells were 
washed three times with cold PBS to terminate experiment and 700µl QIAzol 
Lysis Reagent was then added directly to the cells for lysis.  Cells in QIAzol were 
transferred to RNase free tubes for storage at -80oC until further use. 
2.10.3  RNA Extraction 
RNA was extracted from mouse lungs and human PASMCs using the QIAGEN® 
RNeasy Mini Kit (QIAGEN®, Manchester, UK).  Tubes were brought to room 
temperature allowing dissociation of nucleoprotein complexes.  Chloroform was 
then added directly to the QIAzol and shaken vigorously to encourage phase 
separation in the subsequent step.  Samples were then centrifuged for 15 
minutes at 10,000rpm at 4oC to separate RNA from DNA, and organic proteins 
and lipids.  The upper colourless phase containing the RNA was transferred into a 
clean RNase free tube and 1.5 volumes of 100% ethanol were added to clean the 
RNA by gentle pipette mixing.  Samples were then transferred to a spin column 
and centrifuged at room temperature for 15 seconds at 10,000rpm.  No RNA 
extraction is completely sufficient at eliminating DNA therefore a DNase 
digestion was performed for a more complete DNA removal.  Samples were 
washed in RWT Buffer and then treated with DNase I in RDD Buffer (QIAGEN®, 
Manchester, UK) for 30 minutes.  Another RWT Buffer wash was performed 
before the RNA extraction was continued.  Samples were washed in RPE Buffer 
twice at room temperature and to eliminate carryover of any buffer the spin 
column was then transferred to a 1.5ml tube.  30µl of RNase free water was 
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added directly onto the spin column and samples were then centrifuged at 
10,000rpm for 1 minute at room temperature.  RNA integrity and quantification 
was then assessed immediately using a NanoDrop ND-1000 Spectrophotometer 
(Nano-Drop Technologies, Delaware, USA).  Absorbance of RNA was quantified at 
260nm and 280nm, and the 260/280 ratio was calculated.  A 260/280 ratio of 
≥2.0 was achieved in all samples and was indicative of RNA purity. 
2.10.4  cDNA Synthesis 
High Capacity cDNA Reverse Transcription Kits (Life Technologies, Paisley, UK) 
were used for reverse transcription (RT) of total RNA to single stranded cDNA.  A 
20µl reaction was used with 500ng of RNA.  A master-mix containing dNTPs, 
random hexamers and RNase inhibitor, supplied in the kit, was added to the RNA 
in a 96 well plate and the following cycling conditions were used for 
amplification of cDNA: 10 minutes at 25oC, 30 minutes at 48oC, 5 minutes at 95oC 
and 12oC forever. 
2.10.5  Quantitative Real Time-PCR  
Quantitative real time-PCR (qRT-PCR) was used to validate mRNA expression 
using TaqMan® Gene Expression probes (Applied Biosystems, Paisley, UK).  See 
Table 2-5 for Assay IDs.  mRNA & long non-coding RNA probes (Life Technologies, 
Paisley, UK) consisted of unlabelled PCR primers and a TaqMan® probe with a 
FAM® or VIC® dye label on the 5’ end and a nonfluorescent quencher on the 3’ 
end.  Samples were loaded at 1ug cDNA in triplicate using a 384-well plate 
format.  To assess for reagent and reaction contamination a no template control 
(NTC) was used for each gene tested in triplicate per experiment.  A Viia 7 
machine (Life Technologies, Paisley, UK) was used to assess gene expression 
using the following cycling conditions: 50oC for 2 minutes, 95oC for 10 minutes, 
then 50 cycles of 95oC for 15 seconds and 60oC for 1 minute.  Gene expression 
was defined by the cycle threshold (Ct value) inversely proportional to the 
amount of target nucleic acid in the sample.  Ct values were accepted ≤ 36 given 
technical replicate efficiency and were indicative of positive reactions.  The 
data is represented as the relative quantification (RQ; 2-XXCt) or fold change 
compared to the calibrator. 
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Table 2-5: TaqMan gene expression assay IDs supplied by Applied Biosystems. 
AR=androgen receptor; BMPR2= bone morphogenetic protein receptor-II; ESR1=estrogen receptor 
alpha; ESR2= estrogen receptor beta; Id=Inhibitor of DNA binding; Srd5a1=5α-reductase type I. 
Gene Species Assay ID 
AR Mouse Mm00442688_m1 
BMPR2 Mouse Mn00432134_m1 
ESR1 Mouse Mm00433149_m1 
 Human Hs00174860_m1 
ESR2 Mouse Mm00599821_m1 
 Human  Hs01100353_m1 
GPER Mouse Mm02620446_m1 
 Human Hs01922715_s1 
GAPDH Mouse Mm99999915_g1 
 Human Hs03929097_g1 
Id1 Mouse Mm00775963_g1 
 
Id3 Mouse Mm01188138_g1 
 
Smad1 Mouse Mm00484723_m1 
 
Srd5a1 Mouse Mm00614213_m1 
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2.11  Plasma Testosterone Levels in Mice 
2.11.1  Preparation of Mouse Plasma Samples 
Immediately following necropsy, approximately 1ml of whole blood was removed 
from the open chest of each mouse and stored in a 1.5ml tube.  Whole blood was 
left undisturbed at 4oC for 30 minutes.  Samples were then centrifuged for 15 
minutes at 4000rpm in a refrigerated centrifuge at 4oC, the resulting 
supernatant is designated plasma.  Plasma samples were immediately 
transferred to a clean tube and stored at -80oC until required. 
2.11.2  ELISA 
A testosterone ELISA (R&D Systems™, Abingdon, UK) was performed in mouse 
plasma samples following castration to confirm the successful depletion of 
circulating testosterone levels.  The assay is based on a competitive binding 
technique using a monoclonal antibody specific for testosterone.  Plasma 
samples were diluted 10-fold using calibrator diluent provided.  Reconstituted 
testosterone standard was utilised at concentrations between 10ngml-1 to 
0.041ngml-1 (3-fold dilutions) with 10ngml-1 standard serving as the high standard 
and the calibrator diluent alone serving as the zero standard (B0) (0ngml
-1).  
Briefly, primary antibody solution was added to each well of the microplate for 1 
hour at room temperature under gentle agitation.  For non-specific binding (NSB) 
confirmation, 4 wells received no antibody incubation.  Primary antibody was 
then aspirated and all wells of the microplate received a thorough wash four 
times using wash buffer provided.  100µl standard, control (R&D Systems™, 
Abingdon, UK) or sample was added to each well (in triplicate) and 100µl 
calibrator diluent was then added to NSB and to the zero standard (B0) wells.  
50µl testosterone conjugate was added to each well and incubated for 3 hours at 
room temperature under agitation at 500rpm on a horizontal orbital microplate 
shaker.  Following incubation, all wells were washed 4 times with wash buffer 
and substrate solution was added to each well.  At this stage the microplate was 
concealed and protected from light for 30 minutes at room temperature.  Stop 
solution was subsequently applied and the plate was promptly analysed using a 
microplate reader set to 450nm. 
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2.11.3  Standard Curve Analysis 
Triplicate readings for each standard, control and sample were averaged and the 
NSB optical density was subtracted.  A standard curve was created by plotting 
mean absorbance for each standard against the concentration on a logarithmic 
x-axis and a best-fit curve was obtained.  %B/B0 was calculated by dividing 
corrected optical density for each standard or sample by the corrected B0 optical 
density and multiplying by 100. 
2.12  Statistical Analysis 
All statistical analysis was performed using GraphPad Prism 5.0 Inc© software.   
Unpaired student’s t-tests were used for comparing two treatment groups.  One-
Way ANOVA was employed when two or more independent groups were 
compared, followed by Bonferroni’s or Tukey’s post hoc-test where appropriate.  
Two-Way ANOVAs were used to analyse all in vivo experiments where there was 
more than one independent variable and multiple observations for each variable, 
for example, normoxic/hypoxic and vehicle/MPP treatment.  Two-Way ANOVAs 
were followed by a Bonferroni’s post hoc-test.  All data are expressed as mean ± 
standard error of mean (SEM). 
 
 
Chapter 3. 
Development of Pulmonary Arterial Hypertension 
in Females is Estrogen Receptor Alpha Dependent 
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3  
3.1 Introduction 
The incidence of pulmonary arterial hypertension (PAH) is higher in females 
(Badesch et.al. 2010; Humbert et.al. 2006; Ling et.al. 2012).  For example, the 
female to male ratio is currently reported in the largest REVEAL Registry as 
approximately 4.1:1 in idiopathic pulmonary arterial hypertension (IPAH) and 
3.8:1 in associated PAH (APAH) (Badesch et.al. 2010).  However, despite an 
increased prevalence in females, females with PAH have better right ventricular 
function and survival compared to males (Benza et.al. 2012; Humbert et.al. 
2010a; Shapiro et al. 2012).  Reasons for these gender differences remain 
unclear.  A role for gender-associated factors, such as sex hormones, and in 
particular estrogens, has been proposed to play a pivotal role in PAH 
pathogenesis. 
Until recently, animal models have offered limited insight into gender 
differences in PAH owing to the ‘estrogen paradox’ whereby female rodents 
exhibit less severe hypoxic and monocrotaline PAH compared to males (Benza 
et.al. 2012; Humbert et.al. 2010a; McMurtry et al. 1973; Rabinovitch et.al. 
1981; Resta et.al. 2001; Shapiro et.al. 2012).  In addition, estrogen or estrogen 
metabolites can protect male or ovariectomised female rats against 
monocrotaline and hypoxia induced PAH (Benza et.al. 2012; Farhat et al. 1993; 
Lahm et.al. 2012a; Shapiro et.al. 2012; Yuan et.al. 2013).  However, there is 
converging clinical evidence suggesting that the estrogen pathway is a major risk 
factor in females with PAH (Morse et al. 1999; Pugh & Hemnes 2010).  
Polymorphisms in aromatase (CYP19A1) are associated with higher estrogen 
levels and an increased risk of PAH development in female patients with 
advanced liver disease (Roberts et al. 2009b).  In line with this, physiological 
concentrations of estrogen mediate proliferation of human pulmonary artery 
smooth muscle cells (PASMCs) (White et.al. 2011). Experimentally, in three 
serotonin-dependent models of pulmonary hypertension (PH) there is a female 
susceptibility related to endogenous circulating estrogen (Dempsie et.al. 2011; 
Dempsie et.al. 2013; White et.al. 2011).  In addition, conversion of estrogen to 
active metabolites via cytochrome P450 1B1 (CYP1B1) mediates ER-independent 
effects of estrogen.  Altered estrogen metabolism is implicated in PAH 
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development and CYP1B1 is expressed at elevated levels in lungs from IPAH and 
heritable (HPAH) female patients (White et al. 2012).  Furthermore, CYP1B1 has 
been identified as a modifier gene in bone morphogenetic protein receptor type 
2 (BMPR2) affected female HPAH patients inferring an increased disease risk 
(Austin et.al. 2009; West et.al. 2008). 
Dysfunctional BMPR2 signalling is recognised to play a pivotal role in the 
development of PAH as mutations in BMPR2 are responsible for ~80% of HPAH 
cases (Machado et.al. 2009).  Penetrance for this gene is incomplete however; as 
only 20% of BMPR2 mutation carriers manifest PAH (Newman et.al. 2004).  
Therefore it is assumed additional risk factors, genetic or environmental, are 
involved.  Female gender increases the penetrance of BMPR2 mutations in HPAH 
(Machado et al. 2009) and consistent with this BMPR2 gene expression is higher 
among control males compared to females (Austin et al. 2012).  BMPR2 may be a 
target of ERα (Rajkumar et.al. 2010) and it has been shown that BMPR2 
expression is suppressed via this receptor (Austin et al. 2012) giving a functional 
role for estrogen and ERα in PAH. 
The effects of estrogen are primarily mediated by activation of estrogen 
receptor ERα and ERβ, and these effects can be both genomic and non-genomic.  
Very rapid, non-genomic effects of estrogen have also been described through 
activation of the G-protein coupled receptor, GPER.  ERα and ERβ antagonists 
have been shown to protect against hypoxic PH and monocrotaline PH in male 
rats (Lahm et al. 2012b; Umar et al. 2011b) and indicate both receptors play a 
functional role in the lung during PH.  The potential roles that ERs play in the 
development of PH in ovary intact females, however, have yet to be established. 
The aims of this study were to evaluate gender differences in estrogen receptor 
expression and to characterise the influence of endogenous estrogen activity at 
ERα and ERβ in experimental models of PH.  We hypothesised an ER dependent 
mechanism for estrogen mediated PH in females and suggest that this is a result 
of altered ER expression and signalling.  Moreover we identify novel gender-
specific BMPR2 pathways by which ERα mediates the development of chronic 
hypoxic PH in female mice and spontaneous PH in the SERT+ female mouse 
model.  In addition, we hypothesise that our results are therapeutically relevant 
by using ovary intact females. 
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3.2 Results 
3.2.1  ERα and ERβ are Located in Human Pulmonary Vasculature 
and Expression is Altered in PAH 
ER localisation was investigated in human lung from non-PAH control and PAH 
patients by immunohistochemistry (see Methods: 2.5.2 Immunolocalisation of 
estrogen receptors in human lung).  In females, both ERα and ERβ expression 
was prominent in pulmonary arteries in both non-PAH control and PAH patients 
(Figure 3-1).  ERα was localised to adventitia, smooth muscle cells and 
endothelial cells.  Whilst some ERβ expression was observed in the adventitia 
and smooth muscle cells, expression was largely endothelial.  Smooth muscle 
cell and endothelial cell localisation was confirmed by staining consecutive 
sections with alpha smooth muscle actin (α-SMA) and von Willebrand Factor 
(vWF), respectively. 
Given the expression of both ERs in smooth muscle cells in human lung, we 
investigated the ER expression (both protein and mRNA) in isolated human 
PASMCs from female idiopathic (IPAH) and heritable (HPAH) PAH patients.  ERα 
was significantly elevated in human PASMCs from HPAH patients relative to non-
PAH controls (Figure 3-2A and B).  Additionally, ERβ levels at protein and 
transcript levels were unchanged in control versus both IPAH and HPAH patients 
(Figures 3-2C and D). 
3.2.2  Males and Females Express Different Levels of Estrogen 
Receptors in PASMCs 
We thought it important to also investigate levels of ERs in females compared to 
males in isolated human PASMCs from non-PAH control and PAH patients.  Levels 
of both ERα and ERβ were unchanged between male and female non-PAH 
controls (Figure 3-3A&B).  Interestingly, females expressed significantly higher 
levels of ERα relative to males in PAH (Figure 3-4A).  Conversely, ERβ was 
significantly less in females PAH PASMCs compared to males (Figure 3-4B). 
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3.2.3  ERα and ERβ are Expressed in Mouse Lung and Pulmonary 
Arteries 
Following the observation of altered ER expression in human lung in non-PAH 
control and PAH patients, ER expression was investigated in the female and male 
hypoxic mouse model.  In pulmonary arteries from female hypoxic mice there is 
a significant increase in the protein levels of ERα relative to pulmonary arteries 
from normoxic control mice (Figure 3-5A).  mRNA transcript levels for ESR1, the 
gene encoding ERα, were unchanged between normoxia and hypoxia (Figure 3-
5B).  In contrast, ERβ protein was significantly reduced in pulmonary artery in 
hypoxia although ESR2 transcript levels were unchanged in whole lung (Figure 3-
5C&D).  Both ERα and ERβ protein expression was unchanged in the pulmonary 
arteries from hypoxic male mice (Figure 3.6A&B). 
 
 
 
 
 
 
 
ERα
ERβ
Control PAH IgGα-SMA vWF
 
Figure 3-1: Immunolocalisation of ERα and ERβ in human non-PAH controls and PAH patient lung sections.   
ERα and ERβ stained dark brown.  Consecutive sections stained with α-SMA and vWF depicts smooth muscle and endothelial cell staining, respectively.  α-SMA= 
alpha smooth muscle actin; vWF= Von Willebrand Factor.  Arrows indicate smooth muscle and endothelial cell localisation.  Patient information for controls and PAH 
patients are shown in Materials and Methods section Table 2.1.  Scale bar=200µm.  
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Figure 3-2: Estrogen receptor -α and –β expression in control human female PASMCs 
compared to PAH human female PASMCs. 
ERα protein (A) and mRNA transcript (B) was significantly up-regulated in PAH human PASMCs 
compared to controls whereas ERβ protein (C) and mRNA transcript (D) was unaffected. 
Representative blots are shown for ERα and ERβ. Quantitative data are shown as ± SEM and 
analysed using an unpaired t-test.  *p<0.05 vs. control.  Patient information for three individual 
controls (controls 1-3), and three individual PAH patients (patients 1-3) are shown in Materials and 
Methods section: Table 2-3   n=3 individual patients/controls in each blot and the whole blot 
repeated in triplicate.  n of patients is indicated in each individual bar. 
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Figure 3-3: Comparison between ER expression in male and female human PASMCs from 
control non-PAH patients. 
ERα protein (A) and ERβ protein (B) were unchanged between female human PASMCs compared 
to males.  Representative blots are shown for ERα and ERβ. Quantitative data are shown as ± 
SEM and analysed using an unpaired t-test.  Patient information for females (control 1-3), and male 
non-PAH controls (controls 1-3), are shown in Materials and Methods section: Table 2.3.  n=3 
individual patients repeated in triplicate.  n is indicated in each individual bar. 
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Figure 3-4: Comparison between ER expression in male and female human PASMCs from 
PAH patients. 
ERα protein (A) was significantly higher in female human PASMCs compared to males.  ERβ 
protein (B) was significantly reduced in female human PASMCs compared to males. 
Representative blots are shown for ERα and ERβ. Quantitative data are shown as ± SEM and 
analysed using an unpaired t-test.  *p<0.05 vs. control. Patient information for females (patients 1-
3), and male patients (patients 1-3), are shown in Materials and Methods section: Table 2.3.  
Females: n=3 individual patients repeated in triplicate. n is indicated in each individual bar. 
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Figure 3-5: Estrogen receptor expression is altered in female mouse pulmonary artery in 
hypoxia. 
ERα protein in pulmonary artery (A) and mRNA transcript in whole lung (B) was significantly up-
regulated in hypoxia whereas ERβ protein in pulmonary artery (C) and mRNA transcript in whole 
lung (D) was significantly reduced. Representative blots are shown for ERα and ERβ. Quantitative 
data are shown as ± SEM and analysed using an unpaired t-test.  *p<0.05 vs. control. n=3 
pulmonary artery repeated in triplicate for each Western experiment; qRT-PCR, n=6 mouse whole 
lung samples repeated in triplicate.  n of pulmonary artery/lung is indicated in each individual bar. 
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Figure 3-6: Estrogen receptor expression is unchanged in male mouse pulmonary artery in 
hypoxia. 
ERα protein in pulmonary artery (A) and ERβ protein expression (B) unchanged in hypoxia in 
pulmonary arteries from hypoxic male mice.  Representative blots are shown for ERα and ERβ.  
Quantitative data are shown as ± SEM and analysed using an unpaired t-test.  n=3 pulmonary 
artery repeated in triplicate for each Western experiment. 
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3.2.4  Administration of an ERα Selective Antagonist Attenuates 
Development of Hypoxia-Induced PH in Female Mice 
As expression of ERα was increased in pulmonary arteries from female PAH 
patients and hypoxic female mice, this suggests ERα may play a role in the 
development of PAH specific to females.  To investigate this experimentally, 
both male and ovary intact female mice were dosed with the ERα antagonist MPP 
Dihydrochloride (MPP; 2mgkg-1day-1) or vehicle containing pellets during 
exposure to normoxia or 14 days of chronic hypoxia.  At the end of this 14 day 
period, RVSP, pulmonary vascular remodelling and RVH were assessed (see 
Methods: 2.3.3 Chronic Hypoxia).  Female mice developed hypoxia induced PH; 
RVSP, RVH and pulmonary vascular remodelling were all increased (Figure 3-7A-
C).  MPP attenuated the development of hypoxic PH by reducing elevations in 
RVSP (Figure 3-7A) whilst there was no effect on RVH (Figure 3-7B).  
Representative images of RVSP traces in females are shown in Figure 3-8.  
Furthermore, pulmonary vascular remodelling in response to hypoxia was 
significantly reduced by MPP treatment (Figure 3-7C) and muscularisation of 
distal pulmonary arteries was noticeably reduced (Figure 3-9).  The 
administration of MPP had no effect on the systemic circulation as indicated by 
no changes in mean systemic arterial pressure (mSAP) (Figure 3-10A) and heart 
rate (HR) (Figure 3-10B).  In this instance, hypoxia resulted in an increase in HR 
in vehicle treated mice. 
3.2.5  Administration of an ERα Selective Antagonist has no 
Effect of the Development of Hypoxia Induced PAH in Male 
Mice 
The effect of MPP was then assessed in male mice to determine any gender 
differences in the response to the ERα antagonist.  In contrast to the results 
observed in ovary intact females, MPP had no effect on the development of PH 
in males.  MPP has no effect on RVSP, RVH and pulmonary vascular remodelling 
(Figure 3-11A-C).  Representative images of RVSP traces in males are shown in 
Figure 3-12.  MPP treatment also had no effect on pulmonary arterial 
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muscularisation in male mice (Figure 3-13).  In addition, neither hypoxia nor MPP 
treatment had an effect on mSAP and HR in males (Figure 3-14A&B).  Absolute 
values for haemodynamics are depicted in Table 3-1. 
3.2.6  Body Weight and Uterine Weight were Unaffected by ERα 
Selective Antagonism 
Body weight in both females and males were unaffected by hypoxia and 
administration of MPP (Figure 3-15A&B).  Uterine weight at necropsy was also 
investigated as ERα knockout mice are observed to have abnormal reproductive 
function (Lubahn et al. 1993).  However, we observed no difference in uterine 
weight (Figure 3-16A) or in uterine weight to body weight ratio (Figure 3-16B) 
between vehicle treated and MPP treated groups.  In addition, hypoxia had no 
effect on uterine weight.  Absolute values for body weight and uterine weight 
are shown in Table 3-2. 
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Figure 3-7: MPP (2mgkg
-1
day
-1
)
 
attenuates the development of hypoxic pulmonary 
hypertension in female mice.   
Right ventricular systolic pressure (RVSP) (A), pulmonary vascular remodelling (B) and right 
ventricular hypertrophy (C) assessment in female mice.  Data are expressed as ± SEM analysed 
by Two-Way ANOVA followed by a Bonferroni’s post-hoc test.  † p<0.05; † † p<0.01; † † † p<0.001 
vs. normoxic; * p<0.05 vs. vehicle.  n=6-9 per group; n for each group is indicated on bar. 
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Figure 3-8: Representative RVSP traces from female mice. 
Six second representative traces are shown for vehicle treated normoxic and hypoxic females, and 
a female mouse treated with 2mgkg
-1
day
-1
 MPP. 
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Figure 3-9: MPP (2mgkg
-1
day
-1
) attenuates the development of hypoxic-induced pulmonary 
vascular remodelling in females. 
α-smooth muscle actin stains smooth muscle cells dark brown; counterstain is haematoxylin 
(purple/blue).  Representative images are shown from each group.  Scale bar = 20µm. 
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Figure 3-10: MPP (2mgkg
-1
day
-1
) treatment has no effect on systemic parameters in female 
mice. 
Mean systemic arterial pressure (Mean SAP) (A) and heart rate (HR) (B) are unchanged. Data are 
expressed as ± SEM analysed by Two-Way ANOVA followed by a Bonferroni’s post-hoc test.  
*p<0.05 vs. normoxic vehicle.  n=6-9 per group; n of mice for each group is indicated on bar.  Low 
heart rates observed (normal adult mouse ~500-600bpm) due to prolonged anaesthesia.  
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Figure 3-11: MPP (2mgkg
-1
day
-1
) has no effect on the development of hypoxic pulmonary 
hypertension in male mice. 
Right ventricular systolic pressure (RVSP) (A), pulmonary vascular remodelling (B) and right 
ventricular hypertrophy (C) assessment in male mice.  Data are expressed as ± SEM analysed by 
Two-Way ANOVA followed by a Bonferroni’s post-hoc test.  † p<0.05; † † p<0.01; † † † p<0.001 
vs. normoxic.  n=6-9 per group; n of mice for each group is indicated on bar. 
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Figure 3-12:  Representative RVSP traces from male mice. 
Six second representative traces are shown for vehicle treated normoxic and hypoxic males, and a 
male mouse treated with 2mgkg
-1
day
-1
 MPP. 
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Figure 3-13: MPP (2mgkg
-1
day
-1
) has no effect on the development of hypoxic-induced 
pulmonary vascular remodelling in males. 
α-smooth muscle actin stains smooth muscle cells dark brown; counterstain is haematoxylin 
(purple/blue).  Representative images are shown from each group.  Scale bar = 20µm. 
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Figure 3-14: MPP (2mgkg
-1
day
-1
) treatment and hypoxia have no effect on systemic 
parameters in male mice. 
Mean systemic arterial pressure (Mean SAP) (A) and heart rate (HR) (B) are unchanged.  Data are 
expressed as ± SEM analysed by Two-Way ANOVA followed by a Bonferroni’s post-hoc test.  n=6-
9 per group; n of mice for each group is indicated on bar. 
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Figure 3-15: MPP (2mgkg
-1
day
-1
) treatment and hypoxia have no effect on body weight in 
female and male mice. 
Body weight in female (A) and male (B) mice.  Data are expressed as ± SEM analysed by Two-
Way ANOVA followed by a Bonferroni’s post-hoc test.  n=10 mice per group. 
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Figure 3-16: MPP (2mgkg
-1
day
-1
) treatment and hypoxia have no effect on uterine weight in 
females 
Uterine weight in female mice (A) and uterus weight/body weight ratio (B) are unchanged by 
hypoxia and MPP treatment.  Data are expressed as ± SEM analysed by Two-Way ANOVA 
followed by a Bonferroni’s post-hoc test.  n=10 mice per group. 
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Table 3-1: Haemodynamic parameters in male and female mice dosed with MPP (2mgkg
-
1
day
-1
).   
Right ventricular systolic pressure (RVSP); Mean right ventricular pressure (MRVP); right 
ventricular diastolic pressure (RVDP); systolic systemic arterial pressure (sSAP); mean systemic 
arterial pressure (mSAP); diastolic systemic arterial pressure (dSAP); Heart rate (HR).  Data 
expressed as ± SEM analysed by a Two-way ANOVA followed by a Bonferroni’s post hoc test.  
*p<0.05, **p <0.01, ***p<0.001 vs. normoxic mice. † p <0.05, †† p<0.01, ††† p<0.01 vs. vehicle 
dosed mice.  n = 7-14 mice per group. 
Parameter Male Vehicle Male MPP Female Vehicle Female MPP 
     Normoxic 
 
    RVSP, mmHg 22.6 ± 1.1 24.0 ± 0.5 23.1 ± 0.8 22.8 ± 0.7 
MRVP, mmHg 14.8 ± 0.6 15.3 ± 0.5 13.7 ± 0.6 13.7 ± 0.4 
RVDP, mmHg 4.1 ± 0.34 4.4 ± 0.4 3.6 ± 0.5 3.7 ± 0.27 
sSAP, mmHg 119.9 ± 3.6 115.6 ± 2.6 109.9 ± 10.1 108.4 ± 5.7 
mSAP, mmHg 111.9 ± 3.5 98.7 ± 3.9 98.3 ± 12.9 100.7 ± 4.3 
dSAP, mmHg 102.2 ± 3.5 85.5 ± 5.3 83.1 ± 14.7 86.9 ± 4.2 
HR, bpm 406.6 ± 15.7 442.1 ± 8.9 344.7 ± 40.8 396.2 ± 18.5 
     Hypoxic 
 
    RVSP, mmHg 34.1 ± 2.1 *** 33.5 ± 1.9 *** 38.3 ± 1.9 *** 31.0 ± 1.9 *† 
MRVP, mmHg 16.1 ± 0.9 16.1 ± 0.6 18.7 ± 1.8 * 15.7 ± 1.4 
RVDP, mmHg 3.4 ± 0.8 2.8 ± 0.5 5.5 ± 0.6 * 2.9 ± 0.5 ††† 
sSAP, mmHg 113.0 ± 11.6 144.4 ± 15.9* † 131.3 ± 8.2 118.2 ± 8.5 
mSAP, mmHg 97.9 ± 107 107.4 ± 15.2  110.1 ± 8.3 106.7 ± 8.9 
dSAP, mmHg 84.7 ± 12.5 136.0 ± 20.23 **†† 92.1 ± 7.5 96.9 ± 10.5 
HR, bpm 452.9 ± 22.3 436.7 ± 22.7 450.4 ± 20.9 * 431.9 ± 23.9 
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Table 3-2: Ventricle, body weight and uterus weight in male and female mice WT mice dosed 
with MPP (2mgkg
-1
day
-1
).  Right ventricle (RV); left ventricle plus septum (LV + S);  RV/LV+S 
ratio, body weight and uterus weight.  Data expressed as ± SEM analysed by a Two-way ANOVA 
followed by a Bonferroni’s post hoc test.  * p<0.05 ** p <0.01, *** p<0.001 vs. normoxic mice. † p 
<0.05, †† p<0.01 vs. vehicle dosed mice.  n = 5-14 mice per group. 
 
 Group RV (mg) LV + S (mg) RV/LV+S Body 
weight (g) 
Uterus weight 
(mg) 
      
Normoxic      
Male      
Vehicle 29.6 ± 1.1 111.4 ± 2.3 0.27 ± 0.01 25.8 ± 0.8  
MPP 23.2 ± 0.7 ††† 103.9 ± 2.2 0.22 ± 0.01 24.1 ± 0.3   
Female      
Vehicle 19.6 ± 0.7 87.8 ± 1.6 0.22 ± 0.01 19.6 ± 0.3 85.9 ± 5.7 
MPP 23.1 ± 2.0 79.2 ± 2.7 † 0.26 ± 0.01 † 18.3 ± 0.4 74.9 ± 6.4 
      
Hypoxic      
Male      
Vehicle 25.0 ± 0.9 ** 94.6 ± 3.8 *** 0.27 ± 0.01 24.8 ± 0.8  
MPP 20.9 ± 1.2 85.9 ± 2.1 *** 0.24 ± 0.01 ** 23.2 ± 0.5  
Female      
Vehicle 22.38 ± 0.9 84.61 ± 4.4 0.27 ± 0.01 *** 18.6 ± 0.2  70.9 ± 4.8 
MPP 18.6 ± 0.9 † 70.9 ± 1.4 †† 0.26 ± 0.02 ** 17.1 ± 0.2  72.7 ± 5.3 
 
 
163 
 
3.2.7  ERα and ERβ Expression is Unchanged in Pulmonary 
Arteries from Female SERT+ Mice 
We wished to investigate the role of ERs in another model of PH which did not 
involve hypoxia.  ER expression was therefore examined in the pulmonary 
arteries from the female mice over-expressing the serotonin transporter (SERT+) 
that are susceptible to PH (MacLean et.al. 2004; White et.al. 2011).  Basal levels 
of ERs were investigated at 2 months of age prior to the onset of spontaneous 
PH.  It was observed that both ERα protein and ESR1 gene transcript were 
unchanged in SERT+ female mice relative to wildtype controls (Figure 3-17A&B).  
On the other hand, ERβ protein was down-regulated in female SERT+ pulmonary 
artery (Figure 3-17C) whereas ESR2 gene transcript was unchanged in whole lung 
relative to wildtype controls (Figure 3-17D). 
3.2.8  Spontaneous PH and Exaggerated Hypoxia-Induced PAH in 
Female SERT+ Mice is Reversed by ERα Selective 
Antagonism 
We wished to investigate if the effect of MPP were consistent in another model 
of PH that did not require chronic hypoxia.  We have previously shown that 
normoxic female SERT+ mice develop spontaneous PH at 5 months of age in an 
estrogen-dependent manner whilst male mice do not (White et al. 2011).  We 
hypothesised that the predominant circulating female hormone estrogen 
mediates the development and progression of PH in this model through activity 
at ERα.  We confirmed that vehicle treated female normoxic SERT+ mice 
demonstrated elevated RVSP and pulmonary vascular remodelling relative to 
vehicle-treated wildtype controls.  This was observed in the absence of RVH in 
normoxic conditions (Figure 3-18A-C) as previously described (White et al. 2011).  
The increase in RVSP and pulmonary vascular remodelling was abolished by MPP 
2mgkg-1day-1. 
We also exposed these mice to hypoxia as we previously showed that the PH 
phenotype was greatly enhanced in SERT+ hypoxic mice.  As before, the hypoxic 
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wildtype mice developed PH demonstrating increased RVSP and this was reduced 
by MPP (Figure 3-18A).  Pulmonary vascular remodelling and RVH were also 
elevated in wildtype mice, although MPP did not influence these.  This data 
supports previous results from this study using the C57Bl/6 wildtype background 
strain of wildtype mouse (Figure 3-7A-C).  Increased RVSP in hypoxic SERT+ 
vehicle-treated mice was reversed by MPP administration (Figure 3-18A).  In 
vehicle-treated SERT+ mice, hypoxia caused enhanced pulmonary vascular 
remodelling relative to hypoxic wildtype vehicle treated mice and this was 
markedly reduced by MPP (Figure 3-18B).  Representative images of RVSP traces 
in SERT+ females are shown in Figure 3-19.  Additionally, pulmonary vascular 
muscularisation, as observed by alpha smooth muscle actin staining was notably 
attenuated in normoxic and hypoxic SERT+ mice following MPP treatment (Figure 
3-20). 
Mean systemic arterial pressure was unaffected by hypoxic and MPP treatment in 
both wildtype and SERT+ mice (Figure 3-21A).  MPP treatment did however, 
noticeably reduce heart rate in normoxic SERT+ mice.  Further in hypoxia, 
wildtype mice had a reduced heart rate compared to normoxic wildtype mice 
(Figure 3-21B).  Absolute values for haemodynamics are shown in Table 3-3. 
3.2.9  Uterine Weight is Reduced Following MPP Administration 
ERα, but not ERβ knockout mice have abnormal reproductive function (Lubahn et 
al, 1993) suggesting that ERα may be central to a role in uterine development.  
In line with this we show in both WT and SERT+ mice that MPP significantly 
attenuates uterine weight (Figure 3-22A).  This is also evident when expressed as 
a ratio over body weight (Figure 3-22B).  Absolute values for body weight and 
uterine weight are depicted in Table 3-4. 
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Figure 3-17: Estrogen receptor expression is unchanged in 2 month female SERT
+
 mouse 
pulmonary artery.   
ERα protein in pulmonary artery (A) and mRNA expression in lung (B) is unchanged in female 
SERT
+
 mice.  ERβ protein in pulmonary artery (C) is decreased in SERT
+
 mice and mRNA 
expression (D) in lung is unchanged.  Representative blots are shown for ERα and ERβ. 
Quantitative data are shown as ± SEM and analysed using an unpaired t-test.  *p<0.05 vs. control. 
n=3 pulmonary artery repeated in triplicate for each Western experiment; qRT-PCR, n=6.  n of 
pulmonary arteries/lung for each group is indicated on bar in graph.  WT= wildtype.   
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Figure 3-18: MPP (2mgkg
-1
day
-1
) attenuates the development of pulmonary hypertension in 
female SERT
+
 mice.   
Right ventricular systolic pressure (RVSP) (A), pulmonary vascular remodelling (B) and right 
ventricular hypertrophy assessment (C).  Data are expressed as ± SEM and analysed using a Two-
Way ANOVA followed by a Bonferroni’s post-hoc t-test.  *p<0.05, ** p<0.01, *** p<0.001 vs. 
normoxic mice.  † p <0.05, †† p<0.01 vs. vehicle dosed mice.  ## p<0.01, ###p<0.001 vs. wildtype 
mice.  n=6-11 mice per group; n of mice for each group is indicated in bar of graph.  WT=wildtype. 
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Figure 3-19: Representative RVSP traces from normoxic female SERT
+
 mice. 
Six second representative traces are shown for vehicle treated WT and SERT
+
 females, and a 
female SERT
+
 mouse treated with 2mgkg
-1
day
-1
 MPP.  WT=wildtype. 
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Figure 3-20: MPP (2mgkg
-1
day
-1
) attenuates pulmonary vascular remodelling female SERT
+
 mice.   
α-smooth muscle actin stains smooth muscle cells dark brown; counterstained with haematoxylin.  Representative images are shown from each group stained with 
alpha-smooth muscle actin.  Scale bar=20µm. 
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Figure 3-21: Systemic parameters in SERT
+
 female mice following hypoxia and MPP (2mgkg
-
1
day
-1
) treatment. 
Mean systemic arterial pressure (Mean SAP) (A) and HR (B) in female SERT
+
 mice.  Data are 
expressed as ± SEM and analysed using a Two-Way ANOVA followed by a Bonferroni’s post hoc t-
test.  **p <0.01, ***p<0.001 vs. normoxic mice; †† p<0.01 vs. vehicle dosed mice n=6-9 mice per 
group; n of mice for each group is indicated in bar of graph.  WT= wildtype. 
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Figure 3-22: MPP (2mgkg
-1
day
-1
) treated WT and SERT
+
 mice exhibit reductions in uterine 
weight. 
Uterine weight in WT and SERT
+
 mice (A) and uterus weight/body weight ratio (B) are reduced in 
by MPP treatment.  Data are expressed as ± SEM analysed by Two-Way ANOVA followed by a 
Bonferroni’s post-hoc test.  † p<0.05 vs. vehicle. n=6-10 mice per group; n of mice for each group 
is indicated in bar of graph.  WT= wildtype. 
 
 
171 
 
Table 3-3: Haemodynamic parameters in WT and SERT+ mice dosed with MPP (2mgkg
-1
day
-
1
). 
Right ventricular systolic pressure (RVSP); Mean right ventricular pressure (MRVP); right 
ventricular diastolic pressure (RVDP); systolic systemic arterial pressure (sSAP); mean systemic 
arterial pressure (mSAP); diastolic systemic arterial pressure (dSAP); Heart rate (HR).  Data 
expressed as ± SEM analysed by a Two-way ANOVA followed by a Bonferroni’s post hoc test. 
*p<0.05, ** p<0.01, *** p<0.001 vs. normoxic mice.  † p <0.05, †† p<0.01 vs. vehicle dosed mice.  
## p<0.01 vs. wildtype mice.  n = 6-10 mice.  WT= wildtype. 
 
Parameter WT Vehicle WT MPP SERT+ Vehicle SERT+ MPP 
     Normoxic 
 
    RVSP, mmHg 21.4 ± 1.2 20.3 ± 0.8 26.3 ± 1.0 ## 22.1 ± 1.0 † 
MRVP, mmHg 14.13 ± 0.4 12.7 ± 1.0 14.8 ± 0.2 15.8 ± 0.5 # 
RVDP, mmHg 1.6 ± 0.2 0.8 ± 0.3 1.3 ± 0.3 2.8 ± 0.6 ## † 
sSAP, mmHg 84.2 ± 7.7 92.7 ± 4.9 88.8 ± 7.7 99.9 ± 3.6 
mSAP, mmHg 81.9 ± 7.8 85.7 ± 2.8 82.3 ± 8.0 92.6 ± 4.2 
dSAP, mmHg 76.6 ± 7.3 78.2 ± 3.4 72.8 ± 8.9 83.8 ± 5.7 
HR, bpm 419.0 ± 10.9 385.2 ± 19.5 433.8 ± 5.0 354.1 ± 22.3 †† 
     Hypoxic 
 
    RVSP, mmHg 32.5 ± 1.8 *** 26.4 ± 1.4 ** † 31.7 ± 1.6 * 24.2 ± 1.2 †† 
MRVP, mmHg 18.9 ± 0.8 *** 15.2 ± 1.1 15.7 ± 0.8 † 12.4 ± 0.9 * † 
RVDP, mmHg 1.5 ± 0.1 2.6 ± 0.5 * 1.7 ± 0.6 1.5 ± 0.4 
sSAP, mmHg 99.4 ± 3.1 114.6 ± 3.9 ** † 103.8 ± 4.9 106.6 ± 2.1 
mSAP, mmHg 89.3 ± 2.1 98.1 ± 4.2 93.4 ± 4.2 93.9 ± 2.6 
dSAP, mmHg 78.0 ± 3.7 80.9 ± 4.5 80.89 ± 6.2 75.6 ± 3.6 
HR, bpm 357.3 ± 12.1 ** 357.2 ± 13.7 299.3 ± 11.3 *** 338.5 ± 15.3 
 
 
172 
 
Table 3-4: Ventricle, body weight and uterus weight in WT and SERT+ mice dosed with MPP 
(2mgkg
-1
day
-1
).  Right ventricle (RV); left ventricle plus septum (LV + S); RV/LV+S ratio, body 
weight and uterus weight.  Data expressed as ± SEM analysed by a Two-way ANOVA followed by 
a Bonferroni’s post hoc test. * p<0.05, ** p <0.01, *** p<0.001 vs. normoxic mice. † p <0.05 vs. 
vehicle dosed mice.  ### p<0.001 vs. wildtype mice.   n = 6-12 mice per group. 
 
Group RV (mg) LV + S (mg) RV/LV+S 
Body weight 
(g) 
Uterus 
weight (mg) 
      Normoxic 
 
     Wildtype 
     Vehicle 21.3 ± 1.4 80.9 ± 3.2 0.26 ± 0.02 24.5 ± 0.9 94.5 ± 7.9 
MPP 19.9 ± 2.2 81.7 ± 3.1 0.23 ± 0.01 22.6 ± 1.4 61.1 ± 5.4 † 
SERT+ 
     Vehicle 21.6 ± 1.2 72.3 ± 2.9 0.28 ± 0.01 18.4 ± 0.6 ### 95.7 ± 13.7 
MPP 23.5 ± 2.0 74.6 ± 3.3 0.26 ± 0.02 19.4 ± 0.8 64.79 ± 7.7 † 
      Hypoxic 
 
     Wildtype 
     Vehicle 26.1 ± 3.2 76.1 ± 4.1 0.34 ± 0.04 * 24.9 ± 1.2 90.99 ± 16.7 
MPP 26.3 ± 0.9 * 69.9 ± 1.2 ** † 0.36 ± 0.01 *** 23.4 ± 0.3 63.1 ± 3.3 † 
SERT+ 
     Vehicle 27.3 ± 1.3 66.1 ± 3.2 # 0.41 ± 0.01 ** 18.6 ± 1.4 ### 76.62 ± 9.6 
MPP 22.7 ± 0.8 64.4 ± 1.9 * 0.35 ± 0.01 ** 17.2 ± 0.5 ### 57.5 ± 4.7 † 
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3.2.10 Effects of MPP Administration on Serotonin Induced 
Pulmonary Vascular Reactivity 
To determine if pulmonary vascular reactivity is affected in mice following 
administration of MPP 2mgkg-1day-1, we tested isolated pulmonary arteries by 
wire-myography.  Serotonin is a known potent pulmonary vasoconstrictor, 
therefore serotonin was used to pre-constrict the arteries and measure the 
contractile response.  In addition, estrogen has been shown to relax pre-
constricted pulmonary arteries in an ER-dependent manner (Lahm et al. 2007).   
Pulmonary arteries from female hypoxic vehicle treated mice exhibited an 
increased contractile response to serotonin (Figure 3-23A) and showed higher 
area under the curve (AUC) (Figure 3-23B) values than normoxic vehicle 
pulmonary arteries.  AUC analysis integrated the entire curve and was used as an 
overall measure of the cumulative contractile response for each individual 
treatment (i.e. normoxic or hypoxic conditions ± MPP).  In female mice, 
serotonin-induced vasoconstriction was unaffected by administration of MPP in 
normoxic and hypoxic conditions although there was a trend toward a decreased 
contractile response (Figure 3-23).  MPP administration in male mice showed a 
similar effect on serotonin induced vasoreactivity and hypoxia elevated the 
contractile response to serotonin (Figure 3-24).  As previously reported, the 
potency of serotonin in SERT+ mice is reduced and we observe a rightward shift 
of the dose-response curve and reduced pEC50 in normoxic SERT
+ vehicle treated 
mice and a reduction in the maximal contraction (Figure 3-25A).  This is in line 
with a reduced AUC in SERT+ vehicle mice relative to wildtype vehicle mice 
(Figure 3-25B).  This effect was not further influenced by MPP 2mgkg-1day-1 
administration in normoxic conditions.  Additionally, MPP administration in 
normoxic SERT+ mice appears to increase the contractile response to serotonin 
compared to SERT+ vehicle mice as the maximal contraction (Emax) was 
significantly increased in normoxic SERT+ mice treated with MPP compared to 
vehicle controls.  In contrast, in the pulmonary arteries of chronically hypoxic 
female SERT+ mice, MPP administration has no effect on serotonin- induced 
vasoconstriction (Figure 3-26A) or AUC (Figure 3-26B).  In both normoxic and 
hypoxic conditions, the half maximal effective concentration (EC50) was reduced 
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in SERT+ vehicle control mice (Table 3-6).  Values for EC50 and maximal 
responses (Emax) to serotonin are shown in Table 3-5 and 3-6. 
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Figure 3-23: Serotonin- induced pulmonary artery vasoconstriction is unaffected by MPP 
(2mgkg
-1
day
-1
) administration in female mice. 
(A) Percentage contractile response to 50mmol/l KCl are unchanged in response to MPP. (B) Area 
under the curve (AUC) is increased in hypoxic vehicle relative to normoxic vehicle.  Data are 
represented as ± SEM and (A) analysed by a Two-Way ANOVA followed by a Bonferroni’s post-
hoc t-test and (B) analysed by a One-Way ANOVA followed by a Bonferroni’s post hoc test. 
*p<0.05 vs. Normoxic Vehicle.  n=6-8 mice per group.  Values for Emax and EC50 shown in Table 
3.5. 
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Figure 3-24: Serotonin- induced pulmonary artery vasoconstriction is unaffected by MPP 
(2mgkg
-1
day
-1
) administration in male mice.   
(A) Percentage contractile response to 50mmol/l KCl are unchanged in response to MPP.  (B) Area 
under the curve (AUC) is increased in hypoxic vehicle relative to normoxic vehicle.  Data are 
represented as ± SEM and (A) analysed by a Two-Way ANOVA followed by a Bonferroni’s post-
hoc t-test and (B) AUC analysed by a One-way ANOVA followed by a Bonferroni’s post hoc test. 
*p<0.05 vs. Normoxic Vehicle.  n=6-8 mice per group.  Values for Emax and EC50 shown in Table 
3.5. 
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Figure 3-25: Serotonin- induced pulmonary artery vasoconstriction in normoxic female 
SERT
+
 mice is augmented by MPP (2mgkg
-1
day
-1
) administration.   
(A) Percentage contractile response to 50mmol/l KCl are unchanged in response to MPP.  (B) Area 
under the curve (AUC) is decreased in SERT
+
 vehicle relative to WT vehicle.  Data are represented 
as ± SEM and (A) analysed by a Two-Way ANOVA followed by a Bonferroni’s post-hoc t-test and 
(B) by a one-way ANOVA followed by a Bonferroni’s post hoc test.  **p<0.01 vs. vehicle.  n=6-8 
mice per group.  WT= wildtype.  Values for Emax and EC50 shown in Table 3.6. 
** 
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Figure 3-26: Serotonin- induced pulmonary artery vasoconstriction in hypoxic female SERT
+
 
mice is unaffected by MPP (2mgkg
-1
day
-1
).   
(A) Percentage contractile response to 50mmol/l KCl and (B) area under the curve (AUC) are 
unchanged in response to MPP.  Data are represented as ± SEM and (A) analysed by a Two-Way 
ANOVA followed by a Bonferroni’s post-hoc t-test and (B) by a one-way ANOVA followed by a 
Bonferroni’s post hoc test.  n=6-8 per group.  WT=wildtype.  Values for Emax and EC50 shown in 
Table 3.6. 
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Table 3-5: pEC50 and Emax values in female and male mice administered with MPP (2mgkg
-
1
day
-1
).   
pEC50, half maximal effective dose; Emax, maximal effective dose.  Data are expressed as ± SEM 
and analysed by a One-Way ANOVA followed by a Bonferroni’s post hoc test. n=6-8 mice per 
group. *p<0.05 vs. normoxic vehicle.   
 
 
 
 
 
 
 
 
 
 
Table 3-6: pEC50 and Emax values in female SERT
+
 administered with MPP (2mgkg
-1
day
-1
).   
pEC50, half maximal effective dose; Emax, maximal effective dose.  Data are expressed as ± SEM 
and analysed by a One-Way ANOVA followed by a Bonferroni’s post hoc test.  ###p<0.001 vs. WT; 
**p<0.01 vs. vehicle.  n=6-7 mice per group.  WT= wildtype. 
 
Female Vehicle Female MPP Male Vehicle Male MPP 
Normoxic  
pEC50 6.85 ± 0.1 7.24 ± 0.09 7.06 ± 0.3 7.23 ± 0.1 
Emax 161.8 ± 14.1 264.0 ± 16.3 206.0 ± 58.9 233.5 ± 42.8 
n 7 6 6 6 
Hypoxic  
pEC50 7.51 ± 0.3 7.05 ± 0.1 7.42 ± 0.6 6.69 ± 0.3 
Emax 292.4 ± 41.2* 470.0 ± 75.2 446.8 ± 117.9 502.9 ± 48.6 
n 6 8 6 6 
WT Vehicle WT MPP SERT+ Vehicle SERT+ MPP 
Normoxic 
pEC50 7.52 ± 0.3 7.37 ± 0.1 5.54 ± 0.1 ### 5.80 ± 0.1 
Emax 127.6 ± 17.7 137.3 ± 15.4 77.2 ± 4.8 181.0 ± 27.6 ### ** 
n 6 7 6 6 
Hypoxic 
pEC50 7.26 ± 0.2 7.04 ± 0.3 5.82 ± 0.06 ### 5.98 ± 0.1 
Emax 131.1 ± 11.0 120.6 ± 27.4 155.8 ± 12.6 126.5 ± 13.1 
n 6 6 6 6 
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3.2.11 Effects of Estrogen, PPT and DPN on Human 
Pulmonary Artery Smooth Muscle Cell Proliferation 
To summarise our in vivo studies we demonstrated that development of PH in 
hypoxia and in a female susceptible SERT+ model of PH is ERα dependent.  In 
addition, ERα selective antagonism has no effect on development of hypoxia-
induced PH in male mice.  As we also show that there is elevated expression of 
ERα in the PASMCs from PAH females and in the female hypoxic mouse 
pulmonary arteries, we hypothesised that ERα may be promoting PH specifically 
in females.  To determine potential mechanisms by which ERα activation could 
be facilitating PH we examined the role of estrogen and its receptors in cultured 
female human PASMCs using ERα and ERβ selective agonists and antagonists. 
 
Estrogen was examined at physiological concentrations (0.1-1nmolL-1) and a 
supraphysiological concentration of 10nmolL-1.  At 1nmol/l estrogen induced 
proliferation (Figure 3-27A).  The ERα selective agonist, PPT, also caused 
proliferation of PASMCs at 0.01-0.1nmolL-1 (Figure 3-27B) whereas 
diarylpropionitrile (DPN), the ERβ selective agonist, had no effect on PASMCs 
(Figure 3-27C).  Estrogen induced proliferation at 1nmolL-1 was inhibited by ERα 
selective antagonism using MPP (1µmolL-1) whilst ERβ selective antagonism with 
PHTPP (1µmolL-1) had no effect on PASMC proliferation induced by estrogen.  ICI 
182, 780 (1µmolL-1), a non- selective ERα/β antagonist also had no effect on 17β-
estradiol induced proliferation (Figure 3-28). 
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Figure 3-27: 17β-estradiol induces proliferation of female pulmonary artery smooth muscle 
cells through ERα.   
Estrogen (A) and PPT, an ERα agonist (B) induce proliferation at physiological concentrations 
whilst DPN, an ERβ agonist (C) has no effect on proliferation of hPASMCs.  Data are expressed as 
mean ± SEM analysed using a One-Way ANOVA followed by a Tukey’s post hoc test. ††† p<0.001 
vs. 0.2% FBS; * p<0.05, **p<0.01 vs. 2.5% FBS.  Patient information for controls (1, 2, 3 and 5), 
are shown in Materials and Methods section: Table 2.3 (passage 3-5).  n=4 per experiment and 
performed in triplicate in separate female control cell lines. 
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Figure 3-28: 17β-estradiol induced proliferation is inhibited by an ERα antagonist. 
Proliferation of human PASMCs to 1nmol/l of estrogen was inhibited in the presence of the ERα 
selective antagonist, MPP.  PHTPP, an ERβ selective antagonist, and ICI 182, 780 (ICI), a non-
selective ERα/β antagonist has no effect on estrogen induced proliferation.  Data are expressed as 
mean ± SEM and analysed using a One-Way ANOVA followed by a Tukey’s post hoc test. ††† 
p<0.001 vs. 0.2% FBS; **p<0.01 vs. 2.5%; # p<0.05; ## p<0.01 vs. 1nmol/l E2.  Patient information 
for controls (1, 2, 3 and 5) are shown in Materials and Methods section: Table 2.3 (passage 3-5).  
n=4 per experiment and performed in triplicate in separate female control cell lines. 
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3.2.12 Estrogen Requires Downstream MAPK and PI3K/Akt 
Signalling to Promote Human PASMC Proliferation via ERα  
PI3K/Akt and MAPKs can phosphorylate and activate ER and their co-regulators 
to enhance nuclear effects on transcription and regulate cell survival and 
proliferation (Marino et al. 2006).  We therefore examined the proliferative 
effects of estrogen and PPT on human PASMC proliferation in the presence on 
PI3K and ERK/MAPK inhibitors.  Both estrogen and PPT induced proliferation 
were inhibited in the presence of U0126 (10µmolL-1) and LY294002 (10µmolL-1), a 
MEK inhibitor and a PI3K inhibitor, respectively (Figure 3-29). 
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Figure 3-29: 17β-estradiol and PPT induced proliferation is inhibited by pERK and PI3K 
inhibitors.   
Proliferation of human PASMCs to 1nmol/l of estrogen and 0.01nmol/l PPT was inhibited in the 
presence of the U0126 (10µmol/l) and LY294002 (10µmol/l), pERK and PI3K inhibitors, 
respectively.  Data are expressed as mean ± SEM and analysed using a One-Way ANOVA 
followed by a Tukey’s post hoc test.. ††† p<0.001 vs. 0.2% FBS; *p<0.05 vs. 2.5%; # p<0.05; ## 
p<0.01; ### p<0.001 vs. 1nmol/l E2 or 0.01nmol/l PPT.  Patient information for controls (1, 2, 3 and 
5) are shown in Materials and Methods section: Table 2.3 (passage 3-5).  n=4 per experiment and 
performed in triplicate in separate female control cell lines.  
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3.2.13 Estrogen Suppresses BMPR2 Expression and 
Downstream Smad and Id Expression in the Lung via ERα 
To determine the mechanism by which estrogen and ERα interplay and promote 
PH pathogenesis in females we investigated the BMPR2 pathway and downstream 
signalling molecules as dysregulation of this pathway is involved in aberrant 
smooth muscle cell proliferation.  We examined levels of BMPR2, total Smad-1, 
Id1 and Id3 in lung samples from mice dosed with the ERα selective antagonist, 
MPP. 
In chronic hypoxic female mice BMPR2 expression levels (both protein and 
mRNA) are suppressed.  This loss of BMPR2 expression in pulmonary arteries was 
restored in mice treated with MPP (Figure 3-30A).  Additionally we observed 
rescue of the BMPR2 mRNA transcript in whole lung samples from mice treated 
with MPP (Figure 3-30B).  The BMPR2 protein levels in SERT+ female mice were 
unchanged compared to female WT counterparts (Figure 3-30C) although we did 
observe a down-regulation of the mRNA transcript (Figure 3-30D).  In both WT 
and SERT+ mice, treatment with MPP resulted in an increase in BMPR2 protein 
levels (Figure 3-30C).  In SERT+ mice mRNA levels were also increased by MPP 
(Figure 3-30D). 
We also wished to examine further downstream BMPR2 signalling in lungs from 
both hypoxic and SERT+ female mice treated with MPP.  We decided to 
investigate expression levels of total Smad1, Id1 and Id3 as these downstream 
signalling components have also been shown to be decreased in vascular lesions 
and PASMCs from PAH patients (Yang et al. 2008; Yang et.al. 2005).  In normoxic 
female mice, MPP had no effect on expression levels of Smad1, Id1 or Id3 (Figure 
3-31A-C).  Although hypoxia in vehicle treated mice had no effect on either 
Smad1 levels or Id3 levels, Id1 transcript expression was significantly reduced 
(Figure 3-31B).  Consistent with BMPR2, the expression of Id1 mRNA transcript 
was restored in lungs treated with MPP.  Smad1 levels were also increased 
following MPP treatment in female hypoxic lung (Figure 3-31A). 
In whole lung from female SERT+ mice, Smad1 and Id1 levels were unchanged 
between WT vehicle and SERT+ vehicle mice.  Additionally, MPP had no effect on 
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the expression levels of Smad1 and Id1 mRNA transcript compared to vehicle 
treated mice (Figure 3-32A&B).  On the other hand, we observed a significant 
down-regulation of Id3 in SERT+ vehicle mice compared to WT vehicle mice 
(Figure 3-32C).  The loss of Id3 expression was rescued by MPP treatment. 
Interestingly, in male mice, expression levels of BMPR2 and downstream 
signalling mediators Smad1, Id1 and Id3, were unaffected by hypoxia and/or MPP 
treatment (Figure 3-33A-D). 
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Figure 3-30: Regulation of the BMPR2 pathway by MPP (2mgkg
-1
day
-1
) and chronic hypoxia 
in female mouse pulmonary artery and lung. 
BMPR2 expression levels in pulmonary artery (A) and mRNA transcript in whole lung (B) is 
regulated by estrogen and ERα in chronic hypoxia-induced PH.  BMPR2 protein (C) and mRNA 
transcript (D) is also regulated by ERα in SERT
+
 female mouse lung.  Quantitative data are 
expressed as ± SEM and analysed by a one-way ANOVA followed by a Tukey’s post hoc-test.  
*p<0.05, **p<0.01.  n=6 pulmonary artery and whole lung performed in triplicate. 
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Figure 3-31: Effects of MPP (2mgkg
-1
day
-1
) and chronic hypoxia on regulation of the mRNA 
transcript levels and components of the BMPR2 pathway female mouse lung.   
Figure 4.26: (A) Smad-1 (B) Id1 and (C) Id3 expression levels in female mouse lung.  Data are 
expressed as ± SEM and analysed by a one-way ANOVA followed by a Tukey’s post hoc-test.  
*p<0.05, **p<0.01.  n=6 whole lung performed in triplicate. 
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Figure 3-32: Effects of MPP (2mgkg
-1
day
-1
) on regulation of the mRNA transcript levels and 
components of the BMPR2 pathway in SERT
+ 
female mouse lung.   
(A)Smad-1 (B) Id1 and (C) Id3 expression levels in female SERT+ mouse lung.  Data are 
expressed as ± SEM and analysed by a one-way ANOVA followed by a Tukey’s post hoc-test.  
*p<0.05.  n=6 whole lung performed in triplicate. 
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Figure 3-33: Effects of MPP (2mgkg
-1
day
-1
) and chronic hypoxia on regulation of the mRNA 
transcript levels and components of the BMPR2 pathway in male mouse lung 
BMPR2 (A); Smad-1 (B); Id1 (C) and Id3 (D) mRNA transcript levels are unchanged in male mouse 
lung.  Data are expressed as ± SEM and analysed by a one-way ANOVA followed by a Tukey’s 
post hoc-test.  n=6 mice lungs performed in triplicate. 
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3.2.14 Estrogen Receptor Expression in Human PASMCs is 
Regulated by Serotonin 
We have previously demonstrated that estrogen can increase the expression of 
tryptophan hydroxylase 1 (TPH1), SERT and 5-HT1B (White et al. 2011).  Here we 
wished to examine the effects of serotonin on ER expression in human PASMCs. 
In female human PASMCs we demonstrated that expression of ERα protein was 
significantly increased (Figure 3-34A) whilst expression of ERβ was significantly 
decreased (Figure 3-34B) by 1µmol/l serotonin. 
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Figure 3-34: Estrogen receptor expression in female control human PASMCs stimulated 
with 5-HT. 
ERα (A), ERβ (B).  Data are expressed as ± SEM and analysed by One-Way ANOVA followed by a 
Dunnet’s post-hoc test. Representative blots are shown.  n=3 performed in triplicate. *p<0.05 vs. 0, 
control. 
 
 
3.3 Discussion 
In the most recent worldwide registries, it is reported that women develop both 
idiopathic and heritable PAH up to four times as frequently as men (Badesch 
et.al. 2010; Humbert et.al. 2006; Peacock et al. 2007; Thenappan et al. 2007) 
Although women are more susceptible to PAH, paradoxically in animal models, 
male rodents demonstrate more severe hypoxia induced PH (Rabinovitch et.al. 
1981) and estrogens appear to protect against PH in male animal models (Farhat 
et.al. 1993; Lahm et.al. 2012a).  This is known as the ‘estrogen paradox’ of PAH 
and has been central in impeding our understanding of increased susceptibility 
to PAH in women. 
This study aimed to investigate the role of estrogen receptors, in the 
development of PH by utilising translational in vitro and in situ studies and 
experimental in vivo models.  We also wished to determine the influence of 
gender by comparing males and females.  Our results demonstrate that 
activation of ERα plays a key role in the development of PH in two rodent 
models of PH, the hypoxic mouse model and SERT+ mouse.  This is only observed 
in female mice however.  In addition we demonstrate that there is elevated 
expression of ERα in the lungs from female PAH patients and in female hypoxic 
mouse lung.  Furthermore, ERα is noticeably increased in female human PASMCs 
compared to males.  We demonstrate that ERα activation in female human 
PASMCs leads to proliferation driven by PI3K/Akt and ERK MAPK activation.  We 
also suggest that ERα negatively regulates BMPR2 expression in females and 
contributes to the PH phenotype.  Additionally, the pulmonary mitogen serotonin 
can up-regulate ERα expression in PASMCs. 
Altered Expression of Estrogen Receptors in Translational and 
Experimental Pulmonary Hypertension 
We investigated the classical ERs, ERα and ERβ, which predominantly regulate 
gene transcription (Prossnitz et.al. 2008).  We demonstrated expression of both 
ERα and ERβ in adventitial, smooth muscle and endothelial cells in human 
pulmonary arteries.  In humans, expression of ERα and ERβ has been identified in 
endothelial cells and vascular smooth muscle cells of aortic and coronary 
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vasculature as well as in cardiomyocytes (Mendelsohn 2002; Meyer et.al. 2006).  
The presence of both ERα and ERβ mediate physiologically important effects of 
estrogen in human vasculature.  In the lung, ERβ is thought to be the 
predominant ER (Nilsson et.al. 2001), however here we show an important role 
for ERα in PH and our results suggest that it is ERα that drives the PH phenotype 
in females.   
Firstly, we show that expression of ERα (both protein and mRNA) is increased in 
PASMCs from female HPAH patients relative to normal female controls.  This is 
consistent with gene expression data in PAH patients demonstrating an up-
regulation of ESR1 in PAH subjects relative to controls (Rajkumar et.al. 2010).  
Polymorphisms in ESR1 have also been associated with an increased risk of 
developing portopulmonary hypertension independent of gender (Roberts et.al. 
2009b).  Uniquely we report here that there are higher levels of ERα expression 
in female PAH human PASMCs compared with male human PASMCs from PAH 
patients, whilst ERβ expression is greatest in male PAH PASMCs.  One limitation 
of the expression data reported here is the small number of patient samples 
available due to the rare nature of PAH.  However, gender differences in tissue 
localisation of ERs during development and disease is not an entirely novel 
concept and has been reported in other conditions.  In aortic vasculature during 
aneurysm, a correlation between increased ERα expression in females but not 
males has been identified (Laser et al. 2013) and gender differences in vascular 
function has been attributed to differences in expression, distribution and/or 
activity of ERs in response to vasoconstrictors (Ma et al. 2010; Rubanyi et al. 
1997).  In human PAH however, this is the first direct comparison of ERs in 
females versus males.   
In the lungs of female mice, both ERα and ERβ are required for the formation of 
full functional and morphological development of alveoli structures, although 
they have a much smaller effect on alveolar dimensions in male mice (Massaro & 
Massaro 2004; Massaro & Massaro 2006).  It is likely then, that the ER pathway 
contributes more significantly to pathophysiology of female lung compared to 
male lung.  We therefore investigated ER expression in the pulmonary artery 
from chronic hypoxic female and male mice.  It has been identified previously in 
rat lung that ESR1 is a key regulatory component in response to intermittent 
hypoxia and further, is involved in regulation of ESR2 and androgen receptor, 
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which are also differentially expressed in hypoxia (Wu et al. 2008).  We 
demonstrated expression of both receptors in the pulmonary vasculature of 
female mice in line with previous studies (Lahm et.al. 2012a; Umar et.al. 
2011a).  ERα protein expression was elevated by hypoxia in female mice, 
although expression of mRNA was unchanged suggesting post-transcriptional 
regulation of ERα in mouse pulmonary artery by hypoxia.  Consistent with our 
observations that ERβ expression was reduced in human lung from PAH patients 
we show that ERβ expression is also reduced in the pulmonary artery of the 
female hypoxic mouse.  This is also consistent with the down-regulation of ERβ 
observed in the lung and right heart in a right heart failure rat model (Matori 
et.al. 2012).  It has previously been shown that loss of ERβ in female mice leads 
to abnormal lung structures and systemic hypoxia contributing to ventricular 
hypertrophy (Morani et.al. 2006).  ERα may therefore be pathogenic in PH whilst 
ERβ may be protective (Nadadur et.al. 2012; Umar et.al. 2011a).  The reduced 
expression of ERβ we observe in female human PASMCs and in the female model 
of PH may result in a loss of the protective effects of estrogen. 
Estrogen Receptor-α Antagonist MPP, Attenuates RVSP and 
Pulmonary Vascular Remodeling in Chronic Hypoxic-PH and in the 
Female Susceptible SERT+ Model 
We investigated the potential pathogenic role of ERα further by examining the 
effect of the ERα antagonist, MPP, on the development of PH in the chronic 
hypoxic mouse model.  MPP attenuated the development of PH by reducing RVSP 
and pulmonary vascular remodelling in the ovary intact female chronic hypoxic 
mouse, but not in males.  One explanation for this could be the elevated 
expression of ERα in females compared to males and suggests that endogenous 
estrogen is activating ERα receptors to facilitate the development of PH.  In 
addition, estrogen receptor expression was unchanged in the pulmonary arteries 
of hypoxic male mice suggesting that ERα may play less of a pathogenic role in 
males. 
Transcription of ERs is subject to regulation by hypoxia.  Hypoxia response 
elements have been identified on the promoters of both ERα and ERβ (Wu et al. 
2012) and in breast cancer cells, it has been demonstrated that hypoxia induces 
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ESR1 repression at the transcriptional level in a process dependent on hypoxia-
inducible factor 1α (Ryu et al. 2011).  Due to the effect hypoxia may have on 
transcriptional regulation of ERα, we also wished to examine the effects of ERα 
antagonism in a model of PH that did not require hypoxic exposure.  We have 
previously demonstrated that PH develops in SERT+ mice (White et.al. 2011), 
S100A4/Mts1 over-expressing mice (Dempsie et.al. 2011) and mice dosed with 
dexfenfluramine (Dempsie et.al. 2013).  These models are all serotonin-
dependent and PH only develops in ovary intact females.  Further, we 
demonstrate that ovarian estrogen underpins the PH phenotype in these models.  
To investigate if ERα mediates this effect of endogenous estrogen in females, we 
investigated the effect of the MPP in the SERT+ model in the absence and 
presence of hypoxia.  We show that MPP reversed the PH and associated 
pulmonary vascular remodelling in these mice, both under normoxic and hypoxic 
conditions.  This suggests a pivotal role for ERα in the causative effects of 
endogenous estrogen in the development of PH in this model and this was also 
observed independent of any effects of hypoxia.  Previously we have identified 
an estrogen-dependent regulation of the serotonin system in human PASMCs 
whereby estrogen can up-regulate tryptophan hydroxylase-1 (TPH1), SERT and 
the 5-HT1B receptor (White et.al. 2011).  Here we now show that serotonin can 
indeed regulate the expression of both ERα and ERβ expression in human 
PASMCs.  Serotonin induced an up-regulation of ERα whereas the expression of 
ERβ is decreased by serotonin.  This up-regulation of ERα may contribute to the 
pathogenic effects of serotonin in females during PAH. 
Previous studies have shown that exogenous administration of estrogen can 
protect male rodents from hypoxia-induced PH (Xu et al. 2013) and via 
activation of ERα and ERβ (Lahm et al. 2012).  Although these studies are 
valuable, we do not feel our results are directly comparable as we address the 
role of endogenous estrogen and not artificially elevated circulating estrogen, 
acting via ERs in males and females with intact ovaries.  Given the gender 
specific effects of ERα antagonism, this study has highlighted the value of 
understanding the differential role of endogenous estrogen in the development 
of PH in males and females.  Moreover, our results provide more therapeutically 
relevant data owing to the effect of MPP on naturally occurring estrogens.  Males 
have lower circulating levels of estrogen, and as shown here, low ERα expression 
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compared to females, it would not be surprising therefore, if estrogen plays a 
lesser role in the development of PH in males.  In line with this, we have shown 
that inhibition of estrogen synthesis is protective only in female rodent models 
of PH (Mair et al, unpublished).  In addition in females, altered estrogen 
synthesis and/or metabolism (White et al. 2012) may contribute to PH 
development.  Indeed, there is a putative estrogen receptor element in the 
promoter region of the estrogen metabolising enzyme, CYP1B1, suggesting 
metabolism may also be regulated by ERα (Han et al. 2005). 
Despite the incidence of RVH in both our models of PH we did not detect an ERα 
dependent rescue of the RVH nor did ERα antagonism exacerbate RVH.  Women 
are frequently reported to have an improved prognosis compared to men despite 
their predisposition to developing PAH (Benza et.al. 2012; Humbert et.al. 
2010a).  This has been attributed to an RV cardioprotective effect of estrogen.  
Indeed estrogen levels correlate with higher right ventricular ejection fraction 
and survival in females (Kawut et al. 2009; Ventetuolo et.al. 2011).  Genuinely 
protective effects of exogenous estrogen in PH observed in other studies 
(Nadadur et.al. 2012; Umar et.al. 2011a) may therefore arise from a direct 
structural effect on the right ventricle and an influence on right ventricular 
function as opposed to an effect on vascular remodelling and pulmonary 
pressures.  It is possible that the protective influence of estrogen on the right 
ventricle may be mediated predominantly by ERβ (Pedram et.al. 2008).  Further, 
our results suggest that inhibition of ERα is not having a detrimental effect on 
the RV and therefore this may still be a feasible therapeutic strategy in females 
(Barrett-Connor & Bush 1991).  One limitation of measuring RVH via the weight 
ratio of RV/LV+S is perhaps that development of RVH could be masked by 
alterations in LV weight.  Future investigations should consider the weight of RV 
as a ratio to body weight or tibia length.   
Estrogen has also been identified to have an influence on vascular reactivity in 
the systemic and pulmonary vasculature involving both ERα and ERβ.  In systemic 
vasculature, estrogen promotes vasodilation via genomic and non-genomic 
mechanisms attributed to activation of endothelial nitric oxide synthase (eNOS) 
and release of nitric oxide (NO) in aortic and carotid arteries (Pare et.al. 2002; 
Zhu et.al. 2002).  Further, in both normoxic and hypoxic conditions, estrogen is 
reported to attenuate pulmonary artery vasoconstriction (English et.al. 2001; 
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Lahm et.al. 2012a).  In pulmonary vasculature, the onset of the ERα and ERβ-
mediated decrease in vasoconstriction is rapid and is therefore suggested to be a 
non-genomic effect dependent on NO release (Chambliss et.al. 2000; Lahm et.al. 
2007).  In this study we therefore wished to determine the effect ERα 
antagonism had in isolated pulmonary arteries treated with serotonin.  In 
normoxic conditions in both male and female mice, MPP had no effect on 
serotonin induced vasoconstriction.  Hypoxia augmented the response to 
serotonin compared to normoxic conditions, however, MPP had no further effect 
on serotonin induced vasoconstriction in hypoxic male and female mice.  
Certainly there is evidence implicating estrogen mediated-induction of both 
SERT and the 5-HT2A receptor in the brain which is estrogen receptor dependent 
(Sumner et al. 2007) and the 5-HT2A receptor is the predominant receptor 
involved in hypoxic pulmonary vasoconstriction in mice (MacLean & Dempsie 
2010).  Additionally, we investigated the effect of serotonin and ERα antagonism 
in isolated pulmonary arteries from female SERT+ mice.  In this model, the 
vasoconstricive response to serotonin was heightened in SERT+ mice treated with 
MPP independent of hypoxia.  This may be explained by a loss of re-uptake of 
serotonin by SERT contributing to higher concentrations of circulating levels of 
serotonin available to act on serotonin receptors.  Here, in isolated pulmonary 
arteries, there were no sex-dependent effects of ERα antagonism.   
Estrogen-Induced Proliferation is Mediated Through Estrogen 
Receptor-α and Involves Downstream ERK/MAPK and PI3K 
Signalling Mechanisms 
Excessive smooth muscle cell proliferation is a main component of the 
pulmonary vascular remodelling and lesions observed in PAH.  Estrogen is a pro-
proliferative factor in human PASMCs (White et al. 2010; White et al. 2012), 
breast cancer cells (Pattarozzi et al. 2008), and has been shown to have pro-
inflammatory properties in systemic vasculature (Mendelsohn 2002).  This 
suggests that estrogen may mediate proliferation of human PASMCs and may 
contribute to PAH pathology.  We investigated this further by examining ERα 
mediated proliferation in female human PASMCs.  We demonstrate for the first 
time that estrogen can induce proliferation of human PASMCs via ERα activation, 
although the effect of estrogen and the ERα agonist, PPT are not dose 
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dependent.  The absence of a dose dependent effect for estrogen is surprising 
given previous findings highlighted this effect (White et al, 2011), however our 
results are consistent with reporting estrogen-induced proliferation at 1nmolL-1.  
Levels of estrogen receptors between patient human PASMCs may vary and 
contribute to this anomaly for estrogen and PPT induced proliferation.  In 
addition we show an ERβ agonist, DPN, has no effect on proliferation of human 
PASMCs suggesting that ERα is the receptor that mediates estrogen-induced 
proliferation in PASMCs.  Moreover, we determine the pro-proliferative effects 
of estrogen and the ERα agonist, PPT, are dependent on activation of 
downstream PI3K/Akt and ERK/MAPK signalling.  ERK and Akt signalling pathways 
are closely involved in cardiac hypertrophy and pulmonary vascular remodelling 
and estrogen has been shown to regulate activation of both pathways in right 
heart failure (Nadadur et.al. 2012; Zhou et al. 2011).  Additionally, selective 
activation of ERα in endothelial cells in aorta increases ERK expression and 
ERK1/2 mediated cell proliferation and activation of PI3K/Akt in human 
endothelial cells is dependent on ERα but not ERβ (Chambliss et.al. 2000; Meyer 
et.al. 2006).  These results provide some insight into the molecular mechanisms 
by which estrogen and its receptors may mediate pulmonary vascular 
remodelling during PAH and hence MPP attenuates pulmonary vascular 
remodelling in female mice. 
Dysfunctional BMPR2 signalling plays a pivotal role in aberrant smooth muscle 
growth and endothelial cell proliferation and apoptosis in PAH, and mutations in 
BMPR2 are responsible for ~80% of HPAH cases (Machado et.al. 2009).  Loss of 
BMPR2 function mediates proliferation by reducing induction of cell cycle 
inhibitors (Id proteins), particularly Id1 and Id3 in PASMCs (Yang et.al. 2008; 
Yang et.al. 2005).  A gene-gender relationship for BMPR2 was proposed in a 
recent study where BMPR2 expression was shown to be decreased in lymphocytes 
and whole lung from female patients compared with males (Austin et.al. 2012).  
In line with this, BMPR2 is recognised as a gene target of ESR1 (Rajkumar et.al. 
2010).  A highly conserved functional estrogen response element has recently 
been identified in the BMPR2 promoter and estrogen exposure suppresses the 
BMPR2 signal through ERα (Austin et al. 2012).  In the present study, BMPR2 
protein and mRNA expression was decreased following hypoxia consistent with 
previous studies (Long et al. 2009; Takahashi et al. 2006).  Lung BMPR2 
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expression was also decreased in SERT+ mice at mRNA levels but not protein.  In 
both our chronic hypoxic female mouse model and our hypoxia-independent 
SERT+ mouse model, low levels of BMPR2 were rescued by the ERα antagonist.  
Hence in females we have demonstrated high ERα expression supporting human 
PASMC proliferation and decreased BMPR2 expression.  Combined with high 
circulating endogenous estrogen levels in females this may explain the female 
susceptibility to develop PAH and/or the selective beneficial effects of the ERα 
antagonist in females.  Previously, the growth inhibitory effects of BMPs have 
been shown to be Smad1 dependent (Yang et.al. 2005), therefore we also wished 
to determine the influence of estrogen and ERα on Smad-1 expression.  Id1 and 
Id3 have also been reported to be major targets of BMP signalling in PASMCs 
where they are involved in growth suppression. Furthermore, induction of both 
Id1 and Id3 is dependent on intact BMPR2 (Yang et al. 2013).  Indeed, we report 
here that Smad-1 and Id1 and Id3 are also subject to regulation by estrogen via 
ERα and suggest that therapeutic effects of MPP in vivo involve restoring the 
dysfunctional BMPR2 signalling axis in PASMCs. 
Conclusion   
In conclusion, we have determined an ERα dependent mechanism of PAH 
development in females.  Our data supports a hypothesis whereby the higher 
prevalence of PAH in women may be a result of increased ERα distribution and 
signalling.  We suggest that defective estrogen signalling in PAH drives a female 
susceptibility in concordance with defective estrogen metabolism (White et al. 
2012b).  Furthermore, we propose that in PAH, the genetic susceptibility which 
infers an increased risk in females to develop the condition is related to 
interplay between dysfunctional ERα and the BMPR2 signalling axis.  In the 
setting of PH, gender represents an important modifier of disease and should be 
considered carefully in future research and in clinical implications. 
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Chapter 4. 
Influence of the Novel G Protein-Coupled Estrogen 
Receptor, GPER in the Development of 
Experimental Pulmonary Hypertension 
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4  
4.1 Introduction 
The incidence of PAH is well reported to be more prevalent in women than in 
men (Badesch et.al. 2010; Humbert et.al. 2010a; Ling et.al. 2012).  In fact, in 
the most recent registries, the female to male ratio is approximately 4.1:1 in 
idiopathic PAH (IPAH) and 3.8:1 in associated PAH (APAH) (Badesch et.al. 2010).  
Despite clear epidemiologic evidence demonstrating female susceptibility in 
many forms of PAH, the underlying reasons for this gender disparity remain 
unclear.  This female predominance in PAH has led to numerous studies 
investigating the role of gender and sex hormones in the development of 
experimental PAH.  In particular, estrogen has been proposed to play a pivotal 
role in PAH pathogenesis. 
Classically, cellular signalling of estrogen is mediated through two estrogen 
receptors (ER), ERα and ERβ.  These receptors belong to the super family of 
nuclear receptors.  Activation of these receptors results in slow responses to 
estrogen, involving activation of estrogen response elements (EREs) in the 
promoters of target genes, and influencing gene transcription (Heldring et al. 
2007b).  However, in addition to the well studied transcriptional effects of 
estrogen, rapid non-genomic effects of estrogen occurring within seconds to 
minutes have been observed.  These have been attributed to a third estrogen 
receptor, the seven transmembrane G-protein coupled receptor 30 (GPR30) or 
GPER; (Filardo & Thomas. 2007; (Prossnitz et.al. 2008).   
In PAH, a role for both ERα and ERβ in physiology and pathophysiology has been 
described (Lahm et.al. 2012a; Umar et.al. 2011a).  The identification and 
characterisation of GPER in the pulmonary circulation remains to be 
investigated.  However, several promising cardiovascular responses to G1 suggest 
there may be potential for GPER mediated effects in the pulmonary circulation 
and during PAH.  In a cardiovascular setting, estrogens are observed to exert 
protective effects through ERα whilst it is often presumed that ERβ has opposing 
effects to ERα.  Slowly, evidence is building for a role of GPER in some 
physiological and pathophysiological cardiovascular and metabolic conditions in 
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addition to ERα and ERβ.  GPER has been identified in different vasculature 
including mesenteric and carotid artery (Haas et al, 2009; Martensson et al. 
2009) and localised to the smooth muscle and endothelial cells of carotid and 
cerebral arteries (Lindsey et al. 2009).  It is not surprising therefore that GPER is 
involved in vascular reactivity of estrogen.  For example a GPER selective 
agonist, G1 initiates gender-independent relaxation of vascular smooth muscle 
cells (Broughton et al. 2010) although this is dependent on the vascular bed and 
agonist used for contraction as isolated arterial rings pre-contracted endothelin-
1 are relaxed by G1 whilst those contracted with serotonin are unaffected by G1 
(Haas et al. 2009).  In pulmonary arteries, the potential role of estrogen action 
via GPER is unknown.  In addition, G1 has been demonstrated to reduce blood 
pressure (Lindsey et al. 2009) and elicits an antiproliferative effect in 
endothelial cells (Holm et al. 2011).           
Due to the severe lack of evidence investigating the role of GPER in PAH despite 
the well defined influence of estrogen in development of PAH in females, we 
wished to evaluate and characterise GPER.  To our knowledge, this is the first 
study to characterise GPER in translational in vitro and in situ studies of PAH 
and in an experimental in vivo rodent model of PH.  We use a GPER knockout 
mouse (GPER-/-) to investigate GPER in chronic hypoxia induced-PH.  The aims of 
this study were to evaluate the expression of GPER in human and mouse lungs in 
the development of PAH, and to determine any gender differences in activity of 
GPER. 
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4.2 Results 
4.2.1   GPER Localisation in Human Lung and Pulmonary Artery  
Initially we wished to investigate if GPER was expressed in human lung and 
pulmonary artery and then further determine if localisation was cell type 
specific.  We utilised human lung sections from female non-PAH control and PAH 
patients.  To our knowledge, GPER expression in PAH development and 
progression has never been investigated. 
We observed GPER expression in both non-PAH control and PAH patient lungs.  
GPER was found to be localised to some, but not all, human PASMCs in non-PAH 
control and PAH patient lung sections.  In addition, some GPER was also localised 
to endothelial cells in control and PAH patients.  GPER expression was 
determined by positive dark brown staining (Figure 4-1).  Consecutive sections 
stained for alpha smooth muscle actin and von Willebrand factor further 
identified smooth muscle and endothelial cell specific staining, respectively.  
Lung sections were also counterstained with haemotoxylin (purple/blue).  
4.2.2   GPER Expression in Human Pulmonary Artery Smooth 
Muscle Cells 
In isolated human PASMCs, we then examined if there was a difference in 
expression of GPER between non-PAH control and idiopathic PAH (IPAH) and 
heritable PAH (HPAH) patients.  Levels of expression between non-PAH control 
and both IPAH and HPAH were similar at both protein (Figure 4-2A) and mRNA 
transcript levels (Figure 4-2B).
 
 
 
 
Control PAH α-SMA vWF IgG
 
Figure 4-1: Immunolocalisation of GPER in human lung sections. 
Expression of GPER (dark brown staining) is localised to the pulmonary artery smooth muscle cells and endothelial cells as indicated by the black arrow in control and 
PAH lung sections.  Consecutive sections stained for alpha smooth muscle actin (α-SMA) and von Willebrand factor (vWF) are shown, and the IgG control is shown for 
PAH patient.  Patient information is available in Materials and Methods section Table 2.1.  Scale bar=200µm. 
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Figure 4-2: Expression of GPER in isolated female human PASMCs. 
Expression of GPER protein (A) and mRNA transcript (B) is unchanged in IPAH and HPAH human 
PASMCs compared to non-PAH control.  Representative blots are shown.  Quantitative data are 
represented as ± SEM and analysed by an unpaired t-test.  Patient information is available 
Materials and Methods sections Table 2.3; control samples 1,3, 4 and 5 and patients samples 1-3. 
n=3/4 individual control or patients per group repeated in triplicate; n for each group is indicated on 
bar in graph. 
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4.2.3  GPER Expression in Female Mouse Pulmonary Artery and 
Lung in Chronic Hypoxia Induced-PH 
The expression of GPER in mouse pulmonary artery and lung during the 
development of chronic hypoxia induced-PH is unknown.  Here we wished to 
firstly determine if GPER is expressed in female mouse pulmonary artery and 
lung, and secondly investigate if expression levels of GPER are altered during PH 
development. 
Using female mouse pulmonary artery from wildtype mice we observed a 
significant decrease in expression of GPER protein in hypoxic pulmonary artery 
compared to normoxic controls (Figure 4-3A).  On the other hand, expression of 
GPER mRNA transcript was unchanged in whole lung from hypoxic females 
(Figure 4-3B). 
Interestingly, expression of GPER mRNA transcript was much lower in female 
mouse lung in normoxic and hypoxic conditions compared to ESR1, the gene 
encoding ERα (Figure 4-4A&B). 
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Figure 4-3: Expression of GPER in female mouse pulmonary artery and lung. 
Expression of GPER in hypoxic pulmonary artery is decreased relative to normoxic control (A).  
GPER mRNA transcript expression is unchanged in whole lung in normoxic versus hypoxic (B).  
Representative blots are shown.  Quantitative data are represented as ± SEM and analysed by an 
unpaired t-test.  n=6 pulmonary artery/lung per group repeated in triplicate; n for each group is 
indictaed in bar on graph. 
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Figure 4-4: Estrogen receptor mRNA expression in whole lung from female mice. 
Expression of estrogen receptors in (A) normoxic lung and (B) hypoxic lung.  Data are expressed 
as ± SEM analysed by an unpaired t-test.  *p<0.05 vs. ESR1. n=6 mice/lungs.  ESR1=gene 
encoding ERα; ESR2=gene encoding ERβ 
.
 
 
210 
 
4.2.4   Development of Chronic Hypoxia Induced-PH in Male and 
Female GPER-/- Mice 
GPER is a novel G-protein coupled estrogen receptor and the role of GPER in the 
development of PH is unknown.  To our knowledge, this is the first study 
investigating the role of GPER in an in vivo model of PH.  Here we utilise a GPER 
knockout mouse (GPER-/-) and the chronic hypoxic model of PH to determine the 
influence of GPER in males and females during PH development. 
The development of chronic hypoxia induced-PH was examined by right 
ventricular systolic pressure (RVSP), right ventricular hypertrophy (RVH) and 
percentage of pulmonary vascular remodelling and pulmonary artery 
muscularisation.  In both males and females, development of chronic hypoxia 
induced-PH was confirmed by elevations in RVSP, RVH and pulmonary vascular 
remodelling (Figure 4-5A-C).  In normoxic conditions, deletion of GPER had no 
effect on RVSP, RVH and pulmonary vascular remodelling.  This was observed in 
both males and females.  In hypoxia, the development of PH was unaffected in 
males and females by GPER deletion as RVSP (Figure 4-5A) and RVH (Figure 4-5B) 
were unchanged between wildtype (WT) and GPER-/- mice.  On the other hand, 
pulmonary vascular remodelling was increased in GPER-/- females in hypoxia 
relative to hypoxic wildtype mice.  This effect was not observed in male GPER-/- 
mice (Figure 4-5C).  GPER deletion however, had no effect on pulmonary artery 
muscularisation in normoxic and hypoxic conditions in males and females (Figure 
4-6).  We observed no effects on systemic haemodynamics in GPER-/- mice 
relative to wildtype controls.  Mean systemic arterial pressure (mSAP) (Figure 4-
7A) and heart rate (HR) (Figure 4-7B) were unchanged in males and females in 
normoxia and hypoxia.  Absolute haemodynamic values are shown in Table 4-1. 
4.2.5   Effect of GPER on Body Weight and Uterus Weight in 
Chronic Hypoxia Induced-PH 
Wildtype and GPER-/- males exhibited increased body weights relative to 
wildtype and GPER-/- females, respectively.  However, in both males and 
females, body weight was unaffected by hypoxia.  In males, deletion of GPER 
had no effect on body weight in normoxic and hypoxic conditions, although in 
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females, body weight was significantly increased in GPER-/- mice relative to 
wildtype controls (Figure 4-8A). 
The role of GPER in regulating estrogen dependent uterine biology is unclear.  
Here we identified that GPER deletion in female mice has no effect on uterus 
weight.  Uterus weight was expressed as a ratio corrected for body weight given 
the influence GPER had on overall body weight in females (Figure 4-8B).  
Absolute values for body weight and uterus weight are shown in Table 4-2. 
 
 
212 
 
 
A.
B.
†
C.
8 4 9 6 10 8 8 10
6 6 6 6 6 6 6 6
8 5 10 7 10 8 10 10
 
Figure 4-5: Development of chronic hypoxic PH in male and female GPER
-/-
 mice. 
In vivo, (A) RVSP, (B) RVH and (C) pulmonary vascular remodelling are unchanged in WT versus 
GPER
-/-
 mice in both males and females.  Data are expressed as ± SEM analysed by a Two-Way 
ANOVA followed by a Bonferroni’s post hoc test.  *p<0.05, **p<0.01, ***p<0.001 vs. normoxic; 
†p<0.05 vs. WT.  n=6-9 mice per group; n per group is indicated in the bar in the graph.. 
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Figure 4-6: Pulmonary artery muscularisation in male and female GPER
-/-
 mice. 
Smooth muscle layer stains dark brown with alpha- smooth muscle actin.  Representative images are shown from each group.  Scale bar=20µm. 
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Figure 4-7: Systemic haemodynamic parameters in male and female GPER
-/-
 mice. 
Mean systemic arterial pressure (mSAP (A) and heart rate (HR) (B) are unchanged in male and 
female GPER
-/- 
mice relative to WT controls.  Data are expressed as ± SEM analysed by a Two-
Way ANOVA followed by a Bonferroni’s post hoc test.  n=6-10 mice per group; n of mice per group 
is indicated in the bar in the graph. 
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Figure 4-8: Body weight and uterus weight in male and female GPER
-/-
 mice. 
(A) Body weight is increased in female GPER
-/- 
mice relative to WT controls whilst male GPER
-/-
 
body weight is unaffected.  (B) Uterus weight/body weight ratio is unchanged in female GPER
-/-
 
mice.  Data are expressed as ± SEM analysed by a Two-Way ANOVA followed by a Bonferroni’s 
post hoc test.  ††p<0.01, †††p<0.001 vs. WT; ###p<0.001 vs. female.  n=5-10 mice per group; n 
per group is indicated in bar in graph. 
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Table 4-1: Haemodynamic parameters in male and female WT and GPER
-/-
 mice in chronic 
hypoxia.  
Right ventricular systolic pressure (RVSP); Mean right ventricular pressure (RMVP); right 
ventricular diastolic pressure (RVDP); systemic systolic arterial pressure (sSAP); mean systemic 
arterial pressure (mSAP); diastolic systemic arterial pressure (dSAP); Heart rate (HR).  Data 
expressed as ± SEM analysed by a Two-Way ANOVA followed by a Bonferroni’s post hoc test.  
*p<0.05, **p<0.01, ***p<0.001 vs. normoxic; †† p<0.01 vs. WT.  n = 6-10 mice per group. 
 
Parameter/Group Male WT Male GPER-/- Female WT Female GPER-/- 
 
Normoxic 
 
    RVSP, mmHg 22.52 ± 0.68 24.21 ± 1.07 22.38 ± 0.67 23.98 ± 0.69 
RMVP, mmHg 13.61 ± 0.47 14.36 ± 0.77 14.77 ± 0.46 13.60 ± 1.27 
RVDP, mmHg 1.40 ± 0.40 0.53 ± 0.26 2.74 ± 0.75 1.45 ± 0.67 
sSAP, mmHg 116.6 ± 2.82 99.74 ± 3.38 96.11 ± 1.88 103.2 ± 5.91 
mSAP, mmHg 101.8 ± 1.83 97.85 ± 1.43 92.63 ± 2.70 88.41 ± 7.94 
dSAP, mmHg 83.75 ± 1.55 96.07 ± 3.56 83.59 ± 2.72 73.98 ± 5.74 
HR, bpm 413.8 ± 16.06 470.2 ± 5.00 450.8 ± 12.37 418.2 ± 29.73 
     Hypoxic 
 
    RVSP, mmHg 34.74 ± 0.90*** 32.85 ± 0.66*** 32.76 ± 0.40*** 35.27 ± 1.07*** 
RMVP, mmHg 18.17 ± 0.74*** 18.87 ± 0.62** 19.80 ± 0.68*** 20.39 ± 0.71*** 
RVDP, mmHg 2.21 ± 0.48 2.63 ± 0.38* 2.66 ± 0.39 1.99 ± 0.44 
sSAP, mmHg 123.8 ± 1.61 109.4 ± 3.29†† 113.0 ± 2.09** 111.2 ± 2.83 
mSAP, mmHg 114.3 ± 1.17 101.3 ± 2.54 108.8 ± 1.79 104.9 ± 2.41 
dSAP, mmHg 101.4 ± 2.13*** 89.83 ± 2.68†† 102.8 ± 2.26*** 94.12 ± 2.93** 
HR, bpm 424.1 ± 13.60 437.2 ± 12.92 408.5 ± 13.26 403.1 ± 11.80 
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Table 4-2: Ventricle, body weight and uterus weight in male and female mice WT mice and 
GPER
-/-
 mice 
Right ventricle (RV); left ventricle plus septum (LV + S); RV/LV+S ratio, body weight and uterus 
weight.  * p<0.05 ** p <0.01, *** p<0.001 vs. normoxic mice; †† p<0.01, ††† p<0.001 vs. GPER
-/-
 
mice; ###p<0.001 vs. female mice.  Data are expressed as ± SEM analysed by a Two-Way 
ANOVA followed by a Bonferroni’s post hoc test. n = 6-10 mice per group. 
Group RV (mg) LV + S (mg) RV/LV+S Body  
weight (g) 
Uterus  
weight (mg) 
      
Normoxic      
Male      
WT 31.18 ± 1.58# 112.2 ± 4.74### 0.28 ± 0.02 27.82 ± 0.76###  
GPER-/- 35.14 ± 2.05 128.3 ± 9.55### 0.28 ± 0.03 30.63 ± 1.52###  
Female      
WT 20.47 ± 1.26 81.76 ± 2.85 0.25 ± 0.01 18.90 ± 0.29 82.77 ± 14.22 
GPER-/- 25.79 ± 2.34 91.82 ± 3.88 0.28 ± 0.02 24.52 ± 1.00††† 78.96 ± 18.09 
      
Hypoxic      
Male      
WT 37.81 ± 2.65# 109.7 ± 4.15### 0.35 ± 0.02* 27.55 ± 0.59###  
GPER-/- 45.09 ± 3.16## 109.7 ± 5.09 0.42 ± 0.03** 30.00 ± 0.42###  
Female      
WT 28.02 ± 1.34 79.52 ± 1.78 0.35 ± 0.02*** 19.14 ± 0.24 94.39 ± 11.91 
GPER-/- 32.19 ± 1.28 92.82 ± 2.84 0.35 ± 0.02* 23.20 ± 0.30†† 86.92 ± 9.43 
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4.2.6   Effects of GPER on Human Pulmonary Artery Smooth 
Muscle Cell Proliferation 
Smooth muscle cell proliferation is integral to the pulmonary vascular 
remodelling process.  We therefore utilised human PASMCs in vitro to determine 
the role of GPER using a selective agonist and antagonist. 
The GPER selective agonist, G1, had no effect on proliferation of PASMCs at the 
range of concentrations tested (0.01-10nmolL-1) (Figure 4-9A).  In previous 
studies we have shown estrogen induced proliferation of PASMCs at physiological 
concentrations of 1nmol/l (Dempsie et.al. 2013; White et.al. 2011).  In this 
study we also demonstrate estrogen induced proliferation at 1nmolL-1, however, 
the GPER selective antagonist, G15, has no effect on estrogen induced-human 
PASMC proliferation (Figure 4-9B). 
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Figure 4-9: Proliferation in female human PASMCs is unaffected by a GPER agonist and 
antagonist. 
(A) The GPER selective agonist, G1, has no effect on human PASMC proliferation.  (B) The GPER 
selective antagonist, 1µmolL
-1
 G15, has no effect on estrogen (E2) induced proliferation.  Data are 
expressed as ± SEM analysed by a One-Way ANOVA followed by a Tukey’s post hoc test.  .  n=3 
female control cell lines repeated in triplicate (Controls 1, 4 and 5, See Table 2-3 in Material and 
Methods).   ***p<0.001 vs. 2.5% FBS; ##p<0.01 vs. 1nmoll
-1
 E2. 
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4.2.7  Effect of Serotonin on GPER Expression in Human 
Pulmonary Artery Smooth Muscle Cells 
We have previously demonstrated that physiological estrogen (1nmolL-1) can 
increase the expression of tryptophan hydroxylase 1 (TPH1), the serotonin 
transporter (SERT) and the 5-HT1B receptor in human PASMCs (White et.al. 
2011).  Here we wished to examine the effects of serotonin on GPER expression 
in human PASMCs. 
In female human PASMCs we show that the expression of GPER in human PASMCs 
is unchanged by 1µmolL-1 serotonin (Figure 4-10). 
 
 
 
221 
 
 
GPER 55kDa
0   10    15   30   1      4     24
minutes hours
α-tubulin 50kDa
 
Figure 4-10: Serotonin has no effect on GPER expression in female human PASMCs. 
Representative blots are shown.  Quantitative data is expressed as ± SEM analysed by a One-Way 
ANOVA followed by a Tukey’s post hoc test.  n=3 female control cell lines repeated in triplicate 
(Controls 1, 4 and 5, See Table 2-3 in Material and Methods). 
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4.3 Discussion 
It is clear from the most recent epidemiologic data that there is a female 
predominance in many forms of PAH, including IPAH and HPAH (Badesch et.al. 
2010; Humbert et.al. 2006; Peacock et.al. 2007; Thenappan et.al. 2007).  The 
reasons underlying this gender disparity remain unresolved, although several 
lines of evidence suggest estrogen plays a pivotal role in PAH physiology and 
pathogenesis.  The ‘estrogen paradox’ however, has hampered our 
understanding of estrogen in the development of PAH in women. 
In this study, we aimed to investigate the role of the novel estrogen receptor, 
GPER, in the development of PH by utilising translational in vitro and in situ 
studies, and a GPER-/- mouse in the in vivo chronic hypoxic model of PH.  
Importantly we evaluated the role of GPER in vivo in both males and females to 
determine the influence of gender.  Our results demonstrate that development 
of chronic hypoxia induced-PH is likely independent of estrogen mediated 
effects through GPER.  From our translational human data, we also demonstrate 
that GPER is expressed in human lung and localised to smooth muscle cells and 
endothelial cells, however expression is unchanged in PASMCs in PAH.  
Furthermore, estrogen induced proliferation of human PASMCs is independent of 
GPER.  Together our results indicate GPER is not crucial in estrogen mediated 
effects in PH development. 
GPER mediates rapid and transcriptional events in response to estrogen in cells 
lacking classical nuclear ERα/ERβ, through activation of diverse transduction 
cascades like the ERK1/2 pathway (Filardo et al. 2002; Revankar et al. 2005) and 
phosphatidylinositol-3-kinase (PI3K)/Akt (Thomas et al. 2005).  GPER has 
previously been identified in human internal mammary arteries and saphenous 
veins at a level comparable to ERα, although 10-fold lower than ERβ (Haas et al. 
2007).  Expression of GPER has also been detected in mouse mesenteric artery 
(Martensson et.al. 2009), carotid artery (Haas et.al. 2009) and in the 
cardiomyocytes of both the rodent and human heart (Deschamps & Murphy 2009; 
Filice et al. 2009; Patel et al. 2010).  Furthermore, it is clearly evident that 
vascular GPER protein is localised to both endothelial and smooth muscle cells in 
rat aorta, carotid and cerebral arteries, although more intense staining for GPER 
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is demonstrated in endothelial cells (Broughton et.al. 2010).  GPER is therefore 
believed to contribute to cardiovascular actions of estrogens.  Characterisation 
of GPER in the lung however, is less well defined, although enhanced GPER 
expression has recently been attributed to a pathological role in lung cancer 
cells (Jala et.al. 2012; Siegfried et al. 2009).  In particular, GPER expression and 
localisation in human and mouse lung and pulmonary artery in PH is unknown.  In 
the present study we observed GPER expression in both human non-PAH control 
and PAH patient lung sections, although expression levels were low.  
Additionally, we show no difference in protein and mRNA expression levels of 
GPER between non-PAH controls and IPAH and HPAH patients in isolated PASMCs.  
In contrast, protein expression of GPER was significantly reduced in pulmonary 
arteries from hypoxic female mice relative to controls, although this was not 
observed at the mRNA level, suggesting a post-transcriptional regulation of GPER 
in hypoxia.  This data conflicts previous evidence in cancer cells and 
cardiomyocytes where GPER was identified as a target gene of hypoxia inducible 
factor-1α (HIF-1α), leading to an increase in expression upon hypoxic conditions, 
compared to normoxia (Recchia et al. 2011).  The up-regulation of GPER was 
associated with an adaptive response to stressful microenvironments in the rat 
heart during hypertension.  Here, our results may differ due to tissue and 
species differences.  Interestingly, we show in mouse lung that expression levels 
of GPER mRNA transcript are significantly less than ESR1 levels in both normoxic 
and hypoxic conditions, although comparable to ESR2 levels.  Together this data 
suggests that the role of GPER in the lung during PH development may be less 
important than ERα. 
Despite the low expression levels of GPER in the human and mouse lung, we 
wished to characterise the role of GPER in vivo as these represent novel findings 
in the development of PH.  Moreover, we showed a reduction of GPER protein in 
hypoxic pulmonary arteries from females.  We utilised male and female GPER-/- 
mice between 2-3 months of age due to the age dependent development of 
systemic arterial pressure observed in female GPER-/- mice (Martensson et.al. 
2009).  Chronic hypoxia was used to induce PH in GPER-/- mice as it produces 
potent vasoconstriction in pulmonary arteries (Pugh & Hemnes 2010).  In 
normoxic conditions, deletion of GPER had no influence on RVSP, RVH or 
pulmonary vascular remodelling.  Following exposure to chronic hypoxia, we 
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observed development of chronic hypoxia induced-PH in wildtype male and 
female mice as they exhibited elevations in RVSP, RVH and pulmonary vascular 
remodelling.  However, in male and female GPER-/- mice, hypoxia did not 
attenuate, nor did it exaggerate PH development compared to wildtype 
counterparts.  These findings indicate that GPER is not involved in elevated 
pulmonary pressures and cardiac remodelling in chronic hypoxic PH.  
Interestingly, female GPER-/- mice did demonstrate an increase in pulmonary 
vascular remodelling compared to hypoxic wildtype females, although this effect 
was absent in males.  This may suggest that activation of GPER mediates a 
protective effect in hypoxia although the effects are not sufficient enough to 
completely reverse the PH phenotype.  In addition, other ERs or environmental 
stimuli must be involved. 
G1, a GPER selective agonist has been shown to reduce vascular smooth muscle 
(Haas et.al. 2009) and endothelial cell proliferation (Holm et al. 2011).  Indeed, 
whilst the former provides a protective effect against remodelling, inhibition of 
endothelial cell proliferation may prevent re-endothelialisation in arteries 
following injury and contribute to loss of endothelial function.  In contrast to 
vascular cells, in cancer cells, GPER has been demonstrated to mediate 
proliferative effects of estrogen in endometrial cancer cells and aggressive 
disease in breast cancer cells (Filardo et al. 2006).  G1 induces proliferation via 
epidermal growth factor receptor (EGFR)/ERK1/2 mediated pathways leading to 
elevated cyclin D1 and c-fos expression (Maggiolini et.al. 2004; Sirianni et al. 
2008).  The role of GPER activation in pulmonary vasculature and proliferation is 
not clear.  Here we identify that human PASMCs did not respond to G1 between 
0.01–10nmolL-1 concentration range.  This is in line with our data which shows 
that human PASMC proliferation induced by a physiological estrogen 
concentration (1nmolL-1) is unaffected by the GPER selective antagonist, G15.  
Together, our evidence provides the first insight into the role of GPER in isolated 
human PASMCs and indicates that estrogen-induced proliferation in PAH is likely 
GPER independent.  However, future studies in PASMCs using G1 should use a 
larger concentration range to ensure the effects at higher concentrations are 
investigated, for example, 1µmolL-1 has been shown recently to promote 
proliferation in breast cancer associated fibroblasts (Luo et al. 2014). 
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This we believe is the first study to characterise the role of GPER in the 
development of PAH.  Much more evidence is available on the cardioprotective 
effects of GPER in humans and animal models.  In several vascular beds, for 
example, in rat aorta and carotid artery (Broughton et.al. 2010; Lindsey et.al. 
2011) and in porcine coronary artery (Meyer et al. 2010) it is confirmed that G1 
initiates endothelium-dependent vascular relaxation.  In female GPER-/- mice 
there is an age-dependent increase in mean arterial pressure at 9 months 
associated with an increase in vascular resistance as opposed to an increase in 
heart rate and cardiac output (Martensson et.al. 2009), further implicating 
protective effects on GPER in vasculature.  Consistent with this, in our study 
using mice aged 2-3 months, we observed no difference in mean systemic 
arterial pressure (mSAP) and heart rate in our GPER-/- male and female mice.  In 
addition, G1 has been shown to lower blood pressure in normotensive rats and 
relax rodent and human vessels (Haas et.al. 2009).  In isolated hearts, G1 pre-
treatment attenuates ischemia-reperfusion and infarct size potentially through a 
reduction in inflammation (Bopassa et al. 2010; Deschamps & Murphy 2009; Patel 
et.al. 2010).  Although we show here that the potent vasoconstrictor serotonin 
(MacLean & Dempsie 2010) has no effect on GPER expression in PASMCs, further 
characterisation of GPER is required to decipher vasoactive properties which 
may contribute to pulmonary artery vasoconstriction and development of PH. 
The localisation of GPER to human blood vessels clearly implies a role for this 
receptor in cardiovascular disease and there is confounding evidence to support 
this.  Additionally, a role for GPER in some cancer cells, including breast cancer, 
endometrial cancer and lung cancer is proposed.  In contrast, there is sparse 
evidence describing GPER localisation in pulmonary vasculature and this we 
believe is the first study to characterise GPER in this vascular bed.  From this 
study, we conclude that expression of GPER in PASMCs has a limited influence on 
PH pathology independent of gender.  This evidence builds on answering the 
female predominance observed in PAH. 
 
 
Chapter 5. 
Investigating the Influence of Testosterone in the 
Development of Experimental Pulmonary 
Hypertension 
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5  
5.1 Introduction 
Despite a gender bias in PAH with women up to four-fold more likely to present 
with disease compared to men (Badesch et.al. 2010; Walker et.al. 2006), male 
patients show poorer survival in established PAH, even following treatment 
intervention (Benza et.al. 2012; Humbert et.al. 2010a; Humbert et.al. 2010b).  
There is a paucity of studies in PAH investigating male hormones in pulmonary 
vasculature structure and function, but the exact role of androgens in physiology 
and the pathophysiology of PAH remains uncertain.  Androgens may therefore 
play a crucial role in the progression of PAH in males. 
The influence of testosterone on the pulmonary vasculature is a potential 
mechanism by which males may show shortened survival.  However, right 
ventricular (RV) function is the most important prognostic factor and indicator of 
survival in PAH (D'Alonzo et al. 1991).  In line with this, males show a propensity 
to RV dysfunction and lower right ventricular ejection fraction (RVEF) in PAH 
compared to females, (Kawut et.al. 2009) and estrogen levels are shown to 
strongly correlate with improved RV function (Ventetuolo et.al. 2011).  Androgen 
receptors (AR) have been identified in both the RV and left ventricle (LV), 
although the latter has been more extensively studied. Both testosterone and 
the primary metabolite, dihydrotestosterone (DHT) mediate genomic effects 
through the AR, although DHT is 10-times more potent in activation of the AR 
than testosterone (Liu et.al. 2003).  There is convincing evidence that 
testosterone can initiate concentric hypertrophy via AR dependent mechanisms 
(Achar et.al. 2010; Hayward et.al. 2000).  In addition, structural and 
morphological changes in human hearts are associated with alterations in the 
metabolism of testosterone, with elevated levels of the DHT described in human 
left ventricular hypertrophy (Thum & Borlak 2002). 
Recent evidence from the pulmonary artery banding (PAB) model of PAH which 
exhibits severe RVH and RV dysfunction in the absence of pulmonary vascular 
remodeling, describes a pro-fibrotic effect of testosterone in the RV (Hemnes 
et.al. 2012).  Atrial natriuretic peptide (ANP), a marker of cardiac hypertrophy 
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was significantly attenuated following removal of testosterone by castration in 
PAB mice while myocyte size was augmented with chronic testosterone 
replacement.  The MESA-Right Ventricle Study has also shown in men, that 
testosterone is associated with elevated RV mass and right ventricular end- 
diastolic and systolic volumes, whereas this was not observed in women 
(Ventetuolo et.al. 2011).  A potentially negative effect of testosterone in the 
stressed RV may contribute towards dysfunctional and maladaptive RV 
hypertrophy in males. 
On the other hand, testosterone is known to be a potent vasodilator in the 
isolated pulmonary vascular beds and has been extensively studied in isolated 
vessels from humans where the observed effect is independent of gender (Rowell 
et.al. 2009; Smith et.al. 2008).  Importantly, this effect of testosterone is 
accepted to be a rapid, non-genomic effect and is therefore not mediated via AR 
(Jones et.al. 2002; Yue et.al. 1995)  In addition, the effect is not due to 
conversion to estrogen as the vasodilatory response is unaffected by aromatase 
(CYP19A1) inhibition, the enzyme that converts testosterone to estrogen, or by 
estrogen receptor antagonism (Deenadayalu et.al. 2001; Teoh et.al. 2000; Tep-
areenan et.al. 2002). 
Given the high incidence of idiopathic, heritable and some associated forms of 
PAH in women (Benza et.al. 2012; Humbert et.al. 2010a), research addressing 
the gender bias has been focused on estrogen.  However, the effects of 
testosterone may infer a contradiction in PAH with highlighted multiple actions 
in the RV and pulmonary vasculature.  Since survival is worse in males and 
survival is closely linked to RV function, a negative effect of testosterone or its 
metabolites is proposed in the RV.  Here we investigated the effects of 
testosterone in vitro and in vivo to elucidate the role of male hormones in PAH 
development and progression.  We also determine vasoreactive properties in 
pulmonary arteries following testosterone manipulation. 
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5.2  Results 
5.2.1  Castration Does Not Attenuate the Development of Chronic 
Hypoxia Induced-PH 
To investigate the effects of testosterone on PH in vivo, we castrated wildtype 
C57Bl/6 male mice to deplete their endogenous testosterone.  To assess PH 
development, right ventricular systolic pressure (RVSP), pulmonary vascular 
remodelling and right ventricular hypertrophy (RVH) were measured in normoxic 
and hypoxic conditions.  Following 14 days exposure to chronic hypoxia, 
elevations in RVSP, vascular remodelling and RVH parameters were observed.  
Development of chronic hypoxia induced-PH was not attenuated by removal of 
endogenous testosterone by castration.  There were no changes in RVSP, 
pulmonary vascular remodelling or RVH in castrated mice compared to SHAM 
control mice in both normoxic and hypoxic conditions (Figure 5-1A-C).  
Muscularisation of pulmonary arteries assessed by alpha smooth muscle actin, 
also showed no effect of castration in normoxic or hypoxic conditions (Figure 5-
2). 
Similarly, hypoxia and castration had no effect on systemic arterial pressure 
(Figure 5-3), although a reduction in the heart rate in hypoxic SHAM mice was 
reported, compared to normoxic SHAM controls (Figure 5-4).  Absolute values for 
haemodynamic measurements are depicted in Table 5-1. 
5.2.2  Testosterone levels were halved following castration 
To confirm that castration in mice was effective in reducing testosterone levels, 
an ELISA (R&D Systems, UK) was performed in plasma samples to test remaining 
‘free’ circulating testosterone.  In normoxic SHAM mice we observed 
testosterone levels of 3.59 ± 0.07 ngml-1 which were reduced following 
castration to 1.32 ± 0.009 ngml-1.  In hypoxia we also observed reduced plasma 
testosterone levels following castration from 4.03 ± 0.09 ngml-1 in sham mice 
compared to 1.79 ± 0.02 ngml-1 in hypoxic castrated mice (Figure 5-5). 
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We also wished to determine if exposure to chronic hypoxia had an effect on the 
levels of plasma testosterone in vivo.  Interestingly, no differences were 
observed in testosterone levels between normoxic and hypoxic SHAM mice 
(Figure 5-5). 
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Figure 5-1: Castration has no effect on the development of chronic hypoxia induced- PAH in 
vivo. 
Right ventricular systolic pressure (RVSP; A); pulmonary vascular remodelling (B) and right 
ventricular hypertrophy (RVH; C) were unchanged following castration in both normoxia and 
hypoxia.  Data are expressed as mean ± SEM and analysed by a Two-way ANOVA followed by a 
Bonferroni’s post-hoc test.  Scatter plots were used to identify the spread of data.  **p<0.01, 
***p<0.001 vs. normoxic.  n=4-10 mice per group. 
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Figure 5-2: Castration has no effect on pulmonary vascular remodelling. 
Representative images are shown stained with alpha smooth muscle actin (brown).  Scale bar = 
20µm. 
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Figure 5-3: Castration has no effect on systemic arterial pressure in either normoxia or 
chronically hypoxic conditions.   
Mean systemic arterial pressure (mSAP) is unaffected by removal of testosterone in both normoxia 
and hypoxia.  Data is expressed as mean ± SEM and analysed by a Two-way ANOVA followed by 
a Bonferroni’s post-hoc test.  Scatter plots were used to identify the spread of data.  n=4-6 mice per 
group. 
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Figure 5-4: Castration has no effect on heart rate in either normoxia or chronically hypoxic 
conditions.   
Castration had no effect on heart rate (HR) however HR was significantly reduced in SHAM mice in 
hypoxia.  Data is expressed as mean ± SEM and analysed by a Two-way ANOVA followed by a 
Bonferroni’s post-hoc test.  Scatter plots were used to identify the spread of data.  *p<0.05 vs. 
normoxic.  n=7-10 mice per group. 
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Figure 5-5: Plasma testosterone levels are reduced in mice following castration. 
Plasma levels of testosterone in normoxic and hypoxic mice following castration.  Data is 
expressed as mean ± SEM and was analysed using a non-fit standard curve corrected for the 
dilution factor followed by an unpaired t-test.  #p<0.05 vs. SHAM.  n=6 samples per group. 
 
 
 
236 
 
5.2.3  Body Weight and Heart Weight are Decreased Following 
Castration 
Testosterone is an important androgen in regulation of growth and muscle mass 
(Humbert et.al. 2010a; Nunez et al. 1980) we therefore investigated the effect 
castration had on body weight in both normoxic and hypoxic conditions.  In 
normoxic mice no difference in body weight was observed in castrated mice 
compared to SHAM controls.  However, body weight was significantly decreased 
following castration in hypoxic mice compared to SHAM controls (Figure 5-6).  In 
addition, hypoxia had no effect on body weight compared to normoxic mice. 
Total heart weight was also investigated in SHAM controls and castrated mice in 
both normoxia and hypoxia.  Chronic hypoxia had no effect on the total heart 
weight in both SHAM and CAS mice.  Interestingly, in both normoxic and hypoxic 
conditions, castration resulted in a decrease in heart weight (Figure 5-7).  
5.2.4  Left Ventricular Weight in the Heart is Subject to Regulation 
by Testosterone 
Previous studies have identified an association between left ventricle (LV) mass 
and testosterone (Cavasin et al. 2003).  LV weight was significantly reduced in 
male mice that underwent castration in both normoxic and hypoxic conditions.  
Chronic hypoxic treatment had no effect on LV weight in SHAM control mice 
(Figure 5-8).  LV weight expressed as a ratio to body weight showed there were 
no effects of hypoxia on LV weight. 
On the other hand, right ventricle (RV) weight was increased in both SHAM and 
castrated mice following exposure to chronic hypoxia.  Castration in this 
instance had no effect on RV weight in either normoxia or hypoxia (Figure 5-9).  
RV weight expressed as a ratio to body weight was increased in hypoxia (5-10).  
Absolute values for heart weights and body weights are depicted in Table 5-2. 
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###
###
 
Figure 5-6: Body weight was decreased in hypoxic castrated male mice compared to SHAM 
control mice. 
Heart weight is reduced following castration in hypoxia although remains unchanged in normoxia.  
Data are expressed as mean ± SEM and analysed by a Two-way ANOVA followed by a 
Bonferroni’s post-hoc test.  Scatter plots were used to identify the spread of data. ###p<0.001 vs. 
SHAM.   n=9-10 mice per group. 
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Figure 5-7: Heart weight was decreased in castrated male mice compared to SHAM control 
mice. 
Heart weight is reduced following castration, however hypoxia has no effect on heart weight.  Data 
are expressed as mean ± SEM and analysed by a Two-way ANOVA followed by a Bonferroni’s 
post-hoc test.  Scatter plots were used to identify the spread of data.  #p<0.05; ###p<0.001 vs. 
SHAM.  n=10 mice per group. 
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Figure 5-8: Left ventricular weight was decreased in castrated male mice compared to sham 
mice. 
Left ventricular (LV) weight is reduced following castration, however hypoxia has no effect on LV 
weight.  Data are expressed as mean ± SEM and analysed by a Two-way ANOVA followed by a 
Bonferroni’s post-hoc test.  Scatter plots were used to identify the spread of data. ##p<0.01; 
###p<0.001 vs. SHAM.   n=9-10 mice per group. 
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Figure 5-9: Right ventricular weight is unaffected following castration. 
Castration has no effect on right ventricular (RV) weight in either normoxia or hypoxia, however RV 
weight is increased in both sham and castrated mice in hypoxia.  Data are expressed as mean ± 
SEM and analysed by a Two-way ANOVA followed by a Bonferroni’s post-hoc test.  Scatter plots 
were used to identify the spread of data.  *p<0.05 vs. normoxic.  n=9-10 mice per group. 
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Figure 5-10: LV and RV weight expressed as a ratio to body weight. 
(A) LV weight (mg)/body weight (g) ratio is unchanged in hypoxia whereas (B) RV weight 
(mg)/body weight (g) ratio is increased in hypoxia.  This indicates an increase in RV weight relative 
to the body weight in hypoxia.  Data are expressed as mean ± SEM and analysed by a Two-way 
ANOVA followed by a Bonferroni’s post-hoc test.  *p<0.05, **p<0.01 vs. normoxic.      
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Table 5-1: Haemodynamic parameters in SHAM and castrated mice exposed to chronic 
hypoxia. 
RVSP=right ventricular systolic pressure; MRVP=mean right ventricular pressure; RVDP=right 
ventricular diastolic pressure; sSAP=systolic systemic arterial pressure; mSAP=mean systemic 
arterial pressure; dSAP=diastolic systemic arterial pressure; HR=heart rate; SHAM=control; 
CAS=castration.  Data are expressed as ± SEM analysed by a Two-Way ANOVA followed by a 
Bonferroni’s post hoc test.*p<0.05, ***p<0.001 vs. normoxic. n=4-10 shown in table for individual 
parameters. 
Parameter 
Normoxic 
SHAM 
Normoxic 
CAS 
Hypoxic  
SHAM 
Hypoxic  
CAS 
     RVSP, mmHg 20.43 ± 1.05 22.18 ± 0.85 33.78 ± 0.63*** 30.22 ± 1.56*** 
n 8 7 10 8 
 
MRVP, mmHg 9.83 ± 0.53 12.26 ± 1.54 14.98 ± 0.39*** 14.79 ± 0.66 
n 8 7 10 8 
 
RVDP, mmHg 1.15 ± 0.56 1.91 ± 0.58 3.25 ± 0.38* 3.38 ± 0.32 
n 8 7 10 8 
 
sSAP, mmHg 103.4 ± 2.93 114.3 ± 3.85 102.4 ± 8.38 108.9 ± 5.52 
n 6 6 5 4 
 
mSAP, mmHg 88.14 ± 6.5 100.6 ± 2.29 81.9 ± 7.6 102.5 ± 7.16 
n 6 6 5 4 
 
dSAP, mmHg 77.51 ± 8.01 88.71 ± 3.52 77.93 ± 11.22 95.04 ± 9.09 
n 6 6 5 4 
 
HR, bpm 384.7 ± 15.6 415.6 ± 16.4 322.3 ± 17.7* 362.0 ± 18.7 
n 8 7 10 8 
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Table 5-2: Ventricle, heart and body weight in SHAM and castrated mice exposed to chronic 
hypoxia.  RV= right ventricle; LV+S= left ventricle plus septum; SHAM= control; CAS=castration.  
Data are expressed as ± SEM analysed by a Two-Way ANOVA followed by a Bonferroni’s post hoc 
test.  *p<0.05, ***p<0.001 vs. normoxic; #p<0.05, ##p<0.01, ###p<0.001 vs. SHAM control.  n=6-
10 and shown for individual parameters in table. 
 
Group RV (mg) LV + S (mg) RV/LV+S 
Heart 
weight (mg) 
Body 
weight (g) 
      Normoxic 
 
     SHAM 23.6 ± 1.0 111.3 ± 2.7 0.21 ± 0.007 134.9 ± 3.4 24.8 ± 0.34 
n 10 10 9 10 10 
 
CAS 24.2 ± 1.7 96.5 ± 3.1## 0.24 ± 0.01 120.7 ± 2.6# 23.5 ± 0.52 
n 10 10 8 10 10 
      Hypoxic 
 
     SHAM 33.1 ± 2.8* 106.9 ± 2.5 0.31 ± 0.02*** 140.0 ± 3.5 24.5 ± 0.2 
n 10 10 7 10 10 
 
CAS 33.5 ± 2.7* 84.5 ± 3.2### 0.32 ± 0.01*** 
118.0 ± 
4.1### 
20.8 ± 
0.4### 
n 10 10 6 10 10 
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5.2.5   Effect of Castration on Serotonin Induced Pulmonary 
Artery Vasoconstriction 
To determine if castration in male mice had any effect on hypoxic pulmonary 
vascular reactivity we assessed serotonin-induced vasoconstriction in pulmonary 
arteries.  Serotonin was studied as it is a potent pulmonary vasoconstrictor 
(MacLean & Dempsie 2010).  Pulmonary arteries from hypoxic SHAM mice had an 
increased vasoreactivity to serotonin compared to normoxic SHAM mice as 
evidenced by a significantly increased Emax.  In addition, area under the curve 
analysis further highlights the elevated response to serotonin in hypoxic SHAM 
mice compared to normoxic SHAM mice (Figure 5-11A).   
Serotonin induced-vasoconstriction was similar in both normoxic SHAM mice and 
normoxic castrated mice.  Similarly, vasoconstriction was unaffected in arteries 
from hypoxic SHAM mice compared to hypoxic castrated mice (Figure 5-11A).  
Hypoxic castrated mice however, do not exhibit a heightened hypoxic response 
compared to normoxic castrated mice as Emax and AUC (Figure 5-11B) are not 
increased in hypoxia.  Absolute values for pEC50 and Emax are shown in Table 5-3. 
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Figure 5-11: Serotonin- induced pulmonary arterial contraction is unaffected following 
castration in chronic hypoxic mice.   
(A) Cumulative concentration response curve to serotonin shows no effect of castration on vascular 
activity, however, the response to serotonin in SHAM mice is elevated in hypoxia compared to 
normoxic SHAM mice.  (B) Area under the curve (AUC) demonstrates an elevated response in 
hypoxic SHAM mice relative to normoxic SHAM mice.  Data are expressed as mean ± SEM and 
(A) analysed using a Two-Way ANOVA followed by a Bonferroni’s post hoc test and (B) by a one-
way ANOVA followed by a Bonferroni’s post hoc test.  ***p<0.001 vs. normoxic.   n=4-9. 
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Table 5-3: pEC50 and Emax values in male SHAM and castrated mice in normoxic and 
hypoxic conditions.  pEC50, half maximal effective dose; Emax, maximal effective dose; 
CAS=castrated.  Data are expressed as ± SEM and analysed by a One-Way ANOVA followed by a 
Bonferroni’s post hoc test. n=4-9 mice per group. 
Normoxic SHAM Normoxic CAS Hypoxic SHAM Hypoxic CAS 
pEC50 7.14 ± 0.2 7.12 ± 0.2 7.52 ± 0.1 7.89 ± 0.5 
 
Emax 111.9 ± 7.6 119.2 ± 7.25 210.6 ± 29.0*** 163.7 ± 14.3 
n 9 6 4 6 
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5.2.6 Effects of Testosterone and Dihydrotestosterone in Human 
Pulmonary Artery Smooth Muscle Cells 
To further evaluate possible influences of testosterone we investigated 
proliferative responses to testosterone and its primary metabolite, 
dihydrotestosterone (DHT) in human pulmonary artery smooth muscle cells 
(PASMCs).  Data on a role for androgens in pulmonary vasculature and 
specifically in remodelling of the vasculature is lacking.  The effects of these 
androgens were examined within physiological circulating levels (8-30 nmolL-1) 
(Smith et.al. 2008).  Proliferation in human PASMCs was assessed by [3H] 
thymidine incorporation.  At all concentrations investigated, testosterone had no 
effect on proliferation (Figure 5-12A).  On the other hand, DHT had a dose 
dependent effect on proliferation and at 3 nmolL-1 DHT stimulated PASMC 
proliferation as assessed by [3H] thymidine incorporation (Figure 5-12B). 
5.2.7  Androgen Receptor Expression in Chronic Hypoxic Mouse 
Lung 
Both testosterone and DHT mediate their effects through the androgen receptor 
(AR), although DHT is 10 times more potent at this receptor than testosterone 
itself (Liu et.al. 2003).  We therefore wished to investigate the mRNA transcript 
expression of AR in chronic hypoxic mouse pulmonary artery and determine if 
hypoxia has any effect on the expression of this receptor. 
Firstly, AR mRNA transcript was found to be expressed in the lungs of male mice.  
The levels of AR mRNA however, were unchanged between normoxic SHAM mice 
and hypoxic SHAM mice.  Expression of AR was also unchanged between SHAM 
and CAS mice both in normoxic and hypoxic conditions (Figure 5-13).   
5.2.8  5α-reductase Expression in Chronic Hypoxic Mouse Lung 
Testosterone is metabolised by the cytochrome P450 enzyme aromatase 
(CYP19A1) to estrogen.  Alternatively, some testosterone is also metabolised to 
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DHT by the enzyme 5α-reductase.  As our results demonstrated that DHT caused 
proliferation of human PASMCs, we wished to determine if expression levels of 
5α-reductase mRNA were altered during hypoxia-induced PH in mouse lung.  We 
examined 5α-reductase type 1 as this has previously been identified in the lung 
(Kimura et al. 2003). 
We found expression levels of SRD5A1, the gene encoding 5α-reductase type I 
were unchanged between normoxic SHAM mice and hypoxic SHAM mice.  
Additionally, CAS had no effect on the mRNA levels of SRD5A1 in both normoxia 
and hypoxia (Figure 5-14). 
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Figure 5-12: Dihydrotestosterone stimulates proliferation of control male human pulmonary 
artery smooth muscle cells. 
Testosterone has no effect on proliferation (A) whereas DHT at 3nmol/l increases proliferation (B).  
### p<0.01 vs. 0.2% FBS; **p<0.1 vs. 2.5% FBS.  Data are expressed as mean ± SEM and 
analysed by a One-way ANOVA followed by a Bonferroni’s post-hoc test.  n=3 controls performed 
in triplicate (Control 1-3; See Table 2-3 in Materials and Methods Section).  
DHT=dihydrotestosterone. 
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Figure 5-13: Androgen receptor expression is unchanged in hypoxia and following 
castration. 
Data are expressed as mean ± SEM and analysed by a one-way ANOVA followed by a Tukey’s 
post hoc test.  n=6 lungs/group.  AR= androgen receptor. 
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Figure 5-14: 5α-reductase type 1 expression is unchanged in hypoxia and following 
castration. 
Data are expressed as mean ± SEM and analysed by a one-way ANOVA followed by a Tukey’s 
post hoc test.  n=6 lungs/group.  SRD5A1= 5α-reductase type I. 
 
 
 
5.3 Discussion 
There is a paucity of data on male hormones in PAH development and the role 
they play in both physiology and pathophysiology in the lung.  Here we 
investigated the primary circulating hormone in males in vivo by removal of 
testosterone via surgical castration to address the question “does testosterone 
contribute to development and progression of PAH in males?”  We also wished to 
determine the influence of testosterone and its primary metabolite 
dihydrotestosterone (DHT), in translational studies in vitro in human PASMCs. 
In this study we show that development of chronic hypoxia induced-PH is not 
dependent on testosterone as there were no significant alterations in 
haemodynamic measurements in response to castration.  In line with this we 
observed no effect of hypoxia on plasma testosterone levels in our chronic 
hypoxic mouse model.  Muscularisation of pulmonary arteries was also 
unaffected by testosterone manipulation although we found that DHT induced a 
proliferative response in isolated PASMCs.  Our findings imply that testosterone 
may not be involved in regulation of pulmonary pressures although altered 
metabolism and increased DHT in PASMCs may contribute to the remodelling 
process. 
Recent epidemiological evidence from the REVEAL registry supports female 
gender as a risk factor in development of PAH with a female to male ratio of 
4.3:1 reported in the total PAH group (Walker et.al. 2006) and 4.1:1 within 
idiopathic PAH (IPAH) cases (Badesch et.al. 2010).  Estrogen has since been 
regarded as an environmental risk factor in pulmonary artery smooth muscle 
cells (PASMCs) contributing to proliferation and pulmonary arterial remodelling 
(White et.al. 2011).  Further, alterations in estrogen synthesis (Roberts et.al. 
2009b); Mair et al. unpublished), metabolism (Austin et.al. 2009; West et.al. 
2008; White et al. 2012c), and estrogen receptor expression (Rajkumar et.al. 
2010) all contribute to PAH development.  However, in the most established 
animal models, males exhibit more severe hypoxic and monocrotaline induced-
PH compared to females (McMurtry et.al. 1973; Rabinovitch et.al. 1981; Resta 
et.al. 2001).  In line with this, despite an increased prevalence of PAH in women 
than men, the estimated survival rate in men is consistently worse than in 
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women even with treatment intervention (Benza et.al. 2012; Humbert et.al. 
2010a).  The role of testosterone in PAH may therefore have been overlooked. 
Right ventricular (RV) dysfunction is the most important prognostic factor and 
indicator of survival in PAH (D'Alonzo et.al. 1991).  In males, poor survival rates 
are strongly associated with reduced RV function and cardiac output (Humbert 
et.al. 2010a; Kawut et.al. 2009).  Therefore a correlation between testosterone 
and the RV is proposed.  Higher testosterone levels have previously been 
associated with structural effects on the RV contributing to greater RV mass and 
larger RV volumes in men.  On the other hand, estrogen infers protective 
functional effects whereby estrogen levels strongly correlate with increased 
right ventricular ejection fraction (Ventetuolo et.al. 2011).  Indeed there is a 
lower risk of cardiovascular disease in ageing men with a high estrogen/low 
testosterone state (Arnlov et al. 2006; Tivesten et al. 2007).  In a recent study 
by Hemnes et al (2012) lower testosterone levels were reported to be protective 
in mice with RV load stress associated with pathologic hypertrophy (Hemnes 
et.al. 2012).  Additionally, changes in the morphological structure of the RV, 
including increased myocyte size and fibrosis, in relation to testosterone levels 
were found, although this had minimal effects on RV function (Hemnes et.al. 
2012).  Our data are congruent with this study showing that manipulation of 
testosterone via surgical castration had no effect on RVSP at baseline or 
following hypoxia.  However, surprisingly in our study there was no effect of 
castration observed on the right ventricle and both SHAM and castrated mice 
developed RVH to a similar degree.  Although this study does provide evidence 
that testosterone is involved in regulating myocyte size in the LV as castration 
results in decreased LV weight in both normoxic and hypoxic conditions.  This 
perhaps reflects a difference in the PAB model which induces more substantial 
pressure overload in the RV and RV dysfunction compared to the chronic hypoxic 
model.  RV dysfunction in chronic hypoxia may not be severe enough to evaluate 
the benefit of removing testosterone on the RV.  Together, this evidence 
suggests that the effects of testosterone are primarily involved in dysfunctional 
RV hypertrophy.  Following increased afterload inflicted by elevated pulmonary 
pressures during PAH, testosterone may be the underlying cause of the 
difference in survival rate between males and females.   
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The degree of RVH in rats exposed to high altitude is greater in castrated males 
treated with testosterone (Vander et.al. 1978) and the effects of testosterone 
and hypoxia appear additive.  Testosterone biosynthesis also seems to be 
activated by hypoxia (Hwang et al. 2009).  We therefore examined the plasma 
levels of testosterone in mice in the absence of, and following exposure to, 
chronic hypoxia.  No statistically significant difference in ‘free’-circulating 
testosterone levels were observed in normoxic or hypoxic male mice.  However, 
testosterone has a high affinity for sex hormone binding globulin (SHBG) and 
circulates mainly bound to SHBG, with only 1-2% unbound or ‘free’ to exert its 
biological activity (Dunn et.al. 1981).  In fact, as plasma testosterone levels 
increase and SHBG becomes saturated, albumin binding of testosterone 
increases.  The total testosterone unbound changes relatively little over 
physiological concentration ranges (Dunn et.al. 1981).  It may therefore be 
important to disseminate bound and unbound/’free’ testosterone to confirm 
whether the absence or alteration in testosterone levels between normoxia and 
hypoxia relates to SHBG levels.   
It could also be considered that local production of testosterone in either the 
lung or RV may confer a more important influence than total circulating 
testosterone.  Certainly, elevated testosterone in the human heart causes 
structural and morphological changes (Achar et.al. 2010) and local metabolism 
of testosterone is changed in the hypertrophic heart with increased DHT levels 
described in left ventricular hypertrophy (Thum & Borlak 2002).  Here we also 
show that local metabolism of testosterone is possible in the lung, as the lung 
expresses 5α-reductase.  mRNA levels of 5α-reductase are however, unchanged 
between normoxic and hypoxic mice.  Additionally, the presence of the AR also 
infers activity of either/both testosterone and DHT in the lung.  Although we 
show AR transcriptional expression is unchanged in hypoxia consistent with 
previous findings (Khandrika et al. 2009), others have reported increased 
androgen ligand binding to AR in hypoxia (Mitani et al. 2011; Park et al. 2012).  
Together these findings may infer increased activity of testosterone in 
established hypoxic PH.  Further investigation of the protein levels of both AR 
and 5α-reductase are required to confirm these observations. 
In contrast to the detrimental effects of testosterone reported in the heart, 
testosterone-induced vasodilation has been identified in numerous vascular 
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beds, including isolated rabbit coronary arteries and aorta (Yue et.al. 1995), rat 
pulmonary arteries (English et.al. 2001; Jones et.al. 2002), and more recently 
isolated human pulmonary and mesenteric arteries (Jones et al. 2003).  It is in 
fact, a more potent vasodilator than estrogen in pulmonary vasculature (English 
et.al. 2001) and this effect is independent of gender (Rowell et.al. 2009; Smith 
et.al. 2008).  Importantly, the direct vasodilatory action of testosterone is 
accepted to be a rapid non-genomic effect independent of AR (Jones et.al. 
2002; Yue et.al. 1995).  The mechanism is believed to be through inhibition of 
Ca2+ entry via voltage gated calcium channels (Hall et.al. 2006; Scragg et.al. 
2004) and independent of endothelium (Perusquia et al. 1996; Yue et.al. 1995) 
and nitric oxide release (Honda et al. 1999).  However, these studies are carried 
out in the absence of hypoxia and assess vasodilation in pre-constricted isolated 
vessels.  Therefore, we wished to investigate the effects of castration on 
pulmonary vascular reactivity and analyse the hypoxic pulmonary 
vasoconstrictive response.  We examined the response of isolated pulmonary 
arteries to serotonin, a potent pulmonary vasoconstrictor (MacLean & Dempsie 
2010).  In normoxic conditions we observed no effect of castration on serotonin-
induced vasoconstriction.  SHAM mice exhibited an elevated vasoconstrictive 
response to serotonin in hypoxia, however, this response was absent in hypoxic 
castrated mice.  This suggests that hypoxic pulmonary vasoconstriction in males 
may involve an interaction between serotonin and testosterone.  Indeed, 
testosterone has been shown to increase levels of 5-HT2A receptor in male rat 
brain, although this is likely due to its enzymatic conversion to estrogen via 
aromatase (Sumner & Fink 1998).  5-HT2A is the predominant receptor involved in 
serotonin-induced pulmonary vasoconstriction in hypoxia in rodents (MacLean & 
Dempsie 2010).  Thus, reduced testosterone in castrated mice may result in 
lower levels of 5-HT2A in pulmonary arteries and hence attenuate the hypoxic 
vasoconstrictive response to serotonin.   
These findings suggest that although testosterone may infer protective vascular 
effects at baseline, providing rationale for a lower incidence of PAH in men, as 
PH progresses and the environment becomes more hypoxic due to remodelling, 
protective effects of testosterone may be compromised.  Additionally, disease 
progression in men may become more exaggerated due to negative effects of 
testosterone on the right ventricle, leading to right ventricular failure.  Hence, 
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multiple actions of testosterone in the lung and RV, and in normal and diseased 
states complicate the gender paradox in PAH. 
One limitation of this study is the high remaining circulating testosterone in the 
plasma.  This could be due to length of time after surgery in which 
haemodynamic measurements were assessed which may not be adequate to 
completely deplete testosterone levels.  Alternatively, the high testosterone 
could be a result of conversion of DHEA released from the adrenal glands to 
testosterone.  To eliminate these complications in future studies, the 
testosterone levels should be monitored throughout the study to ensure that 
haemodynamic parameters are measured when testosterone levels are low.    
Our results indicate that elevated pulmonary pressures and pulmonary arterial 
muscularisation develop independent of testosterone in chronic hypoxia induced-
PH.  In hypoxic PH, testosterone levels are unchanged, however we suggest 
altered testosterone metabolism in the lung and pulmonary arteries may 
promote enhanced PASMC proliferation via DHT, leading to remodelling as PH 
progresses.  In conclusion we suggest that testosterone may not be involved in 
initiating disease development but rather facilitates disease progression in 
established PAH. 
 Chapter 6. 
General Discussion 
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6  
6.0 General Discussion 
The impact of sex hormones in the development of PAH is complex and 
incompletely understood owing to the ‘estrogen paradox’.  Both estrogen and 
androgens are vasoactive in the pulmonary vasculature and PASMCs.  The effects 
of estrogen are mediated either through conversion to estrogen metabolites, or 
directly via two classical estrogen receptors, ERα and ERβ.  In the lung, ERα and 
ERβ are expressed in PAECs (Venkov et al. 1996), PASMCs (Karas et al. 1994) and 
the airway (Hamidi et al. 2011).  In general, however, the role and expression of 
ERα and ERβ in physiology and pathophysiology of the pulmonary vasculature is 
not as well described as in the systemic vasculature. 
Increased female susceptibility in human PAH is well described.  Recent 
epidemiological studies highlight this gender bias and the Registry to Evaluate 
Early and Long-term PAH Disease Management (REVEAL) reports a strong gender 
bias whereby 79.5% of prevalent adult PAH patients were female.  This female 
predominance was observed across the majority of PAH subtypes (Badesch et.al. 
2010; Benza et.al. 2012).  In addition, incident cases of PAH in UK and Ireland 
support a female susceptibility with 69.9% PAH cases reported in females (Ling 
et.al. 2012).  Together, this emerging evidence with regard to a gender bias has 
implicated an influence of sex hormones on the pulmonary vasculature and right 
heart.  In particular, estrogen and estrogen metabolites have been attributed to 
PAH development and progression.  Indeed, polymorphisms in aromatase, the 
estrogen synthesising enzyme, have been linked to elevated estrogen levels in 
the lungs of female patients with portopulmonary hypertension (Roberts et.al. 
2009b).  Moreover, altered estrogen metabolism arising from polymorphisms in 
the estrogen metabolising enzyme, CYP1B1, have also been associated with PAH 
development in women (West et.al. 2008).  Currently, no animal model has 
recapitulated this female susceptibility.  Additionally, exogenous administration 
of estrogen appears protective in male rodents (Lahm et.al. 2012a; Resta et.al. 
2001) and paradoxically, male rodents exhibit a susceptibility to both hypoxic- 
and moncrotaline-induced PH and exhibit more severe PH compared to females 
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(Rabinovitch et.al. 1981).  Male rodents are therefore more commonly utilised in 
PAH research although this has offered limited insight into the female gender 
bias observed in human PAH.  For this reason, we investigated the effects of 
endogenous estrogen and estrogen antagonism in both males and females.  We 
hypothesised that there may be a disparity in the effects of an ERα antagonist 
between males and females. 
Here, we provide evidence that development of PAH is ERα dependent in 
females only (Chapter 3).  Dysregulation of the BMPR2 pathway via ERα appears 
central to this gender specific effect.  We observed that expression of ERα 
transcript and protein was increased in PASMCs from female PAH patients 
compared to normal female controls whilst ERβ was down-regulated in PASMCs 
from female PAH patients.  This is consistent with gene expression data that 
implicates up-regulation of ESR1 in PAH pathogenesis (Rajkumar et.al. 2010) and 
polymorphisms in ESR1 associated with higher expression and an increased risk of 
developing portopulmonary hypertension (Roberts et.al. 2009b).  Uniquely we 
report that there are higher levels of ERα in female PAH PASMCs compared with 
male PASMCs from PAH patients.  We suggest it is likely then, that the ERα 
pathway contributes more significantly to pathophysiology of the female lung 
during PAH compared to the male lung.  To translate functional and clinical 
relevance to our findings we investigated the effects of ER agonists and 
antagonists in vitro in isolated human PASMCs.  Consistent with previous findings 
(White et.al. 2011; White et.al. 2012c) we demonstrate that estrogen stimulates 
proliferation of PASMCs at physiological concentrations.  Excessive PASMC 
proliferation is a main component of pulmonary vascular remodelling and 
lesions, and is currently considered irreversible in PAH (Humbert et.al. 2004).  
Indeed we show for the first time that estrogen can induce proliferation in 
PASMCs via ERα activation, whilst an ERβ agonist and antagonist have no effect 
on proliferation of PASMCs.  Moreover, we determine the pro-proliferative 
effects of estrogen and the ERα agonist, PPT, are dependent on activation of 
downstream PI3K/Akt and ERK MAPK signalling (Figure 6-1).  These pathways 
have both been implicated previously in cardiac hypertrophy and pulmonary 
vascular remodelling in right heart failure during PAH (Nadadur et.al. 2012; Zhou 
et.al. 2011).  Pro-proliferative effects of estrogen in PASMCs may therefore be 
essential to the observed female susceptibility in PAH by initiating vascular 
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remodelling involving activation of ERs and transcription of proliferative genes, 
for example cyclin D1 and c-fos.  Of further interest, evaluation of the effect of 
estrogen and ERs in PAECs involved in development of plexiform lesions observed 
in severe PAH may offer some insight into PAH progression in females. 
We investigated ERα in vivo in two models of PAH.  In chronic hypoxia-induced 
PH, the ERα antagonist, MPP attenuated the development of PH in female mice, 
but not in males.  Given the elevated expression of ERα we observed in 
pulmonary arteries from female mice in hypoxia we propose that endogenous 
estrogen activates ERα to facilitate the development of PH in females.  On the 
other hand, ERα expression was unchanged in the pulmonary arteries of hypoxic 
male mice suggesting that ERα may not be involved in pathogenesis of PH in 
males in chronic hypoxia.  Furthermore, we examined the effects of MPP in 
SERT+ mice which demonstrate a female susceptibility dependent on circulating 
estrogen and serotonin.  We show that MPP reversed PH in SERT+ females under 
both normoxic and hypoxic conditions.  Here, we suggest a pivotal role for ERα 
in the causative effects of endogenous estrogen in the development of PH 
independent of hypoxia.  Interactions between the estrogen and the serotonin 
system have been described previously whereby estrogen can up-regulate TPH-1, 
SERT and 5-HT1B (White et.al. 2011).  We now show that serotonin can also up-
regulate the expression of ERα and therefore we propose that synergistically 
these mediators may contribute to the pathogenesis of PAH in females.  In 
addition, we identify an important interaction between ERα and BMPR2 in these 
in vivo models specific to females.  Dysfunctional BMPR2 signalling plays a 
pivotal role in aberrant smooth muscle growth and endothelial cell proliferation 
and apoptosis in PAH.  Loss of BMPR2 function mediates proliferation by reducing 
cell cycle inhibitors, Id1 and Id3 in PASMCs (Yang et.al. 2008; Yang et.al. 2005) 
and is responsible for ~80% of HPAH cases (Machado et.al. 2009).  In the present 
study, we demonstrate decreased BMPR2 expression in the lung (Figure 6-1), 
associated with loss of downstream Smad 1 and Id signalling, following hypoxia 
and in SERT+ female mice.  Interestingly, this loss of expression was restored in 
female mice treated with MPP although male mice remained unaffected.  This is 
consistent with a previous report in which a highly conserved functional estrogen 
response element with a co-repressor function was observed in the BMPR2 
promoter whereby estrogen exposure resulted in suppression of the BMPR2 signal 
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through ERα (Austin et.al. 2009).  In conclusion of our findings, we describe a 
mechanism of female susceptibility in PAH which combines elevated endogenous 
estrogen levels in females during PAH, with increased ERα expression and 
defective signalling, resulting in dysfunctional BMPR2 expression and function 
(Figure 6-1).  Hence in females we propose that the selective effects of the ERα 
antagonist are likely through restoration of the dysfunctional BMPR2 signalling 
axis.  Future studies investigating ERα should examine if the effects of estrogen 
are via membrane bound ERα or an effect on the transcription of genes in the 
nucleus.  In addition, more studies are required to highlight the interactions 
between ERα and the serotonin system, for example, SERT, 5-HT receptors and 
THP-1.  
Given the diverse effects of estrogen on the pulmonary vasculature, we also 
wished to investigate the novel G-protein coupled estrogen receptor, GPER 
which mediates rapid, non-genomic effects of estrogen (Chapter 4).  The 
influence of GPER in pulmonary vasculature and during PAH development and 
progression is unknown.  To our knowledge, this is the first study to determine 
immunolocalisation of GPER to smooth muscle cells in human non-PAH control 
and PAH patient lung.  Immunoblotting and qRT-PCR revealed that expression of 
GPER was however unchanged between female non-PAH control and PAH 
patients.  In contrast, protein expression of GPER was significantly reduced in 
pulmonary arteries from hypoxic female mice relative to controls.  In response 
to hypoxia in cancer cells and cardiomyocytes, it has previously been shown that 
GPER expression is increased as an adaptive response to stressful 
microenvironments (Recchia et.al. 2011).  Here, our results may differ due to 
tissue and species differences.  Regardless, the relevance of this observation of 
a down-regulation of GPER expression to the pathogenesis of experimental PH is 
unclear; therefore we characterised GPER in vivo using GPER-/- mice.  Due to 
age-dependent development of systemic arterial hypertension in female GPER-/- 
mice we investigated chronic hypoxia induced-PH in both male and female aged 
2-3 months (Martensson et.al. 2009).  In both normoxic conditions in the absence 
of PH, and following development of chronic hypoxic-PH we observed no effect 
of GPER deletion in male mice.  In female mice, hypoxic GPER-/- mice exhibited 
exaggerated pulmonary vascular remodelling compared to wildtype hypoxic mice 
although in the absence of any elevations in RVSP and RVH.  We therefore 
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suggest that activation of GPER may mediate a protective effect in hypoxia, 
although the effect is not sufficient enough to reverse completely the hypoxic 
PH phenotype.  However, the implications of this remains unresolved as the 
GPER selective agonist, G1 had no effect on PASMC proliferation.  Moreover, the 
G15, a GPER selective antagonist, did not influence estrogen induced 
proliferation.  In conclusion, our data suggests that activation of GPER has a 
limited effect on PH pathology.  However, further characterisation of GPER is 
required to decipher vasoactive properties in the pulmonary vasculature.  
Certainly, G1 has been shown to lower blood pressure in isolated human aorta 
(Haas et al, 2009) and reduce inflammation in the heart during ischemia-
reperfusion (Deschamps & Murphy 2009). 
Despite clear epidemiologic evidence demonstrating a female predominance in 
the development of multiple forms of PAH, PAH is often more severe in men and 
they show worse survival rates compared to women (Shapiro et.al. 2012).  Here 
we investigated testosterone, the main circulating sex hormone in men, to 
address if testosterone is the key to the gender paradox observed in 
translational and experimental PH (Chapter 5).  Males are demonstrated to 
exhibit more severe hypoxia induced-PH compared to females, however in this 
study we show that elevated RVSP, pulmonary vascular remodelling and RVH in 
hypoxia are not dependent on testosterone.  Our data are congruent with a 
recent study showing that manipulation of testosterone via surgical castration 
has no effect on pulmonary haemodynamics (Hemnes et.al. 2012).  In addition, 
we show that plasma testosterone levels are unaffected in hypoxia.  It would be 
of interest however, to investigate local testosterone production in the lung and 
RV as poor survival rates in males are strongly associated with reduced RV 
function and cardiac output (Humbert et.al. 2010a; Kawut et.al. 2009).  For 
example, high testosterone levels have previously been associated with 
structural effects on the RV contributing to greater RV mass and larger RV 
volumes in men (Ventetuolo et.al. 2011).  Indeed, testosterone has recently 
been shown to increase RV myocyte size and fibrosis in male mice with RV load 
stress (Hemnes et.al. 2012).  Moreover, altered testosterone metabolism and 
elevated DHT levels, the primary metabolite of testosterone, are described in 
left ventricular hypertrophy (Thum & Borlak 2002).  Here, we also demonstrate 
that DHT stimulates proliferation of human PASMCs.  Although we determined 
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that expression of 5α-reductase, the testosterone metabolising enzyme, and 
androgen receptor are unchanged in whole lung from male mice, expression in 
the RV may be of more importance.  Certainly RV dysfunction is the most 
important prognostic factor and indicator of survival in PAH (D'Alonzo et.al. 
1991).   
From this evidence we suggest that the absence of testosterone in females is 
therefore unlikely to drive the female predominance.  We propose that 
testosterone may not be involved in protection against PAH nor is it involved in 
initiating disease development in males.  Instead we suggest that altered 
testosterone levels and/or metabolism of testosterone facilitate disease 
progression in established PAH by multiple actions on RV structure and function. 
In summary, through a translational approach we have identified key concepts 
that have improved our understanding of the female susceptibility in PAH.  This 
includes the up-regulation of ERα in PASMCs which results in dysfunctional 
BMPR2 signalling specific to females.  For future perspective, the estrogen 
pathway and particularly targeting the estrogen receptors provides a novel 
therapeutic strategy and hold promise for treating PAH in females. 
Future Perspectives 
Therapeutic targeting of the estrogen pathway is a promising candidate for PAH 
therapy.  Moreover, this provides the potential for a personalised medicine 
approach to treatment with regards to women who exhibit estrogen responsive 
PAH.  For example, SERMs are currently a successful treatment in women with 
ER positive breast cancer by preventing proliferation of breast cancer cells (Park 
& Jordan 2002; Swaby et al. 2007).  Indeed, raloxifene has already been 
implicated as a beneficial treatment in monocroaline-induced PH with effects on 
vascular and cardiac remodelling (Nishida et.al. 2009).  Future studies are 
required to evaluate the influence of raloxifene and tamoxifen in isolated human 
PASMCs and in additional experimental PH models which better recapitulate the 
human phenotype such as the Sugen-hypoxic model. 
The value of understanding the downstream pathways activated by ERs during 
PAH will also highlight further routes of interest for therapy.  In particular, pro-
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proliferative genes activated by genomic ERs may offer novel targets which 
could be crucial in attenuating or reversing, the pulmonary vascular remodelling 
process which leads to these plexiform lesions, and which obliterate arteries in 
severe/end-stage PAH. 
Targeting the estrogen pathway, estrogens biosynthesis, metabolism or 
activation of ERs, will provide novel therapeutic targets in treatment of PAH 
treating females selectively.  Indeed, antioxidant therapy appears more 
beneficial in treatment of coronary artery disease in females compared to men.  
Gender specific treatments may therefore be a novel approach in treating PAH. 
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Figure 6-1: Key findings and conclusions of estrogen signalling via ERα in PAH (Chapter 3). 
In Chapter 3 of this study we demonstrate (1) ERα is elevated in female human PASMCs, possibly via 5-HT; (2) expression of BMPR2 is reduced in lungs via ERα, and 
(3) in isolated female human PASMCs, estrogen, via ERα, activates pro-proliferative kinases in PASMCs.  It is unclear from this study if the effects on ERK/MAPK and 
BMPR2 are via membrane bound ERα or via an effect on transcription in the nucleus.  Overall, we suggest these mechanisms contribute to SMC proliferation and 
pulmonary vascular remodeling in vivo.  Furthermore, an ERα antagonist, MPP, effectively attenuates development of PH in chronic hypoxic PH and PH in SERT
+ 
female mice. 
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